# Patent

## Title
Antigen binding polypeptides

## Abstract

The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.

## Background
RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 12/497,239, filed Jul. 2, 2009 which claims the benefit of priority of U.S. Provisional Application Ser. No. 61/077,730, filed Jul. 2, 2008, and U.S. Provisional Application Ser. No. 61/110,161, filed Oct. 31, 2008, which is incorporated herein by reference. This application also claims the benefit of foreign priority to GB 0812120.4, filed Jul. 2, 2008, which is incorporated herein by reference.


FIELD OF THE INVENTION
The invention relates to a novel platform for generation of antigen binding polypeptides, including monoclonal antibodies, which share a high degree of sequence and structural homology with the variable domains of human antibodies.
BACKGROUND TO THE INVENTION
Monoclonal antibodies have many applications as research tools and, increasingly, as therapeutic or diagnostic agents. Currently more than 20 different monoclonal antibodies have received regulatory approval to treat a variety of different diseases, including cancer, inflammation, auto-immune disorders, infectious disease, asthma, cardiovascular diseases and transplant rejection and the number of monoclonal antibody drugs in the development pipeline is increasing year-on-year.
The utility of rodent (specifically murine) monoclonal antibodies in human therapy is limited because of problems associated with their non-human origin, in particular their immunogenicity in a human host. In order to minimize the human immune response against therapeutic antibody drugs, monoclonal antibody technology has evolved from full mouse antibodies to chimeric antibodies (mouse variable domains grafted on a human IgG backbone), to humanized antibodies (mouse CDRs grafted on a human IgG backbone), to “fully human” antibodies derived from synthetic libraries or immunized transgenic mice expressing part of the human IgG repertoire.
A number of technology platforms have been developed which allow production of fully human or “humanized” monoclonal antibodies against target antigens of therapeutic interest. Each of these platforms has its own particular characteristics and potential shortcomings.
Humanisation of mouse monoclonal antibodies was initially achieved by combining mouse variable domains with human constant domains, creating so called chimeric antibodies having about 70% of human content. A further degree of humanization was subsequently achieved by grafting the complementarity-determining regions (CDRs) of mouse monoclonal antibodies onto human framework regions of the variable antibody domains of human antibodies. In addition, several amino acid residues present in those framework regions were identified as interacting with the CDRs or antigen and were back mutated in the humanized antibody to improve binding. (Almagro et al. Frontiers in Bioscience. 13: 1619-1633 (2008)). Monoclonal antibodies engineered using this approach have a relatively high degree of primary sequence homology to human VH and VL domain sequences after humanisation, but a drawback is the possibility of ending up with hypervariable loops not having human-like structure, because not all mouse-encoded CDRs use canonical folds, and canonical fold combinations, which are not found in human antibodies (Almagro et al., Mol. Immunol. 34:1199-1214 (1997); Almagro et al., Immunogen. 47:355-63 (1998)). A further drawback is the large number of mutations typically required to humanise such antibodies (the procedure for which is complex and time-consuming), with the consequent risk of losing affinity and potency as a result of the number of changes needed for humanisation and, the fact that VKappa domains are mainly used in the murine repertoire, whereas approximately half of all human antibodies possess VLambda domains.
As a potential improvement on humanised mouse monoclonal antibodies, “fully human” monoclonal antibodies can be produced by two very different approaches. The first approach is selection from a fully synthetic human combinatorial antibody library (for example HuCAL®, MorphoSys). The potential drawback of this approach is that the synthetic library only approximates the functional diversity naturally present in the human germline, thus the diversity is somewhat limited. Also, antibodies generated using this approach are not derived from in vivo selection of CDRs via active immunisation, and typically affinity maturation has to be done in order to improve affinity for the target antigen. Affinity maturation is a lengthy process which may add considerable time to the antibody discovery process. Also, in the process of affinity maturation certain amino acid residues may be changed which may negatively affect the binding specificity or stability of the resulting antibody (Wu et al., J. Mol. Biol. 368: 652-65 (2007)).
Alternative “fully human” platforms are based on transgenic mice which have been engineered to replace the murine immunoglobulin encoding region with antibody-encoding sequences from the human germline (for example HuMab, Medarex). These systems have the advantage that antibodies are raised by active immunisation, with the target antigen, i.e. they have a high starting affinity for the antigen, and that no or only minimal antibody engineering of the original antibodies is required in order to make them more human-like. However, the transgenic mouse strains are by definition highly inbred and this has adverse consequences for the strength and diversity of the antibody response. Another drawback with this platform may be impaired B cell maturation due to human Fc/mouse Fc receptor interaction in some transgenic mouse systems.
A further platform is based on immunisation of non-human primates, specifically cynomologous monkeys. Due to the high degree of amino acid sequence identity between monkey and human immunoglobulins it is postulated that antibodies raised in monkeys will require little or no additional “humanisation” in the variable domains in order to render them useful as human therapeutics (see WO 93/02108).
SUMMARY OF THE INVENTION
The present inventors have recognised the need for a “humanised” monoclonal antibody (antigen binding polypeptide) platform which avoids some or all of the shortcomings they have observed with prior art humanised or fully human antibody platforms and which enables the production of antibodies of high specificity and affinity against a broad range of target antigens of therapeutic importance whilst minimising immunogenicity in a human host.
The present inventors have observed that both the VH and the VL domains of conventional antibodies from the family Camelidae exhibit a high degree of amino acid sequence identity with the VH and VL domains of human antibodies over the framework regions. In fact, the degree of sequence identity between camelid conventional VH domains and human VH domains, and between camelid conventional VL domains and human VL domains can approach that observed between humans and other primate species, e.g. cynomologous monkeys, and is much higher than might be expected given the phylogenetic distance between humans and camelids. This finding is surprising given that the variable domains of heavy-chain camelid antibodies (VHH) do not show this high degree of sequence homology with human variable domains.
In addition, the inventors have observed that the hypervariable loops (H1, H2, L1, L2 and L3) of camelid VH and VL domains often exhibit a high degree of structural homology with the hypervariable loops of human VH and VL domains, which is again unexpected given the evolutionary distance between humans and camelids. The high degree of structural homology between camelid conventional antibodies (or rather the hypervariable loops of such antibodies) and human antibodies is also surprising since the hypervariable loops of heavy-chain camelid antibodies have been reported to vary substantially in conformation and length from the corresponding loops in human and mouse VH (see review De Genst et al., Develop Comp. Immunol. 30:187-98 (2006)).
The high degree of primary amino acid sequence homology with the framework regions of human antibodies, coupled with the high degree of structural homology of the antigen binding sites comprising the hypervariable loops with the binding sites of human antibodies, plus the fact that Camelidae conventional antibodies can be raised by active immunisation of an outbred animal population, which are phylogenetically quite distant from humans, has led the present inventors to surmise that conventional antibodies from the family Camelidae are an attractive starting point for engineering monoclonal antibodies having potential utility as human therapeutics.
Therefore, in accordance with a first aspect of the invention there is provided an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.
In one embodiment the antigen binding polypeptide of the invention may be immunoreactive with a target antigen. In another embodiment the antigen binding polypeptide may bind specifically to a target antigen.
In a non-limiting embodiment the antigen binding polypeptide of the invention may be a recombinant polypeptide.
In a non-limiting embodiment the antigen binding polypeptide of the invention may be a chimeric polypeptide.
In a non-limiting embodiment the antigen binding polypeptide of the invention may be a monoclonal antibody.
In a non-limiting embodiment the antigen binding polypeptide of the invention may be a recombinantly expressed chimeric monoclonal antibody.
In a non-limiting embodiment the antigen binding polypeptide according to the invention may comprise hypervariable loops or complementarity determining regions which have been obtained by active immunisation of a species in the family Camelidae.
In a second aspect the invention provides a process for preparing an antigen binding polypeptide immunoreactive with a target antigen, said process comprising:

    
    
        (a) determining the nucleotide sequence encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen; and
        (b) expressing an antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).
    
    


In a third aspect the invention provides a process for preparing a recombinant antigen binding polypeptide that is immunoreactive with (or specifically binds to) a target antigen, said antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a species in the family Camelidae, said process comprising the steps of:

    
    
        (a) isolating Camelidae nucleic acid encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen;
        (b) preparing a polynucleotide comprising a nucleotide sequence encoding hypervariable loop(s) or complementarity determining region(s) having amino acid sequence identical to the hypervariable loop(s) or complementarity determining region(s) encoded by the nucleic acid isolated in step (a), which polynucleotide encodes an antigen binding polypeptide comprising a VH domain and a VL domain that is immunoreactive with (or specifically binds to) said target antigen; and
        (c) expressing said antigen binding polypeptide from the recombinant polynucleotide of step (b).
    
    


The polynucleotide prepared in step (b) is preferably recombinant.
The invention further provides a polynucleotide comprising a nucleotide sequence which encodes an antigen binding polypeptide according to the first aspect of the invention, or which encodes a fragment of said antigen binding polypeptide, which fragment comprises at least one hypervariable loop or complementarity determining region (CDR) obtained from a VH or VL domain of a species in the family Camelidae.
The invention also provides an expression vector comprising the polynucleotide defined above operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system, a host cell or cell-free expression system containing the expression vector, and a method of producing a recombinant antigen binding polypeptide which comprises culturing the host cell or cell free expression system under conditions which permit expression of the antigen binding polypeptide and recovering the expressed antigen binding polypeptide.
Still further, the invention provides a test kit comprising an antigen binding polypeptide according to the first aspect of the invention and a pharmaceutical formulation comprising an antigen binding polypeptide according to the first aspect of the invention and at least one pharmaceutically acceptable diluent, excipient or carrier.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1—shows the results of an ELISA in which sera from llamas immunised with IL1-Beta were tested for the presence of antibodies against IL1-Beta, on day 0 and day 28 following immunisation.
FIG. 2—illustrates the amino acid sequences (SEQ ID NOS: 21, 255-268, respectively) of “humanized” variants of two Fabs immunoreactive with IL-1 Beta, coded 1E2 and 1F2. Based on the alignment against the closest human germlines, mutations in the VH and Vλ framework regions of 1E2 and 1F2 were proposed. Besides the fully humanized (hum) and the wild type (wt) V regions, also a “safe variant” with only three wild type residues remaining was proposed (safe).
FIG. 3—shows the results of an ELISA in which recombinantly expressed Fabs were tested for their ability to bind biot-IL-1Beta. For this the Fabs were captured on an anti-myc coated Maxisorp plate. Biotinylated human IL-1Beta was added and bound cytokine was detected using HRP-conjugated streptavidin.
FIG. 4—shows the results of phage ELISA in which phage displaying humanized variants of Fabs 1E2 and 1F2 were tested for binding to IL-1Beta.
FIG. 5—shows the results of ELISA in which chimeric 1E2 was tested for binding to IL-1Beta.



DETAILED DESCRIPTION OF THE INVENTION
The invention relates to a new platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform.
Thus, in a first aspect the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.
In the following passages different aspects of the invention are defined in more detail. Each aspect so-defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
Definitions
The term “antigen binding polypeptide” refers to any polypeptide comprising a VH domain and a VL domain which is immunoreactive with, exhibits specific binding to, a target antigen. Exemplary antigen binding polypeptides include antibodies and immunoglobulins, and also antibody fragments, as discussed elsewhere herein.
The term “antigen”, when referring to the “target antigen” against which the antigen binding polypeptide is immunoreactive, takes its normal meaning to a person of ordinary skill in the art, and includes, inter alia, polypeptide, peptide, polysaccharide, glycoprotein, polynucleotide (e.g. DNA), or synthetic chemical antigens.
The term “antigen” can also be used to describe the material employed in the immunisation of animals (e.g. camelids) during the manufacture of antigen binding polypeptides of the invention. In this context the term “antigen” may take a wider meaning, and could encompass purified forms of the antigen, and also crude or semi-purified preparations of the antigen, such as for example cells, cell lysates or supernatants, cell fractions, e.g. cell membranes, etc., plus haptens conjugated with an appropriate carrier protein. The “antigen” used in an immunisation protocol is not necessarily structurally identical to the “target antigen” with which the resulting antigen binding polypeptide is to immunoreact. Typically the “antigen” used for immunisation may be a truncated form of the “target antigen”, e.g. a fragment containing an immunogenic epitope. Further characteristics of “antigens” used for active immunisation are described elsewhere herein, and would be generally known to a person skilled in the art.
“Specific binding” between and antigen binding polypeptide and a target antigen refers to immunological specificity. An antigen binding polypeptide binds “specifically” to its target antigen if it binds an epitope on the target antigen in preference to other epitopes.
“Specific binding” does not exclude cross-reactivity with other antigens bearing similar antigenic epitopes.
“Antibodies” (Abs) and “immunoglobulins” (Igs) are glycoproteins which exhibit binding specificity to a (target) antigen.
The camelid species are known to possess two different types of antibodies; the classical or “conventional” antibodies and also the heavy-chain antibodies.
As used herein, the term “conventional antibody” refers to antibodies of any isotype, including IgA, IgG, IgD, IgE or IgM. Native or naturally occurring “conventional” camelid antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end (N-terminal) a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain (VL) at one end (N-terminal) and a constant domain (CL) at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.
The term “heavy-chain antibody” refers to the second type of antibodies known to occur naturally in camelid species, such antibodies being naturally devoid of light chains (Hamers-Casterman, et al. Nature. 1993; 363; 446-8). The heavy-chain antibodies (abbreviated to HCAb) are composed of two heavy chains linked by a covalent disulphide bond. Each heavy chain in the HCAb has a variable domain at one end. The variable domains of HCAbs are referred to as “VHH” in order to distinguish them from the variable domains of the heavy chains of “conventional” camelid antibodies (VH). The VHH domains and VH domains are entirely distinct and are encoded by different gene segments in the camelid genome.
The VL domains in the polypeptide of the invention may be of the VLambda type or the Vkappa type. The term “VL domain” therefore refers to both VKappa and VLambda isotypes from Camelidae, and engineered variants thereof which contain one or more amino acid substitutions, insertions or deletions relative to a Camelidae VL domain.
The term “VH domain” refers to a VH domain of any known heavy chain isotype of Camelidae, including γ, ε, δ, α or β isotypes, as well as engineered variants thereof which contain one or more amino acid substitutions, insertions or deletions relative to a Camelidae VH domain. The term “VH domain” refers only to VH domains of camelid conventional antibodies and does not encompass camelid VHH domains.
The term “variable” refers to the fact that certain portions of the variable domains VH and VL differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its target antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called “hypervariable loops” in each of the VL domain and the VH domain which form part of the antigen binding site. The first, second and third hypervariable loops of the VLambda light chain domain are referred to herein as L1(λ), L2(λ) and L3(λ) and may be defined as comprising residues 24-33 (L1(λ), consisting of 9, 10 or 11 amino acid residues), 49-53 (L2(λ), consisting of 3 residues) and 90-96 (L3(λ), consisting of 5 residues) in the VL domain (Morea et al., Methods 20:267-279 (2000)). The first, second and third hypervariable loops of the VKappa light chain domain are referred to herein as L1(κ), L2(κ) and L3(κ) and may be defined as comprising residues 25-33 (L1(κ), consisting of 6, 7, 8, 11, 12 or 13 residues), 49-53 (L2(κ), consisting of 3 residues) and 90-97 (L3(κ), consisting of 6 residues) in the VL domain (Morea et al., Methods 20:267-279 (2000)). The first, second and third hypervariable loops of the VH domain are referred to herein as H1, H2 and H3 and may be defined as comprising residues 25-33 (H1, consisting of 7, 8 or 9 residues), 52-56 (H2, consisting of 3 or 4 residues) and 91-105 (H3, highly variable in length) in the VH domain (Morea et al., Methods 20:267-279 (2000)).
Unless otherwise indicated, the terms L1, L2 and L3 respectively refer to the first, second and third hypervariable loops of a VL domain, and encompass hypervariable loops obtained from both Vkappa and Vlambda isotypes from Camelidae. The terms H1, H2 and H3 respectively refer to the first, second and third hypervariable loops of the VH domain, and encompass hypervariable loops obtained from any of the known heavy chain isotypes from Camelidae, including γ, ε, δ, α or μ.
The hypervariable loops L1, L2, L3, H1, H2 and H3 may each comprise part of a “complementarity determining region” or “CDR”. The terms “hypervariable loop” and “complementarity determining region” are not strictly synonymous, since the hypervariable loops (HVs) are defined on the basis of structure, whereas complementarity determining regions (CDRs) are defined based on sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1983) and the limits of the HVs and the CDRs may be different in some VH and VL domains.
The CDRs of the VL and VH domains can typically be defined as comprising the following amino acids: residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3) in the light chain variable domain, and residues 31-35 or 31-35b (CDRH1), 50-65 (CDRH2) and 95-102 (CDRH3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). Thus, the HVs may be comprised within the corresponding CDRs and references herein to the “hypervariable loops” of VH and VL domains should be interpreted as also encompassing the corresponding CDRs, and vice versa, unless otherwise indicated.
The more highly conserved portions of variable domains are called the framework region (FR). The variable domains of native heavy and light chains each comprise four FRs (FR1, FR2, FR3 and FR4, respectively), largely adopting a β-sheet configuration, connected by the three hypervariable loops. The hypervariable loops in each chain are held together in close proximity by the FRs and, with the hypervariable loops from the other chain, contribute to the formation of the antigen-binding site of antibodies. Structural analysis of antibodies revealed the relationship between the sequence and the shape of the binding site formed by the complementarity determining regions (Chothia et al., J. Mol. Biol. 227: 799-817 (1992)); Tramontano et al., J. Mol. Biol, 215:175-182 (1990)). Despite their high sequence variability, five of the six loops adopt just a small repertoire of main-chain conformations, called “canonical structures”. These conformations are first of all determined by the length of the loops and secondly by the presence of key residues at certain positions in the loops and in the framework regions that determine the conformation through their packing, hydrogen bonding or the ability to assume unusual main-chain conformations.
The constant domains are not involved directly in binding of an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity (ADCC) or complement-dependent cytotoxicity (CDC).
In all aspects and embodiments of the invention, the Camelidae (or camelid) species (from which the hypervariable loops or CDRs of the antigen binding polypeptide of the invention are obtained) can be camel, llama, dromedary, vicunia, guanaco or alpaca and any crossings thereof. Llama (Lama glama) and alpaca (Lama pacos) are the preferred Camelidae species for all aspects of the invention.
The antigen binding polypeptides of the invention are characterised in that they contain at least one hypervariable loop or complementarity determining region which is obtained from a VH domain or a VL domain of a species in the family Camelidae. For the avoidance of doubt, the terms “VH domain” “VL domain” refer to domains derived from camelid conventional antibodies. This definition excludes the camelid heavy chain only VHH antibodies, and recombinant constructs containing solely HVs or CDRs of camelid VHH domains, which are not encompassed within the scope of the present invention.
By “hypervariable loop or complementarity determining region obtained from a VH domain or a VL domain of a species in the family Camelidae” is meant that that hypervariable loop (HV) or CDR has an amino acid sequence which is identical, or substantially identical, to the amino acid sequence of a hypervariable loop or CDR which is encoded by a Camelidae immunoglobulin gene. In this context “immunoglobulin gene” includes germline genes, immunoglobulin genes which have undergone rearrangement, and also somatically mutated genes. Thus, the amino acid sequence of the HV or CDR obtained from a VH or VL domain of a Camelidae species may be identical to the amino acid sequence of a HV or CDR present in a mature Camelidae conventional antibody. The term “obtained from” in this context implies a structural relationship, in the sense that the HVs or CDRs of the antigen binding polypeptide of the invention embody an amino acid sequence (or minor variants thereof) which was originally encoded by a Camelidae immunoglobulin gene. However, this does not necessarily imply a particular relationship in terms of the production process used to prepare the antigen binding polypeptide of the invention. As will be discussed below, there are several processes which may be used to prepare antigen binding polypeptides comprising HVs or CDRs with amino acid sequences identical to (or substantially identical to) sequences originally encoded by a Camelidae immunoglobulin gene.
For the avoidance of doubt, the terms “VH domain of a conventional antibody of a camelid” and “VH domain obtained from a species of Camelidae” are used synonymously and encompass VH domains which are the products of synthetic or engineered recombinant genes (including codon-optimised synthetic genes), which VH domains have an amino acid sequence identical to (or substantially identical to) the amino acid sequence of a VH domain encoded by a Camelidae immunoglobulin gene (germline, rearranged or somatically mutated). Similarly, the terms “VL domain of a conventional antibody of a camelid” and “VL domain obtained from a species of Camelidae” are used synonymously and encompass VL domains which are the products of synthetic or engineered recombinant genes (including codon-optimised synthetic genes), which VL domains have an amino acid sequence identical to (or substantially identical to) the amino acid sequence of a VL domain encoded by a Camelidae immunoglobulin gene (germline, rearranged or somatically mutated).
The antigen binding polypeptides of the invention are typically recombinantly expressed polypeptides, and may be chimeric polypeptides. The term “chimeric polypeptide” refers to an artificial (non-naturally occurring) polypeptide which is created by juxtaposition of two or more peptide fragments which do not otherwise occur contiguously. Included within this definition are “species” chimeric polypeptides created by juxtaposition of peptide fragments encoded by two or more species, e.g. camelid and human.
The antigen binding polypeptides of the invention are not naturally occurring human antibodies, specifically human autoantibodies, due to the requirement for at least one hypervariable loop (or CDR) from camelid. By “naturally occurring” human antibody is meant an antibody which is naturally expressed within a human subject. Antigen binding polypeptides having an amino acid sequence which is 100% identical to the amino acid sequence of a naturally occurring human antibody, or a fragment thereof, which natural antibody or fragment is not chimeric and has not been subject to any engineered changes in amino acid sequence (excluding somatic mutations) are excluded from the scope of the invention.
The antigen binding polypeptides according to the invention comprise both a heavy chain variable (VH) domain and a light chain variable (VL) domain, and are characterised in that at least one hypervariable loop or complementarity determining region in either the VH domain or the VL domain is obtained from a species in the family Camelidae.
In alternative embodiments, either H1 or H2, or both H1 and H2 in the VH domain may be obtained from a species in the family Camelidae, and independently either L1 or L2 or both L1 and L2 in the VL domain may be obtained from a species in the family Camelidae. In further embodiments H3 in the VH domain or L3 in the VL domain may also be obtained from a species in the family Camelidae. All possible permutations of the foregoing are permitted.
In one specific embodiment each of the hypervariable loops H1, H2, H3, L1, L2 and L3 in both the VH domain and the VL domain may be obtained from a species in the family Camelidae.
In one embodiment the entire VH domain and/or the entire VL domain may be obtained from a species in the family Camelidae. The Camelidae VH domain and/or the Camelidae VL domain may then be subject to protein engineering, in which one or more amino acid substitutions, insertions or deletions are introduced into the Camelidae sequence. These engineered changes preferably include amino acid substitutions relative to the Camelidae sequence. Such changes include “humanisation” or “germlining” wherein one or more amino acid residues in a camelid-encoded VH or VL domain are replaced with equivalent residues from a homologous human-encoded VH or VL domain.
In certain embodiments, Camelidae hypervariable loops (or CDRs) may be obtained by active immunisation of a species in the family Camelidae with a desired target antigen. As discussed and exemplified in detail herein, following immunisation of Camelidae (either the native animal or a transgenic animal, engineered to express the immunoglobulin repertoire of a camelid species) with the target antigen, B cells producing (conventional Camelidae) antibodies having specificity for the desired antigen can be identified and polynucleotide encoding the VH and VL domains of such antibodies can be isolated using known techniques.
Thus, in a specific embodiment, the invention provides a recombinant antigen binding polypeptide immunoreactive with a target antigen, the polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae, which antigen binding polypeptide is obtainable by a process comprising the steps of:

    
    
        (a) immunising a species in the family Camelidae with a target antigen or with a polynucleotide encoding said target antigen and raising an antibody to said target antigen;
        (b) determining the nucleotide sequence encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen; and
        (c) expressing an antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).
    
    


Isolated Camelidae VH and VL domains obtained by active immunisation can be used as a basis for engineering antigen binding polypeptides according to the invention. Starting from intact Camelidae VH and VL domains, it is possible to engineer one or more amino acid substitutions, insertions or deletions which depart from the starting Camelidae sequence. In certain embodiments, such substitutions, insertions or deletions may be present in the framework regions of the VH domain and/or the VL domain. The purpose of such changes in primary amino acid sequence may be to reduce presumably unfavourable properties (e.g. immunogenicity in a human host (so-called humanization), sites of potential product heterogeneity and or instability (glycosylation, deamidation, isomerisation, etc.) or to enhance some other favourable property of the molecule (e.g. solubility, stability, bioavailability, etc.). In other embodiments, changes in primary amino acid sequence can be engineered in one or more of the hypervariable loops (or CDRs) of a Camelidae VH and/or VL domain obtained by active immunisation. Such changes may be introduced in order to enhance antigen binding affinity and/or specificity, or to reduce presumably unfavourable properties, e.g. immunogenicity in a human host (so-called humanization), sites of potential product heterogeneity and or instability, glycosylation, deamidation, isomerisation, etc., or, to enhance some other favourable property of the molecule, e.g. solubility, stability, bioavailability, etc.
Thus, in one embodiment, the invention provides a recombinant antigen binding polypeptide which contains at least one amino acid substitution in at least one framework or CDR region of either the VH domain or the VL domain in comparison to a Camelidae VH or VL domain obtained by active immunisation of a species in the family Camelidae with a target antigen. This particular embodiment excludes antigen binding polypeptides containing native Camelidae VH and VL domains produced by active immunisation
As an alternative to “active immunisation” with a target antigen (or a composition comprising the target antigen or a polynucleotide encoding it) it is also possible to make use of immune responses in diseased Camelidae animals or naturally occurring immune responses within Camelidae species as a source of VH and/or VL domains which can be used as components of antigen binding polypeptides with the desired antigen-binding properties. Such VH/VL domains may also be used as the starting point for engineering antigen-binding polypeptides in an analogous manner to VH/VL domains obtained by active immunisation. The invention still further encompasses the use of non-immune libraries, and to antigen-binding polypeptides obtained/derived therefrom.
In other embodiments, the invention encompasses “chimeric” antibody molecules comprising VH and VL domains from Camelidae (or engineered variants thereof) and one or more constant domains from a non-camelid antibody, for example human-encoded constant domains (or engineered variants thereof). The invention also extends to chimeric antigen binding polypeptides (e.g. antibody molecules) wherein one of the VH or the VL domain is camelid-encoded, and the other variable domain is non-camelid (e.g. human). In such embodiments it is preferred that both the VH domain and the VL domain are obtained from the same species of camelid, for example both VH and VL may be from Lama glama or both VH and VL may be from Lama pacos (prior to introduction of engineered amino acid sequence variation). In such embodiments both the VH and the VL domain may be derived from a single animal, particularly a single animal which has been actively immunised.
As an alternative to engineering changes in the primary amino acid sequence of Camelidae VH and/or VL domains, individual Camelidae hypervariable loops or CDRs, or combinations thereof, can be isolated from Camelidae VH/VL domains and transferred to an alternative (i.e. non-Camelidae) framework, e.g. a human VH/VL framework, by CDR grafting.
Sequence Identity/Homology with Human Variable Domains
The present inventors have observed that Camelidae germline and somatically mutated DNA sequences encoding both the VH and the VL domains of conventional antibodies from species in the family Camelidae exhibit a high degree of sequence identity/sequence homology with the human germline DNA sequences which encode VH and VL domains of human antibodies, over the framework regions.
Thus, the antigen binding polypeptides of the invention are characterised in that they exhibit a high degree of amino acid sequence homology with VH and VL domains of human antibodies.
In one embodiment the VH domain of the antigen binding polypeptide according to the invention may exhibit an amino acid sequence identity or sequence homology of 80% or greater with one or more human VH domains across the framework regions FR1, FR2, FR3 and FR4. In other embodiments the amino acid sequence identity or sequence homology between the VH domain of the polypeptide of the invention and one or more human VH domains may be 85% or greater, 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100%, of course with the proviso that at least one hypervariable loop or CDR is obtained from Camelidae, i.e. has an amino acid sequence which is identical (or substantially identical) to the amino acid sequence of a hypervariable loop or CDR encoded by a Camelidae VH or VL gene.
In one embodiment the VH domain of the polypeptide of the invention may contain one or more amino acid sequence mis-matches across the framework regions FR1, FR2, FR3 and FR4, in comparison to the closest matched human VH sequence. This latter embodiment would expressly exclude polypeptides comprising a VH domain, or both VH and VL domains, in which the framework region has entirely human sequence.
In another embodiment the VL domain of the antigen binding polypeptide according to the invention may exhibit a sequence identity or sequence homology of 80% or greater with one or more human VL domains across the framework regions FR1, FR2, FR3 and FR4. In other embodiments the amino acid sequence identity or sequence homology between the VL domain of the polypeptide of the invention and one or more human VL domains may be 80% or greater 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100%.
In one embodiment the VL domain of the polypeptide of the invention may contain one or more amino acid sequence mis-matches across the framework regions FR1, FR2, FR3 and FR4, in comparison to the closest matched human VL sequence. This latter embodiment would expressly exclude polypeptides comprising VL domain, or both VL and VH domains in which the framework region has entirely human sequence.
The antigen binding polypeptide of the invention may comprise a “fully human” VH or VL domain, provided that only one fully human variable domain is present, and then in combination with a variable domain comprising hypervariable loop(s) or CDR(s) obtained from Camelidae.
Representative alignments of Camelidae and human germline sequences included in the accompanying examples reveal that the conventional camelid VH and VL domains exhibit a remarkably high sequence homology to their human counterparts. From these examples it can be concluded that typically less than 8, and often only as few as 5 amino acid residues present in the framework regions of a VH or VL domain differ in a given position from the closest human germline-encoded sequences. Given that there are no structural limitations associated with those positions, humanization by site directed mutagenesis is expected to be straightforward.
Therefore, in a particular embodiment, the antigen binding polypeptides of the invention may comprise VH and/or VL domains of conventional Camelidae antibodies, for example conventional Camelidae antibodies obtained (obtainable) by active immunisation of camelidae with a target antigen (or polynucleotide encoding the target antigen), wherein said VH and VL domains have been (independently) engineered to introduce a total of between 1 and 10, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions across the framework regions FR1, FR2, FR3 and FR4 in either one or both of the VH domain and the VL domain. Such amino acid substitutions may include (but are not limited to) substitutions which result in “humanisation”, by replacing mis-matched amino acid residues in a starting Camelidae VH or VL domain with the equivalent residue found in a human germline-encoded VH or VL domain. It is also possible to independently make amino acid substitutions in the hypervariable loops (CDRs) of said camelid-derived VH and VL domains, and such variants may form part of the present invention. References herein to “amino acid substitutions” include substitutions in which a naturally occurring amino acid is replaced with a non-natural amino acid, or an amino acid subjected to post-translational modification.
Before analyzing the percentage sequence identity between Camelidae and human germline VH and VL, the canonical folds may be determined, which allows the identification of the family of human germline segments with the identical combination of canonical folds for H1 and H2 or L1 and L2 (and L3). Subsequently the human germline family member that has the highest degree of sequence homology with the Camelidae variable region of interest is chosen for scoring the sequence homology. The determination of Chothia canonical classes of hypervariable loops L1, L2, L3, H1 and H2 was performed with the bioinformatics tools publicly available on webpage www.bioinf.org.uk/abs/chothia.html.page. The output of the program shows the key residue requirements in a datafile. In these datafiles, the key residue positions are shown with the allowed amino acids at each position. The sequence of the variable region of the antibody is given as input and is first aligned with a consensus antibody sequence to assign the Kabat numbering scheme. The analysis of the canonical folds uses a set of key residue templates derived by an automated method developed by Martin and Thornton (Martin et al., J. Mol. Biol. 263:800-815 (1996)).
With the particular human germline V segment known, which uses the same combination of canonical folds for H1 and H2 or L1 and L2 (and L3), the best matching family member in terms of sequence homology was determined With bioinformatics tools the percentage sequence identity between Camelidae VH and VL domain framework amino acid sequences and corresponding sequences encoded by the human germline can be determined, but actually manual aligning of the sequences can be applied as well. Human immunoglobulin sequences can be identified from several protein data bases, such as VBase (vbase.mrc-cpe.cam.ac.uk) or the Pluckthun/Honegger database (www.bioc.unizh ch/antibody/Sequences/Germlines). To compare the human sequences to the V regions of Camelidae VH or VL domains a sequence alignment algorithm such as available via websites like www.expasy.ch/toolsflialign can be used, but also manual alignment with the limited set of sequences can be performed. Human germline light and heavy chain sequences of the families with the same combinations of canonical folds and with the highest degree of homology with the framework regions 1, 2, and 3 of each chain are selected and compared with the Camelidae variable region of interest; also the FR4 is checked against the human germline JH and JK or JL regions.
Note that in the calculation of overall percent sequence homology the residues of FR1, FR2 and FR3 are evaluated using the closest match sequence from the human germline family with the identical combination of canonical folds. Only residues different from the closest match or other members of the same family with the same combination of canonical folds are scored (NB—excluding any primer-encoded differences). However, for the purposes of humanization, residues in framework regions identical to members of other human germline families, which do not have the same combination of canonical folds, can be considered “human”, despite the fact that these are scored “negative” according to the stringent conditions described above. This assumption is based on the “mix and match” approach for humanization, in which each of FR1, FR2, FR3 and FR4 is separately compared to its closest matching human germline sequence and the humanized molecule therefore contains a combination of different FRs as was done by Qu and colleagues (Qu et al., Clin. Cancer Res. 5:3095-3100 (1999)) and Ono and colleagues (Ono et al., Mol. Immunol. 36:387-395 (1999)).
The boundaries of the individual framework regions may be assigned using the IMGT numbering scheme, which is an adaptation of the numbering scheme of Chothia (Lefranc et al., NAR 27: 209-212 (1999); imgt.cines.fr).
Despite the unexpectedly high sequence homology between Camelidae and human across the framework regions of the VH and VL domains, it is nevertheless possible to distinguish camelid-encoded hypervariable loops (CDRs) from human-encoded hypervariable loops (CDRs) by straightforward sequence comparison with camelid and human germline VH and VL sequences.
Structural Homology with Human-Encoded VH and VL Domains
A preferred embodiment is also to use Camelid hypervariable loops or CDRs having human or human-like canonical folds, as discussed in detail below.
Thus, in one embodiment at least one hypervariable loop or CDR in either the VH domain or the VL domain of the antigen binding polypeptide of the invention is obtained from a VH or VL domain obtained from a species of Camelidae, yet exhibits a predicted or actual canonical fold structure which is substantially identical to a canonical fold structure which occurs in human antibodies.
It is well established in the art that although the primary amino acid sequences of hypervariable loops present in both VH domains and VL domains encoded by the human germline are, by definition, highly variable, all hypervariable loops, except CDR H3 of the VH domain, adopt only a few distinct structural conformations, termed canonical folds (Chothia et al., J. Mol. Biol. 196:901-917 (1987); Tramontano et al. Proteins 6:382-94 (1989)), which depend on both the length of the hypervariable loop and presence of the so-called canonical amino acid residues (Chothia et al., J. Mol. Biol. 196:901-917 (1987)). Actual canonical structures of the hypervariable loops in intact VH or VL domains can be determined by structural analysis (e.g. X-ray crystallography), but it is also possible to predict canonical structure on the basis of key amino acid residues which are characteristic of a particular structure (discussed further below). In essence, the specific pattern of residues that determines each canonical structure forms a “signature” which enables the canonical structure to be recognised in hypervariable loops of a VH or VL domain of unknown structure; canonical structures can therefore be predicted on the basis of primary amino acid sequence alone.
Based on analysis of germline and somatically mutated VH and VL sequences, the present inventors predict that the hypervariable loops of Camelidae VH and VL domains (with the exception of H3 in the VH domain and sometimes also L3 in the VL domain) also adopt canonical fold structures which are substantially identical to canonical fold structures adopted by the hypervariable loops of human antibodies.
The predicted canonical fold structures for the hypervariable loops of any given VH or VL sequence in an antigen binding polypeptide can be analysed using algorithms which are publicly available from www.bioinf.org.uk/abs/chothia.html, www.biochem.ucl.ac.uk/ ̃martin/antibodies.html and www.bioc.unizh.ch/antibody/Sequences/GermlinesVbase_hVk.html. These tools permit query VH or VL sequences to be aligned against human VH or VL domain sequences of known canonical structure, and a prediction of canonical structure made for the hypervariable loops of the query sequence.
In the case of the VH domain, H1 and H2 loops derived from Camelidae may be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if at least the first, and preferable both, of the following criteria are fulfilled:
1. An identical length, determined by the number of residues, to the closest matching human canonical structural class.
2. At least 33% identity, preferably at least 50% identity with the key amino acid residues described for the corresponding human H1 and H2 canonical structural classes.
(note for the purposes of the foregoing analysis the H1 and H2 loops are treated separately and each compared against its closest matching human canonical structural class)
The foregoing analysis relies on prediction of the canonical structure of the Camelidae H1 and H2 loops. If the actual structure of the H1 and H2 loops is known, for example based on X-ray crystallography, then the H1 and H2 loops derived from Camelidae may also be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if the length of the loop differs from that of the closest matching human canonical structural class (typically by ±1 or ±2 amino acids) but the actual structure of the Camelidae H1 and H2 loops matches the structure of a human canonical fold.
Key amino acid residues found in the human canonical structural classes for the first and second hypervariable loops of human VH domains (H1 and H2) are described by Chothia et al., J. Mol. Biol. 227:799-817 (1992), the contents of which are incorporated herein in their entirety by reference. In particular, Table 3 on page 802 of Chothia et al., which is specifically incorporated herein by reference, lists preferred amino acid residues at key sites for H1 canonical structures found in the human germline, whereas Table 4 on page 803, also specifically incorporated by reference, lists preferred amino acid residues at key sites for CDR H2 canonical structures found in the human germline.
The accompanying examples contain an analysis of germline VH sequences from Camelidae species (specifically llama and dromedary) comparing the actual amino acid residues found in Camelidae versus the amino acid residues in the closest human germline VH sequence, for each of the positions in H1 and H2, and underlying framework regions, considered to be key for the canonical fold structure according to the criteria of Chothia et al., J Mol Biol. 227:799-817 (1992). It is observed that the number of identical key residues between camelid and human is most often above 33%, and typically in the range of from 50 to 100%.
In one embodiment, both H1 and H2 in the VH domain of the antigen binding polypeptide of the invention are obtained from a VH domain of a Camelidae species, yet exhibit a predicted or actual canonical fold structure which is substantially identical to a canonical fold structure which occurs in human antibodies.
The inventors surmise that it is important not only for the hypervariable loops, specifically H1 and H2 in the VH domain, individually to have canonical structures of a type which occurs naturally in human antibodies, it is also important for H1 and H2 in any given VH domain to form a combination of canonical fold structures which is identical to a combination of canonical structures known to occur in at least one human germline VH domain. It has been observed that only certain combinations of canonical fold structures at H1 and H2 actually occur in VH domains encoded by the human germline. The present inventors were surprised to discover that every available Camelidae germline or somatically mutated VH sequence which could be analysed exhibited not only individual canonical fold structures at H1 and H2 substantially identical to those used in human antibodies, but also the correct combinations of structures at H1 and H2 to match combinations found in human antibodies. This represents a distinct advantage over other platforms for production of antibodies for potential therapeutic use in humans which may produce antibodies having “correct” human-like canonical fold structures at H1 and H2 but in a combination which does not occur in human antibodies. By way of example, the inventors' own analysis of the structure of antibodies derived from non-human primates (Biogen IDEC's galiximab (anti-CD80) an lumiliximab (anti-CD23) and the non-human primate mAb against Anthrax Toxin from Pelat et al., J. Mol. Biol. 384:1400-7 (2008)) indicates that structurally they are not consistently very close to the human antibody structure, particularly having regard to the combination of canonical folds. The absence of a correct combination of canonical folds at H1 and H2 could lead to a given antigen binding polypeptide (which is “humanised” in the framework regions) being immunogenic in a human host.
Thus, in a further embodiment H1 and H2 in the VH domain of the antigen binding polypeptide of the invention are obtained from a VH domain of a Camelidae species, yet form a combination of predicted or actual canonical fold structures which is identical to a combination of canonical fold structures known to occur in a human germline or somatically mutated VH domain.
In non-limiting embodiments H1 and H2 in the VH domain of the antigen binding polypeptide of the invention are obtained from a VH domain of a Camelidae species, and form one of the following canonical fold combinations: 1-1, 1-2, 1-3, 1-6, 1-4, 2-1, 3-1 and 3-5.
It is preferred that the VH domain of the antigen binding polypeptide of the invention exhibit both high sequence identity/sequence homology with human VH, and also that the hypervariable loops in the VH domain exhibit structural homology with human VH.
It may be advantageous for the canonical folds present at H1 and H2 in the VH domain of the antigen binding polypeptide according to the invention, and the combination thereof, to be “correct” for the human VH germline sequence which represents the closest match with the VH domain of the antigen binding polypeptide of the invention in terms of overall primary amino acid sequence identity. By way of example, if the closest sequence match is with a human germline VH3 domain, then it may be advantageous for H1 and H2 (obtained from Camelidae) to form a combination of canonical folds which also occurs naturally in a human VH3 domain.
Thus, in one embodiment the VH domain of the antigen binding polypeptide of the invention may exhibit a sequence identity or sequence homology of 80% or greater, 85% or greater, 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100% with a human VH domain across the framework regions FR1, FR2, FR3 and FR4, and in addition H1 and H2 in the same antigen binding polypeptide are obtained from a VH domain of a Camelidae species, but form a combination of predicted or actual canonical fold structures which is the same as a canonical fold combination known to occur naturally in the same human VH domain.
In other embodiments, L1 and L2 in the VL domain of the antigen binding polypeptide of the invention are each obtained from a VL domain of a Camelidae species, and each exhibit a predicted or actual canonical fold structure which is substantially identical to a canonical fold structure which occurs in human antibodies.
As with the VH domains, the hypervariable loops of VL domains of both VLambda and VKappa types can adopt a limited number of conformations or canonical structures, determined in part by length and also by the presence of key amino acid residues at certain canonical positions.
L1, L2 and L3 loops obtained from a VL domain of a Camelidae species, yet may be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if at least the first, and preferable both, of the following criteria are fulfilled:
1. An identical length, determined by the number of residues, to the closest matching human structural class.
2. At least 33% identity, preferably at least 50% identity with the key amino acid residues described for the corresponding human L1 or L2 canonical structural classes, from either the VLambda or the VKappa repertoire.
(note for the purposes of the foregoing analysis the L1 and L2 loops are treated separately and each compared against its closest matching human canonical structural class)
The foregoing analysis relies on prediction of the canonical structure of the Camelidae L1, L2 and L3 loops. If the actual structure of the L1, L2 and L3 loops is known, for example based on X-ray crystallography, then L1, L2 or L3 loops derived from Camelidae may also be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if the length of the loop differs from that of the closest matching human canonical structural class (typically by ±1 or ±2 amino acids) but the actual structure of the Camelidae loops matches a human canonical fold.
Key amino acid residues found in the human canonical structural classes for the CDRs of human VLambda and VKappa domains are described by Morea et al. Methods, 20: 267-279 (2000) and Martin et al., J. Mol. Biol., 263:800-815 (1996). The structural repertoire of the human VKappa domain is also described by Tomlinson et al. EMBO J. 14:4628-4638 (1995), and that of the VLambda domain by Williams et al. J. Mol. Biol., 264:220-232 (1996). The contents of all these documents are to be incorporated herein by reference.
The accompanying examples contain an analysis of germline VL sequences or both kappa and lambda type from Camelidae species (specifically llama and dromedary), comparing the actual amino acid residues found in Camelidae versus the amino acid residues in the closest human germline VLambda or VKappa sequence, for each of the positions in L1 and L2 considered to be key for the canonical fold structure. It is observed that the number of identical key residues between camelid and human is typically in the range of from 33 to 100%, more often between 50 to 100%, typically closer to 100%.
L1 and L2 in the VL domain may form a combination of predicted or actual canonical fold structures which is identical to a combination of canonical fold structures known to occur in a human germline VL domain.
In non-limiting embodiments L1 and L2 in the VLambda domain may form one of the following canonical fold combinations: 11-7, 13-7(A,B,C), 14-7(A,B), 12-11, 14-11 and 12-12 (as defined in Williams et al. J. Mol. Biol. 264:220-32 (1996) and as shown on www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVL). In non-limiting embodiments L1 and L2 in the Vkappa domain may form one of the following canonical fold combinations: 2-1, 3-1, 4-1 and 6-1 (as defined in Tomlinson et al. EMBO J. 14:4628-38 (1995) and as shown on www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVK
In a further embodiment, all three of L1, L2 and L3 in the VL domain may exhibit a substantially human structure. Most human Vκ germline segments encode also a single conformation of the L3 loop (type 1), which is stabilized by the conserved cis-proline on position 95, but other conformations in rearranged sequences are possible due to the process of V-J joining and the potential loss of this proline residue. The publicly available somatically mutated dromedary Vκ sequences have a type 1 canonical fold for L3(x) like is found in human kappa germline sequences, and Proline on position 95 occurs in six out of seven dromedary Vκ domains. Therefore, where the antigen binding polypeptide contains a Vκ domain, this domain may possess the conserved Proline residue on position 95.
The structural repertoire of the human VL germline sequences was analyzed by Williams and colleagues (Williams et al., J. Mol. Biol. 264:220-232 (1996)). The three families analyzed here encode identical conformations of the L2 loop. The L3 loop conformation is thought to be more highly variable, as there is some length variation and no cis-proline residue. Indeed the available somatically mutated dromedary Vλ sequences show a high variability in the length of L3. Most of these have a canonical fold for L3 (f.i. VLambda 3-1 family members Camvl19 (10A) and Camvl20 (1/9A), VLambda 2-18 family members Camvl5, 17, 30, 36 and 52 (all 10B) and VLambda 1-40 family member Camvl44 (5/11A)).
It is preferred that the VL domain of the antigen binding polypeptide of the invention exhibit both high sequence identity/sequence homology with human VL, and also that the hypervariable loops in the VL domain exhibit structural homology with human VL.
In one embodiment, the VL domain of the antigen binding polypeptide of the invention may exhibit a sequence identity of 80% or greater, 85% or greater, 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100% with a human VL domain across the framework regions FR1, FR2, FR3 and FR4, and in addition hypervariable loop L1 and hypervariable loop L2 may form a combination of predicted or actual canonical fold structures which is the same as a canonical fold combination known to occur naturally in the same human VL domain.
It is, of course, envisaged that VH domains exhibiting high sequence identity/sequence homology with human VH, and also structural homology with hypervariable loops of human VH will be combined with VL domains exhibiting high sequence identity/sequence homology with human VL, and also structural homology with hypervariable loops of human VL to provide antigen binding polypeptides containing (camelid-derived) VH/VL pairings with maximal sequence and structural homology to human-encoded VH/VL pairings. A particular advantage of the camelid platform provided by the invention is that both the VH domain and the VL domain exhibit high sequence and structural homology with the variable domains of human antibodies.
Structure of the Antigen Binding Polypeptide
The antigen binding polypeptide of the invention can take various different embodiments, provided that both a VH domain and a VL domain are present. Thus, in non-limiting embodiments the antigen binding polypeptide may be an immunoglobulin, an antibody or antibody fragment. The term “antibody” herein is used in the broadest sense and encompasses, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), so long as they exhibit the appropriate specificity for a target antigen. The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes) on the antigen, each monoclonal antibody is directed against a single determinant or epitope on the antigen.
“Antibody fragments” comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof. Examples of antibody fragments include Fab, Fab′, F(ab′)2, bi-specific Fab's, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, a single chain variable fragment (scFv) and multispecific antibodies formed from antibody fragments (see Holliger and Hudson, Nature Biotechnol. 23:1126-36 (2005), the contents of which are incorporated herein by reference).
In non-limiting embodiments, antibodies and antibody fragments according to the invention may comprise CH1 domains and/or CL domains, the amino acid sequence of which is fully or substantially human. Where the antigen binding polypeptide of the invention is an antibody intended for human therapeutic use, it is typical for the entire constant region of the antibody, or at least a part thereof, to have fully or substantially human amino acid sequence. Therefore, an antibody of the invention must comprise VH and VL domains, at least one of which includes at least one hypervariable loop derived from Camelidae, but one or more or any combination of the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain (and CH4 domain if present) may be fully or substantially human with respect to it's amino acid sequence.
Advantageously, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain (and CH4 domain if present) may all have fully or substantially human amino acid sequence. In the context of the constant region of a humanised or chimeric antibody, or an antibody fragment, the term “substantially human” refers to an amino acid sequence identity of at least 90%, or at least 95%, or at least 97%, or at least 99% with a human constant region. The term “human amino acid sequence” in this context refers to an amino acid sequence which is encoded by a human immunoglobulin gene, which includes germline, rearranged and somatically mutated genes. The invention also contemplates polypeptides comprising constant domains of “human” sequence which have been altered, by one or more amino acid additions, deletions or substitutions with respect to the human sequence.
As discussed elsewhere herein, it is contemplated that one or more amino acid substitutions, insertions or deletions may be made within the constant region of the heavy and/or the light chain, particularly within the Fc region. Amino acid substitutions may result in replacement of the substituted amino acid with a different naturally occurring amino acid, or with a non-natural or modified amino acid. Other structural modifications are also permitted, such as for example changes in glycosylation pattern (e.g. by addition or deletion of N- or O-linked glycosylation sites). Depending on the intended use of the antibody, it may be desirable to modify the antibody of the invention with respect to its binding properties to Fc receptors, for example to modulate effector function. For example cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp. Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design 3:219-230 (1989). The invention also contemplates immunoconjugates comprising an antibody as described herein conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate). Fc regions may also be engineered for half-life extension.
The invention can, in certain embodiments, encompass chimeric Camelidae/human antibodies, and in particular chimeric antibodies in which the VH and VL domains are of fully camelid sequence (e.g. Llama or alpaca) and the remainder of the antibody is of fully human sequence. In preferred embodiments the invention also encompasses “humanised” or “germlined” Camelidae antibodies, and Camelidae/human chimeric antibodies, in which the VH and VL domains contain one or more amino acid substitutions in the framework regions in comparison to Camelidae VH and VL domains obtained by active immunisation. Such “humanisation” increases the % sequence identity with human germline VH or VL domains by replacing mis-matched amino acid residues in a starting Camelidae VH or VL domain with the equivalent residue found in a human germline-encoded VH or VL domain.
The invention still further encompasses CDR-grafted antibodies in which CDRs (or hypervariable loops) derived from a Camelidae antibody, for example an Camelidae antibody raised by active immunisation with a target antigen, or otherwise encoded by a camelid gene, are grafted onto a human VH and VL framework, with the remainder of the antibody also being of fully human origin. However, given the high degree of amino acid sequence homology and structural homology they have observed between Camelidae and human immunoglobulins, the inventors anticipate that in the majority of cases it will be possible to achieve the levels of human homology required for in vivo therapeutic use via “humanisation” of the framework regions of camelid-derived VH and VL domains without the need for CDR grafting or via CDR grafting on to limited number of backbone sequences without the need for veneering (also see Almagro et al, Frontiers in Bioscience 13: 1619-1633 (2008), the contents of which are incorporated herein by reference).
Humanised, chimeric and CDR-grafted antibodies according to the invention, particularly antibodies comprising hypervariable loops derived from active immunisation of Camelidae with a target antigen, can be readily produced using conventional recombinant DNA manipulation and expression techniques, making use of prokaryotic and eukaryotic host cells engineered to produce the polypeptide of interest and including but not limited to bacterial cells, yeast cells, mammalian cells, insect cells, plant cells, some of them as described herein and illustrated in the accompanying examples.
The invention also encompasses antigen binding polypeptides wherein either one or other of the VH or VL domain is obtained from Camelidae, or contains at least one CDR or hypervariable region derived from Camelidae, and the “other” variable domain has non-camelid, e.g. human, amino acid sequence. Thus, it is contemplated to pair a camelid VH domain with a human VL domain, or to pair a human VH domain with a camelid VL domain. Such pairings may increase the available antigen-binding repertoire from which to select high affinity binders with the desired antigen binding properties.
The invention still further extends to antigen binding polypeptides wherein the hypervariable loop(s) or CDR(s) of the VH domain and/or the VL domain are obtained from Camelidae, but wherein at least one of said (camelid-derived) hypervariable loops or CDRS has been engineered to include one or more amino acid substitutions, additions or deletions relative to the camelid-encoded sequence. Such changes include “humanisation” of the hypervariable loops/CDRs. Camelid-derived HVs/CDRs which have been engineered in this manner may still exhibit an amino acid sequence which is “substantially identical” to the amino acid sequence of a camelid-encoded HV/CDR. In this context, “substantial identity” may permit no more than one, or no more than two amino acid sequence mis-matches with the camelid-encoded HV/CDR.
Antibodies according to the invention may be of any isotype. Antibodies intended for human therapeutic use will typically be of the IgA, IgD, IgE IgG, IgM type, often of the IgG type, in which case they can belong to any of the four sub-classes IgG1, IgG2a and b, IgG3 or IgG4. Within each of these sub-classes it is permitted to make one or more amino acid substitutions, insertions or deletions within the Fc portion, or to make other structural modifications, for example to enhance or reduce Fc-dependent functionalities.
Antigen binding polypeptides according to the invention may be useful in a wide range of applications, both in research and in the diagnosis and/or treatment of diseases. Because of the high degree of amino acid sequence identity with the VH and VL domains of natural human antibodies, and the high degree of structural homology (specifically the correct combinations of canonical folds as are found in human antibodies) the antigen binding polypeptides of the invention, particularly in the form of monoclonal antibodies, will find particular utility as human therapeutic agents.
The invention provides a platform for production of antigen binding polypeptides, and specifically monoclonal antibodies, against a wide range of antigens and in its broadest aspect the invention is not intended to be limited with respect to the exact identity of the target antigen, nor indeed the specificity or affinity of binding to the target antigen. However, in particular, non-limiting, embodiments the target antigen may be a non-camelid antigen, a bacterial antigen, a viral antigen or a human antigen. In a preferred embodiment the target antigen may be an antigen of particular therapeutic importance. The term “target of therapeutic importance” refers to a target involved in formation, onset, progression, mediation of human or animal diseases or of the effects related to the respective disease. Included within this definition are targets wherein the expression levels and/or activity of the target are modulated by antibody binding (e.g. receptors whose activity may be modulated by binding of agonist or antagonist antibodies), and targets wherein the activity and/or expression of the target has a direct or indirect impact on a disease.
By way of example, “human antigens” may include naturally occurring human polypeptides (proteins) which function as receptors, receptor ligands, cell-signalling molecules, hormones, cytokines or cytokine receptors, neurotransmitters, etc. By “naturally occurring” is meant that the polypeptide is expressed within the human body, at any stage if its development, including polypeptides expressed by the human body during the course of a disease.
Non-limiting embodiments of the antigen binding polypeptide of the invention include the following:
A chimeric antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
A recombinantly expressed antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
A monoclonal antibody comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
An antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae and wherein said antigen binding polypeptide is immunoreactive with a target antigen of therapeutic or diagnostic importance. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
A chimeric antigen binding polypeptide comprising or consisting of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and one or more constant domains of a human antibody. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
A chimeric antigen binding polypeptide immunoreactive with a target antigen of therapeutic or diagnostic importance, which antigen binding polypeptide comprises or consists of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and one or more constant domains of a human antibody. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
A chimeric antibody comprising or consisting of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and the constant domains of a human antibody of an isotype selected from the group consisting of: IgG, IgM, IgD, IgE and IgA. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
A chimeric antigen binding polypeptide immunoreactive with a target antigen of therapeutic or diagnostic importance, which antigen binding polypeptide comprises or consists of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and the constant domains of a human antibody of an isotype selected from the group consisting of: IgG, IgM, IgD, IgE, IgA. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (Lama glama).
In particular embodiments of the foregoing, both the VH and the VL domain may be from the same species of camelid (in particular Llama or alpaca), and may even be from the same animal within this species, for example a single animal which has been actively immunised. In particular, both the VH domain and the VL domain may be obtained from a single actively immunised Llama. However, it is not excluded that the VH and VL domain may be obtained from different animals, or non-immune libraries.
In the foregoing embodiments, the terms “VH domain of a conventional antibody of a camelid” and “VL domain of a conventional antibody of a camelid” are intended to encompass variants which have been engineered to introduce one or more changes in amino acid sequence, such as variants which have been “humanised” or “germlined” in one or more framework regions, as described elsewhere herein, and also encompass the products of synthetic (e.g. codon-optimised) genes, as described elsewhere herein.
Polynucleotides, Vectors and Recombinant Expression
The invention also provides a polynucleotide molecule encoding the antigen binding polypeptide of the invention, an expression vector containing a nucleotide sequence encoding the antigen binding polypeptide of the invention operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system, and a host cell or cell-free expression system containing this expression vector.
Polynucleotide molecules encoding the antigen binding polypeptide of the invention include, for example, recombinant DNA molecules.
The terms “nucleic acid”, “polynucleotide” or a “polynucleotide molecule” as used herein interchangeably and refer to any DNA or RNA molecule, either single- or double-stranded and, if single-stranded, the molecule of its complementary sequence. In discussing nucleic acid molecules, a sequence or structure of a particular nucleic acid molecule may be described herein according to the normal convention of providing the sequence in the 5′ to 3′ direction. In some embodiments of the invention, nucleic acids or polynucleotides are “isolated.” This term, when applied to a nucleic acid molecule, refers to a nucleic acid molecule that is separated from sequences with which it is immediately contiguous in the naturally occurring genome of the organism in which it originated. For example, an “isolated nucleic acid” may comprise a DNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryotic or eukaryotic cell or non-human host organism. When applied to RNA, the term “isolated polynucleotide” refers primarily to an RNA molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been purified/separated from other nucleic acids with which it would be associated in its natural state (i.e., in cells or tissues). An isolated polynucleotide (either DNA or RNA) may further represent a molecule produced directly by biological or synthetic means and separated from other components present during its production.
For recombinant production of an antigen binding polypeptide according to the invention, a recombinant polynucleotide encoding it may be prepared (using standard molecular biology techniques) and inserted into a replicable vector for expression in a chosen host cell, or a cell-free expression system. Suitable host cells may be prokaryote, yeast, or higher eukaryote cells, specifically mammalian cells. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/−DHFR(CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); mouse myeloma cells SP2/0-AG14 (ATCC CRL 1581; ATCC CRL 8287) or NS0 (HPA culture collections no. 85110503); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2), as well as DSM's PERC-6 cell line. Expression vectors suitable for use in each of these host cells are also generally known in the art.
It should be noted that the term “host cell” generally refers to a cultured cell line. Whole human beings into which an expression vector encoding an antigen binding polypeptide according to the invention has been introduced are explicitly excluded from the scope of the invention.
In an important aspect, the invention also provides a method of producing a recombinant antigen binding polypeptide which comprises culturing a host cell (or cell free expression system) containing polynucleotide (e.g. an expression vector) encoding the recombinant antigen binding polypeptide under conditions which permit expression of the antigen binding polypeptide, and recovering the expressed antigen binding polypeptide. This recombinant expression process can be used for large scale production of antigen binding polypeptides according to the invention, including monoclonal antibodies intended for human therapeutic use. Suitable vectors, cell lines and production processes for large scale manufacture of recombinant antibodies suitable for in vivo therapeutic use are generally available in the art and will be well known to the skilled person.
Further aspects of the invention relate to test kits, including diagnostic kits etc. comprising an antigen binding polypeptide according to the invention, and also pharmaceutical formulations comprising an antigen binding polypeptide according to the invention.
Where the antigen binding polypeptide is intended for diagnostic use, for example where the antigen binding polypeptide is specific for an antigen which is a biomarker of a disease state or a disease susceptibility, then it may be convenient to supply the antigen binding polypeptide as a component of a test kit. Diagnostic tests typically take the form of standard immunoassays, such as ELISA, radioimmunoassay, Elispot, etc. The components of such a test kit may vary depending on the nature of the test or assay it is intended to carry out using the antigen binding polypeptide of the invention, but will typically include additional reagents required to carry out an immunoassay using the antigen binding polypeptide of the invention. Antigen binding polypeptides for use as diagnostic reagents may carry a revealing label, such as for example a fluorescent moiety, enzymatic label, or radiolabel.
Antigen binding polypeptides intended for in vivo therapeutic use are typically formulated into pharmaceutical dosage forms, together with one or more pharmaceutically acceptable diluents, carriers or excipients (Remington's Pharmaceutical Sciences, 16th edition., Osol, A. Ed. 1980). Antigen binding polypeptides according to the invention are typically formulated as sterile aqueous solutions, to be administered intravenously, or by intramuscular, intraperitoneal, intra-cerebrospinal, intratumoral, oral, peritumoral, subcutaneous, intra-synovial, intrathecal, topical, sublingual or inhalation routes, to a mammalian subject, typically a human patient, in need thereof. For the prevention or treatment of disease, the appropriate dosage of antigen binding polypeptide will depend on the type of disease to be treated, the severity and clinical course of the disease, plus the patient's age, weight and clinical history, and will be determined by the judgement of the attending physician.
Processes for the Production of Antigen Binding Polypeptides
A key aspect of the present invention relates to processes for the production of high affinity antigen binding polypeptides, and specifically monoclonal antibodies, against a target antigen of interest.
Accordingly, the invention provides a process for preparing an antigen binding polypeptide immunoreactive with a target antigen, said process comprising:

    
    
        (a) determining the nucleotide sequence encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen; and
        (b) expressing an antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).
    
    


In one embodiment, the antigen binding polypeptide expressed in part (b) is not identical to the Camelidae conventional antibody of part (a).
In one non-limiting embodiment, the invention provides a process for preparing a recombinant antigen binding polypeptide that is immunoreactive with (or specifically binds to) a target antigen, said an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a species in the family Camelidae, said process comprising the steps of:

    
    
        (a) isolating Camelidae nucleic acid encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen;
        (b) preparing a recombinant polynucleotide comprising a nucleotide sequence encoding hypervariable loop(s) or complementarity determining region(s) having amino acid sequence identical to the hypervariable loop(s) or complementarity determining region(s) encoded by the nucleic acid isolated in step (a), which recombinant polynucleotide encodes an antigen binding polypeptide comprising a VH domain and a VL domain that is immunoreactive with (or specifically binds to) said target antigen; and
        (c) expressing said antigen binding polypeptide from the recombinant polynucleotide of step (b).
    
    


In one embodiment, the antigen binding polypeptide expressed in part (c) is not identical to the Camelidae conventional antibody of part (a).
The foregoing methods may be referred to herein as “general processes” for preparing antigen binding polypeptides.
The first step of either process may involve active immunisation of a species in the family Camelidae in order to elicit an immune response against the target antigen, thereby raising camelid conventional antibodies immunoreactive with the target antigen. Protocols for immunisation of camelids are described in the accompanying examples. The antigen preparation used for immunisation may be a purified form of the target antigen, for example recombinantly expressed polypeptide, or an immunogenic fragment thereof. However, it is also possible to immunise with crude preparations of the antigen, such as like isolated cells or tissue preparations expressing or encoding the target antigen, cell lysates, cell supernatants or fractions such as cell membranes, etc., or with, a polynucleotide encoding said target antigen (a DNA immunisation).
The process will typically involve immunisation of animals of a Camelidae species (including, but limited to, llamas and alpacas), and advantageously these animals will belong to an outbred population. However, it is also contemplated to use transgenic animals (e.g. transgenic mice) containing the Camelid conventional Ig locus, or at least a portion thereof.
A topic of increasing interest seems to be the difference between the complementarity determining regions (CDRs) of in vivo and in vitro generated antibodies. The inventors surmise that the in vivo selection has a favourable impact on the immunogenicity, functionality, stability and therefore improved manufacturability of the resulting antibodies, whilst synthetic CDRs generated and selected in vitro may have a disadvantage from this point of view. This is important since a given therapeutic antibody risks to be neutralized by the so called anti-idiotypic antibody response from the patient (Lonberg, Nature Biotechnology, 23: 1117-1125, (2005)).
A key advantage of processes according to the invention based on active immunisation of camelids stems from the fact that all species of Camelidae can be maintained in large outbred populations where the individual animals have a different genetic background. It is therefore possible to use active immunisation to elicit a strong and diverse immune response against the antigen of interest from which a diverse pool of potential antigen binding molecules can be obtained. As illustrated in the accompanying examples, the present inventors have observed that active immunisation of camelids can generate Fab fragments binding to a target antigen with a high degree of immunodiversity. Without wishing to be bound by theory, the inventors surmise that the phylogenetic distance between humans and camelids may be important for production of a diverse immune response against a given target antigen. In contrast, the non-human primates are phylogenetically close to humans, thus targets with high homology between non-human primates and humans may elicit only a limited immune response in terms of strength and diversity in non-human primates.
The ability to use active immunisation in an outbred population which is phylogenetically distant from human would not be particularly advantageous if the antibodies so-produced were to exhibit a low sequence and structural homology with human antibodies such that substantial “protein engineering” would be required to create a candidate antibody with therapeutic potential. It is therefore extremely important that the inventors have shown that the Camelidae germline (and somatically mutated sequences) encodes both VH and VL domains with a very high degree of sequence and structural homology with human VH and VL domains (as explained above). This high degree of homology in combination with the availability of large outbred populations results in a very powerful platform for development of monoclonal antibodies for use as human therapeutics.
Following active immunisation with the target antigen, peripheral blood lymphocytes or biopsies such as lymph nodes or spleen biopsies may be isolated from the immunised animal and screened for production of conventional camelid antibodies against the target antigen. Techniques such as enrichment using panning or FACS sorting may be used at this stage to reduce the complexity of the B cell repertoire to be screened, as illustrated in the examples. Antigen-specific B cells are then selected and used for total RNA extraction and subsequent cDNA synthesis. Nucleic acid encoding the native camelid VH and VL domains (specific for the target antigen) can be isolated by PCR.
It is not essential to use active immunisation in order to identify camelid convention antibodies immunoreactive with a target of interest. In other embodiments it may be possible to make use of the camelid's own immune response, either the immunodiversity naturally present in the animal, or for example a diseased animal or animal which has been naturally exposed to a particular pathogen, e.g. by normal infection routes. In this regard, the invention encompasses the use of non-immune libraries. If “natural” immune responses within the camelid already give rise to antibodies which bind the target antigen of interest, then it is possible to make use of the genetic engineering techniques described herein, and other standard techniques known in the art, in order to culture and isolate B cells producing such antibodies, or produce monoclonal cultures of such antibodies, and/or to determine the nucleotide sequence of the camelid gene segments encoding the VH and/or VL domains of such antibodies. Armed with this sequence information, it is then possible to engineer recombinant DNA constructs encoding antigen binding polypeptides which embody the camelid derived VH and/or VL, or the hypervariable loops (or CDRs) thereof.
Nucleic acid encoding camelid VH and VL domains (whether obtained by active immunisation or by other means) may be cloned directly into an expression vector for the production of an antigen binding polypeptide according to the invention. In particular, these sequences could be cloned into an expression vector which also encodes a human antibody constant region, or a portion thereof, in order to produce a chimeric antibody. However, it is typical to carry out further manipulations on the isolated camelid VH and VL sequences before cloning and expression with human constant region sequences.
As a first step, candidate camelid VH and VL sequences (including sequences isolated following the active immunisation) may be used to prepare a camelid libraries (e.g. Fab libraries, as described in the accompanying examples). The library may then be screened (e.g. using phage display) for binding to the target antigen. Promising lead candidates can be further tested for target antigen binding, for example using Biacore or a suitable bioassay. Finally, the sequences encoding the VH and VL domains of the most promising leads can be cloned as an in-frame fusion with sequences encoding a human antibody constant region.
It is not essential that the polynucleotide sequence used to encode the (camelid-derived) HVs/CDRs (e.g. for recombinant expression of the antigen binding polypeptide of the invention) is identical to the native polynucleotide sequence which naturally encodes the HVs/CDRs in the camelid. Therefore, the invention encompasses/permits codon optimisation, and other changes in polynucleotide sequence related to cloning and/or expression, which do not alter the encoded amino acid sequence.
In certain embodiments, “chain shuffling” may be performed in which a particular variable domain known to bind the antigen of interest is paired with each of a set of variable domains of the opposite type (i.e. VH paired with VL library or vice versa), to create libraries, and the resulting “promiscuous” combinations of VH/VL tested for antigen binding affinity and/or specificity. Alternatively, a library of VH domains could be paired with a library of VL domains, either randomly or in a hierarchical manner, and the resulting combinations tested (see Clackson et al., Nature., Vol. 352. pp 624-638, 1991). In this process, the libraries may be libraries of rearranged VH and VL (Vκ or Vλ) from camelids which display immunity to the antigen of interest (including animals which have been actively immunised). The chain shuffling process can increase immunodiversity and produce pairings with significantly enhanced affinity.
The invention also contemplates performing epitope imprinted selection (so-called “guided selection”) starting from a camelid VH or VL domain, wherein the other variable domain is taken from a non-camelid species, e.g. human. Thus, in one embodiment a camelid VH domain may be “shuffled” with a library of human-encoded VL domains, to replace the native camelid-encoded VL domain, resulting in camelid VH/human VL pairings. One or more of these pairings may then be subjected a second chain shuffling step in which the human VL domain is shuffled against a library of VH domains, which may be human-encoded. This second step may produce human-encoded VH/VL combinations which have the epitope imprint of the original camelid-encoded VH/VL combination.
Also included within the scope of the invention is the reverse “chain shuffling” process, starting with non-camelid (preferably human)-encoded VH/VL domain combination which binds to an antigen of interest. This could be, for example, a fully human therapeutic antibody against a validated disease target. Starting from this VH/VL combination, it is possible to carry out a first round of selection in which the VH domain is “shuffled” with a library of camelid-encoded VL domains (or vice versa), and the pairings tested for antigen binding. Selected non-camelid (e.g. human) VH/camelid VL pairings may then be subjected to a second round of selection in which the camelid-encoded VL is shuffled against a library of camelid-encoded VH, and the resulting pairings tested for antigen binding. As a result, it may be possible to produce a camelid VH/camelid VL combination which carries the epitope imprint of the starting VH/VL combination. This camelid VH/VL combination could be further engineered/modified and combined with human-encoded constant domains as required, using any of the processes described herein.
In the processes of the invention, “native” camelid-derived VH and VL domains may be subject to protein engineering in which one or more selective amino acid substitutions are introduced, typically in the framework regions. The reasons for introducing such substitutions into the “wild type” camelid sequence can be (i) humanisation of the framework region, (ii) improvement in stability, bioavailability, product uniformity, tissue penetration, etc., or (iii) optimisation of target antigen binding.
“Humanisation” of camelid-derived VH and VL domains by selective replacement of one or more amino acid residues in the framework regions may be carried out according to well-established principles (as illustrated in the accompanying examples, and reviewed by Almagro et al. Frontiers in Bioscience 13:1619-1633 (2008), the contents of which are specifically incorporated herein by reference). It will be appreciated that the precise identity of the amino acid changes made to achieve acceptable “humanisation” of any given VH domain, VL domain or combination thereof will vary on a case-by-case basis, since this will depend upon the sequence of the framework regions derived from Camelidae and the starting homology between these framework regions and the closest aligning human germline (or somatically mutated) framework region, and possible also on the sequence and conformation of the hypervariable loops which form the antigen binding site.
The overall aim of humanisation is to produce a molecule in which the VH and VL domains exhibit minimal immunogenicity when introduced into a human subject, whilst retaining the specificity and affinity of the antigen binding site formed by the parental VH and VL domains encoded by Camelidae (e.g. camelid VH/VL obtained by active immunisation). There are a number of established approaches to humanisation which, can be used to achieve this aim. Techniques can be generally classified as either rational approaches or empirical approaches. Rational approaches include CDR-grafting, resurfacing or veneering, superhumanization and human string content optimisation. Empirical approaches include the FR library approach, guided selection, FR shuffling and humaneering. All of these techniques are reviewed in Almagro, Frontiers in Bioscience 2008, ibid. and any of these techniques, or combinations or modifications thereof, can be used to prepare “humanised” antigen binding polypeptides according to the invention.
Methods of Library Construction
In a related aspect, the invention also encompasses a method of producing a library of expression vectors encoding VH and/or VL domains of camelid conventional antibodies, said method comprising the steps:
a) amplifying regions of nucleic acid molecules encoding VH and/or VL domains of camelid conventional antibodies to obtain amplified gene segments, each gene segment containing a sequence of nucleotides encoding a VH domain or a sequence of nucleotides encoding a VL domain of a camelid conventional antibody, and

b) cloning the gene segments obtained in a) into expression vectors, such that each expression vector contains at least a gene segment encoding a VH domain and/or a gene segment encoding a VL domain, whereby a library of expression vectors is obtained.

The above methods of “library construction” may also form part of the general process for production of antigen binding polypeptides of the invention, described above. Hence, any feature described as being preferred or advantageous in relation to this aspect of the invention may also be taken as preferred or advantageous in relation to the general process, and vice versa, unless otherwise stated.
In one embodiment, the nucleic acid amplified in step a) comprises cDNA or genomic DNA prepared from lymphoid tissue of a camelid, said lymphoid tissue comprising one or more B cells, lymph nodes, spleen cells, bone marrow cells, or a combination thereof. Circulating B cells are particularly preferred. The present inventors have surprisingly found that peripheral blood lymphocytes (PBLs) can be used as a source of nucleic acid encoding VH and VL domains of conventional camelid antibodies, i.e. there is sufficient quantity of plasma cells (expressing antibodies) present in a sample of PBLs to enable direct amplification. This is advantageous because PBLs can be prepared from a whole blood sample taken from the animal (camelid). This avoids the need to use invasive procedures to obtain tissue biopsies (e.g. from spleen or lymph node), and means that the sampling procedure can be repeated as often as necessary, with minimal impact on the animal. For example, it is possible to actively immunise the camelid, remove a first blood sample from the animal and prepare PBLs, then immunise the same animal a second time, either with a “boosting” dose of the same antigen or with a different antigen, then remove a second blood sample and prepare PBLs.
Accordingly, a particular embodiment of this method of the invention may involve: preparing a sample containing PBLs from a camelid, preparing cDNA or genomic DNA from the PBLs and using this cDNA or genomic DNA as a template for amplification of gene segments encoding VH or VL domains of camelid conventional antibodies.
In one embodiment the lymphoid tissue (e.g. circulating B cells) is obtained from a camelid which has been actively immunised, as described elsewhere herein. However, this embodiment is non-limiting and it is also contemplated to prepare non-immune libraries and libraries derived from lymphoid tissue of diseased camelids, also described elsewhere herein.
Conveniently, total RNA (or mRNA) can be prepared from the lymphoid tissue sample (e.g. peripheral blood cells or tissue biopsy) and converted to cDNA by standard techniques. It is also possible to use genomic DNA as a starting material.
This aspect of the invention encompasses both a diverse library approach, and a B cell selection approach for construction of the library. In a diverse library approach, repertoires of VH and VL-encoding gene segments may be amplified from nucleic acid prepared from lymphoid tissue without any prior selection of B cells. In a B cell selection approach, B cells displaying antibodies with desired antigen-binding characteristics may be selected, prior to nucleic acid extraction and amplification of VH and VL-encoding gene segments.
Various conventional methods may be used to select camelid B cells expressing antibodies with desired antigen-binding characteristics. For example, B cells can be stained for cell surface display of conventional IgG with fluorescently labelled monoclonal antibody (mAb, specifically recognizing conventional antibodies from llama or other camelids) and with target antigen labelled with another fluorescent dye. Individual double positive B cells may then be isolated by FACS, and total RNA (or genomic DNA) extracted from individual cells. Alternatively cells can be subjected to in vitro proliferation and culture supernatants with secreted IgG can be screened, and total RNA (or genomic DNA) extracted from positive cells. In a still further approach, individual B cells may be transformed with specific genes or fused with tumor cell lines to generate cell lines, which can be grown “at will”, and total RNA (or genomic DNA) subsequently prepared from these cells.
Instead of sorting by FACS, target specific B cells expressing conventional IgG can be “panned” on immobilized monoclonal antibodies (directed against camelid conventional antibodies) and subsequently on immobilized target antigen. RNA (or genomic DNA) can be extracted from pools of antigen specific B cells or these pools can be transformed and individual cells cloned out by limited dilution or FACS.
B cell selection methods may involve positive selection, or negative selection.
Whether using a diverse library approach without any B cell selection, or a B cell selection approach, nucleic acid (cDNA or genomic DNA) prepared from the lymphoid tissue is subject to an amplification step in order to amplify gene segments encoding individual VH domains or VL domains.
Total RNA extracted from the lymphoid tissue (e.g. peripheral B cells or tissue biopsy) may be converted into random primed cDNA or oligo dT primer can be used for cDNA synthesis, alternatively Ig specific oligonucleotide primers can be applied for cDNA synthesis, or mRNA (i.e. poly A RNA) can be purified from total RNA with oligo dT cellulose prior to cDNA synthesis. Genomic DNA isolated from B cells can be used for PCR.
PCR amplification of heavy chain and light chain (kappa and lambda) gene segments encoding at least VH or VL can be performed with FR1 primers annealing to the 5′ end of the variable region in combination with primers annealing to the 3′ end of CH1 or Ckappa/Clambda region with the advantage that for these constant region primers only one primer is needed for each type. This approach enables camelid Fabs to be cloned. Alternatively sets of FR4 primers annealing to the 3′ end of the variable regions can be used, again for cloning as Fabs (fused to vector encoded constant regions) or as scFv (single chain Fv, in which the heavy and light chain variable regions are linked via a flexible linker sequence); alternatively the variable regions can be cloned in expression vectors allowing the production of full length IgG molecules displayed on mammalian cells.
In general the amplification is performed in two steps; in the first step with non-tagged primers using a large amount of cDNA (to maintain diversity) and in the second step the amplicons are re-amplified in only a few cycles with tagged primers, which are extended primers with restriction sites introduced at the 5′ for cloning. Amplicons produced in the first amplification step (non-tagged primers) may be gel-purified to remove excess primers, prior to the second amplification step. Alternatively, promoter sequences may be introduced, which allow transcription into RNA for ribosome display. Instead of restriction sites recombination sites can be introduced, like the Cre-Lox or TOPO sites, that permit the site directed insertion into appropriate vectors.
Amplified gene segments encoding camelid conventional VH and VL domains may then be cloned into vectors suitable for expression of VH/VL combinations as functional antigen binding polypeptides. By way of example, amplified VHCH1/VKCK/VLCL gene segments from pools of B cells (or other lymphoid tissue not subject to any B cell selection) may be first cloned separately as individual libraries (primary libraries), then in a second step Fab or scFV libraries may be assembled by cutting out the light chain fragments and ligating these into vectors encoding the heavy chain fragments. The two step procedure supports the generation of large libraries, because the cloning of PCR products is relatively inefficient (due to suboptimal digestion with restriction enzymes). scFv encoding DNA fragments can be generated by splicing-by-overlap extension PCR (SOE) based on a small overlap in sequence in amplicons; by mixing VH and VL encoding amplicons with a small DNA fragment encoding the linker in a PCR a single DNA fragment is formed due to the overlapping sequences.
Amplicons comprising VH and VL-encoding gene segments can be cloned in phage or phagemid vectors, allowing selection of target specific antibody fragments by using phage display based selection methods. Alternatively amplicons can be cloned into expression vectors which permit display on yeast cells (as Fab, scFv or full length IgG) or mammalian cells (as IgG).
In other embodiments, cloning can be avoided by using the amplicons for ribosome display, in which a T7 (or other) promoter sequence and ribosome binding site is included in the primers for amplification. After selection for binding to target antigen, pools are cloned and individual clones are analyzed. In theory, larger immune repertoires can be sampled using this approach as opposed to a phage display library approach, because cloning of libraries and selection with phage is limited to 1010 to 1012 clones.
When applying B cell sorting, amplicons contain VH or VL-encoding gene segments of individual target specific B cells can be cloned directly into bacterial or mammalian expression vectors for the production of antibody fragments (scFVs or Fabs) or even full length IgG.
In a particular, non-limiting, embodiment of the “library construction” process, the invention provides a method of producing a library of expression vectors encoding VH and VL domains of camelid conventional antibodies, said method comprising the steps:
a) actively immunising a camelid, thereby raising conventional camelid antibodies against a target antigen;
b) preparing cDNA or genomic DNA from a sample comprising lymphoid tissue (e.g. circulating B cells) from said immunised camelid (including, but not limited to, Llama or alpaca);
c) amplifying regions of said cDNA or genomic DNA to obtain amplified gene segments, each gene segment comprising a sequence of nucleotides encoding a VH domain or a sequence of nucleotides encoding a VL domain of a camelid conventional antibody; and
d) cloning the gene segments obtained in c) into expression vectors, such that each expression vector contains a gene segment encoding a VH domain and a gene segment encoding a VL domain and directs expression of an antigen binding polypeptide comprising said VH domain and said VL domain, whereby a library of expression vectors is obtained.
The foregoing methods may be used to prepare libraries of camelid-encoded VH and VL domains (in particular Llama and alpaca VH and VL domains), suitable for expression of VH/VL combinations as functional antigen-binding polypeptides, e.g. in the form of scFVs, Fabs or full-length antibodies.
Libraries of expression vectors prepared according to the foregoing process, and encoding camelid (including but not limited to Llama or alpaca) VH and VL domains, also form part of the subject-matter of the present invention.
In a particular embodiment the invention provides a library of phage vectors encoding Fab or scFV molecules, wherein each Fab or scFV encoded in the library comprises a VH domain of a camelid conventional antibody and a VL domain of a camelid conventional antibody.
In one embodiment the library is a “diverse” library, in which the majority of clones in the library encode VH domains of unique amino acid sequence, and/or VL domains of unique amino acid sequence, including diverse libraries of camelid VH domains and camelid VL domains. Therefore, the majority (e.g. >90%) of clones in a diverse library encode a VH/VL pairing which differs from any other VH/VL pairing encoded in the same library with respect to amino acid sequence of the VH domain and/or the VL domain.
The invention also encompasses expression vectors containing VH and VL-encoding gene segments isolated from a single selected B cell of a camelid (e.g. Llama or alpaca).
In a further aspect, the present invention also provides a method of selecting an expression vector encoding an antigen binding polypeptide immunoreactive with a target antigen, the method comprising steps of:
i) providing a library of expression vectors, wherein each vector in said library comprises a gene segment encoding a VH domain and a gene segment encoding a VL domain, wherein at least one of said VH domain or said VL domain is from a camelid conventional antibody, and wherein each vector in said library directs expression of an antigen binding polypeptide comprising said VH domain and VL domain;

ii) screening antigen binding polypeptides encoded by said library for immunoreactivity with said target antigen, and thereby selecting an expression vector encoding an antigen binding polypeptide immunoreactive with said target antigen.

This method of the invention encompasses screening/selection of clones immunoreactive with target antigen, from a library of clones encoding VH/VL pairings. The method may also encompass library construction, which may be carried out using the library construction method described above. Optional downstream processing/optimisation steps may be carried out on selected clones, as described below. This method of selection and screening, may also form part of the general process for production of antigen binding polypeptides of the invention, described above. Hence, any feature described as being preferred or advantageous in relation to this aspect of the invention may also be taken as preferred or advantageous in relation to the general process, and vice versa, unless otherwise stated.
Screening and Selection of Clones Immunoreactive with Target Antigen
Screening/selection typically involves contacting expression products encoded by clones in the library (ie. VH/VL pairings in the form of antigen binding polypeptides, e.g. Fabs, scFVs or antibodies) with a target antigen, and selecting one or more clones which encode a VH/VL pairings exhibiting the desired antigen binding characteristics.
Phage display libraries may be selected on immobilized target antigen or on soluble (often biotinylated) target antigen. The Fab format allows affinity driven selection due to its monomeric appearance and its monovalent display on phage, which is not possible for scFv (as a consequence of aggregation and multivalent display on phage) and IgG (bivalent format). Two to three rounds of selections are typically needed to get sufficient enrichment of target specific binders.
Affinity driven selections can be performed by lowering the amount of target antigen in subsequent rounds of selection, whereas extended washes with non-biotinylated target enables the identification of binders with extremely good affinities.
The selection procedure allows the user to home in on certain epitopes; whereas the classical method for elution of phage clones from the immobilized target is based on a pH shock, which denatures the antibody fragment and/or target, competition with a reference mAb against the target antigen or soluble receptor or cytokine leads to the elution of phage displaying antibody fragments binding to the relevant epitope of the target (this is of course applicable to other display systems as well, including the B cells selection method).
Individual clones taken from the selection outputs may be used for small scale production of antigen-binding polypeptides (e.g. antibody fragments) using periplasmic fractions prepared from the cells or the culture supernatants, into which the fragments “leaked” from the cells. Expression may be driven by an inducible promoter (e.g. the lac promoter), meaning that upon addition of the inducer (IPTG) production of the fragment is initiated. A leader sequence ensures the transport of the fragment into the periplasm, where it is properly folded and the intramolecular disulphide bridges are formed.
The resulting crude protein fractions may be used in target binding assays, such as ELISA. For binding studies, phage prepared from individual clones can be used to circumvent the low expression yields of Fabs, which in general give very low binding signals. These protein fractions can also be screened using in vitro receptor—ligand binding assays to identify antagonistic antibodies; ELISA based receptor—ligand binding assays can be used, also high throughput assays like Alphascreen are possible. Screening may be performed in radiolabelled ligand binding assays, in which membrane fractions of receptor overexpressing cell lines are immobilized; the latter assay is extremely sensitive, since only picomolar amounts of radioactive cytokine are needed, meaning that minute amounts of antagonistic Fabs present in the crude protein fraction will give a positive read-out. Alternatively, FACS can be applied to screen for antibodies, which inhibit binding of a fluorescently labelled cytokine to its receptor as expressed on cells, while FMAT is the high throughput variant of this.
Fabs present in periplasmic fractions or partially purified by IMAC on its hexahistidine tag or by protein G (known to bind to the CH1 domain of Fabs) can be directly used in bioassays using cells, which are not sensitive to bacterial impurities; alternatively, Fabs from individual E. coli cells can be recloned in mammalian systems for the expression of Fabs or IgG and subsequently screened in bioassays.
Following identification of positive expression vector clones, i.e. clones encoding a functional VH/VL combination which binds to the desired target antigen, it is a matter of routine to determine the nucleotide sequences of the variable regions, and hence deduce the amino acid sequences of the encoded VH and VL domains.
If desired, the Fab (or scFV) encoding region may be recloned into an alternative expression platform, e.g. a bacterial expression vector (identical to the phagemid vector, but without the gene 3 necessary for display on phage), which allows larger amounts of the encoded fragment to be produced and purified.
The affinity of target binding may be determined for the purified Fab (or scFV) by surface plasmon resonance (e.g. Biacore) or via other methods, and the neutralizing potency tested using in vitro receptor—ligand binding assays and cell based assays.
Families of antigen-binding, and especially antagonistic Fabs (or scFVs) may be identified on the basis of sequence analysis (mainly of VH, in particular the length and amino acid sequence of CDR3 of the VH domain).
Potency Optimisation
Clones identified by screening/selection as encoding a VH/VL combination with affinity for the desired target antigen may, if desired, be subject to downstream steps in which the affinity and/or neutralising potency is optimised.
Potency optimization of the best performing member of each VH family can be achieved via light chain shuffling, heavy chain shuffling or a combination thereof, thereby selecting the affinity variants naturally occurring in the animal. This is particularly advantageous in embodiments where the original camelid VH/VL domains were selected from an actively immunised camelid, since it is possible to perform chain shuffling using the original library prepared from the same immunised animal, thereby screening affinity variants arising in the same immunised animal.
For light chain shuffling the gene segment encoding the VH region (or VHCH1) of VH/VL pairing with desirable antigen binding characteristics (e.g. an antagonistic Fab) may be used to construct a library in which this single VH-encoding gene segment is combined with the light chain repertoire of the library from which the clone was originally selected. For example, if the VH-encoding segment was selected from a library (e.g. Fab library) prepared from a camelid animal actively immunised to elicit an immune response against a target antigen, then the “chain shuffling” library may be constructed by combining this VH-encoding segment with the light chain (VL) repertoire of the same immunised camelid. The resulting library may then be subject to selection of the target antigen, but under stringent conditions (low concentrations of target, extensive washing with non-biotinylated target in solution) to ensure the isolation of the best affinity variant. Off-rate screening of periplasmic fractions may also assist in the identification of improved clones. After sequence analysis and recloning into a bacterial production vector, purified selected Fabs may be tested for affinity (e.g. by surface plasmon resonance) and potency (e.g. by bioassay).
Heavy chain shuffling can be performed by cloning back the gene segment encoding the light chain (VL) of a clone selected after light-chain shuffling into the original heavy chain library from the same animal (from which the original VH/VL-encoding clone was selected). Alternatively a CDR3 specific oligonucleotide primer can be used for the amplification of the family of VH regions, which can be cloned as a repertoire in combination with the light chain of the antagonistic Fab. Affinity driven selections and off-rate screening then allow the identification of the best performing VH within the family.
It will be appreciated that the light chain shuffling and heavy chain shuffling steps may, in practice, be performed in either order, i.e. light chain shuffling may be performed first and followed by heavy chain shuffling, or heavy chain shuffling may be performed first and followed by light chain shuffling. Both possibilities are encompassed within the scope of the invention.
From light chains or heavy chains of VH/VL pairings (e.g. Fabs) with improved affinity and potency the sequences of, in particular, the CDRs can be used to generate engineered variants in which mutations of the individual Fabs are combined. It is known that often mutations can be additive, meaning that combining these mutations may lead to an even more increased affinity.
Germlining and Formatting for Human Therapeutic Use
The VH and VL-encoding gene segments of selected expression clones encoding VH/VL pairings exhibiting desirable antigen-binding characteristics (e.g. phage clones encoding scFVs or Fabs) may be subjected to downstream processing steps and recloned into alternative expression platforms, such as vectors encoding antigen binding polypeptide formats suitable for human therapeutic use (e.g. full length antibodies with fully human constant domains).
Promising “lead” selected clones may be engineered to introduce one or more changes in the nucleotide sequence encoding the VH domain and/or the VL domain, which changes may or may not alter the encoded amino acid sequence of the VH domain and/or the VL domain. Such changes in sequence of the VH or VL domain may be engineered for any of the purposes described elsewhere herein, including germlining or humanisation, codon optimisation, enhanced stability, optimal affinity etc.
The general principles germlining or humanisation described herein apply equally in this embodiment of the invention. By way of example, lead selected clones containing camelid-encoded VH and VL domains may be germlined/humanised in their framework regions (FRs) by applying a library approach. After alignment against the closest human germline (for VH and VL) and other human germlines with the identical canonical folds of CDR1 and CDR2, the residues to be changed in the FRs are identified and the preferred human residue selected, as described elsewhere herein in detail. Whilst germlining may involve replacement of camelid-encoded residues with an equivalent residue from the closest matching human germline this is not essential, and residues from other human germlines could also be used.
The germlining of a VH domain having an amino acid sequence homologous to a member of the human VH3 family will often involve replacement/substitution of a number of residues, which already deviate in publically known Lama glama, Lama pacos or Camelus dromedarius derived germline sequences. Permitted amino acid substitutions for germlining/humanisation of a VH3 domain of Lama glama, Lama pacos or Camelus dromedarius, and in particular Lama glama include, but are not limited to, amino acid replacements at any one or any combination of positions 71, 83 and 84 in the framework region (using Kabat numbering). Such replacement(s) will involve substitution of the camelid-encoded residue(s) at these positions with a different amino acid, which may be a natural or non-natural amino acid, and is preferably an amino acid known to occur at the equivalent position in a human-encoded VH3 domain. For example, Alanine at position 71 might be replaced with serine or alanine, Lysine at position 83 might be replaced with Arginine and Proline at position 84 might be replaced with Alanine. Accordingly, particular non-limiting embodiments of the antigen binding polypeptide of the invention include variants comprising a camelid (and more specifically llama, alpaca or dromedary) VH domain exhibiting sequence homology to a human VH3 domain, which VH domain includes amino acid substitutions (versus the camelid-encoded sequence) at one or more or all of positions 71, 83 and 84 (using Kabat numbering). In particular, variants with one or more or any combination of the following substitutions are permitted: A changed to S at position 71, K changed to R at position 83 or P changed to A at position 84.
Once the amino acid sequences of the lead VH and VL domains (following potency optimisation, as appropriate) are known, synthetic genes of VH and VL can be designed, in which residues deviating from the human germline are replaced with the preferred human residue (from the closest matching human germline, or with residues occurring in other human germlines, or even the camelid wild type residue). At this stage the gene segments encoding the variable domains may be re-cloned into expression vectors in which they are fused to human constant regions of the Fab, either during gene synthesis or by cloning in an appropriate display vector.
The resulting VH and VL synthetic genes can be recombined into a Fab library or the germlined VH can be recombined with the wild type VL (and vice versa, referred to as “hybrid” libraries). Affinity-driven selections will allow the isolation of the best performing germlined version, in case of the “hybrid” libraries, the best performing germlined VH can be recombined with the best performing germlined VL.
Amino acid and nucleotide sequence information for the germlined Fabs can be used to generate codon-optimized synthetic genes for the production of full length human IgG of the preferred isotype (IgG1 for ADCC and CDC, IgG2 for limited effector functions, IgG4 as for IgG2, but when monovalent binding is required). For non-chronic applications and acute indications bacterially or mammalian cell produced human Fab can produced as well.
Combining steps of the above-described processes, in a particular non-limiting embodiment the present invention provides a method of producing an expression vector encoding a chimeric antigen binding polypeptide immunoreactive with a target antigen, said method comprising the steps of:
a) actively immunising a camelid (including but not limited to Llama or alpaca), thereby raising conventional camelid antibodies against a target antigen;
b) preparing cDNA or genomic DNA from a sample comprising lymphoid tissue (e.g. circulating B cells) from said immunised camelid;
c) amplifying regions of said cDNA or genomic DNA to obtain amplified gene segments, each gene segment comprising a sequence of nucleotides encoding a VH domain or a sequence of nucleotides encoding a VL domain of a camelid conventional antibody;
d) cloning the gene segments obtained in c) into expression vectors, such that each expression vector contains a gene segment encoding a VH domain and a gene segment encoding a VL domain and directs expression of an antigen binding polypeptide comprising said VH domain and said VL domain, thereby producing a library of expression vectors;

e) screening antigen binding polypeptides encoded by the library obtained in step d) for immunoreactivity with said target antigen, and thereby selecting an expression vector encoding an antigen binding polypeptide immunoreactive with said target antigen;

f) optionally performing a light chain shuffling step and/or a heavy chain shuffling step to select an expression vector encoding a potency-optimised antigen binding polypeptide immunoreactive with said target antigen;

g) optionally subjecting the gene segment encoding the VH domain of the vector selected in step e) or step f) and/or the gene segment encoding the VL domain of the vector selected in step e) or step f) to germlining and/or codon optimisation; and

h) cloning the gene segment encoding the VH domain of the vector selected in part e) or f) or the germlined and/or codon optimised VH gene segment produced in step g) and the gene segment encoding the VL domain of the vector selected in part e) or f) or the germlined and/or codon optimised VL gene segment produced in step g) into a further expression vector, in operable linkage with a sequence of nucleotides encoding one or more constant domains of a human antibody, thereby producing an expression vector encoding a chimeric antigen binding polypeptide comprising the VH and VL domains fused to one or more constant domains of a human antibody.

The invention also extends to expression vectors prepared according to the above-described processes, and to a method of producing an antigen binding polypeptide immunoreactive with a target antigen, the method comprising steps of:
a) preparing expression vector encoding an antigen binding polypeptide immunoreactive with a target antigen using the method described above;
b) introducing said expression vector into host cell or cell-free expression system under conditions which permit expression of the encoded antigen binding polypeptide; and
c) recovering the expressed antigen binding polypeptide.
In one embodiment, the latter process encompasses bulk production-scale manufacture of the antigen-binding polypeptide of the invention, particularly bulk-scale manufacture of therapeutic antibodies intended for use as pharmaceutically active agents, by recombinant expression. In such embodiments, the expression vector prepared in step a) and the host cell/expression system used in step b) are selected to be suitable for large-scale production of recombinant antibodies intended for administration to human patients. The general characteristics of suitable vectors and expression systems for this purpose are well known in the art.
The invention will be further understood with reference to the following non-limiting experimental examples.
Examples 1 to 9 illustrate the process of raising an antibody against an example antigen denoted “cytokine x”, starting from immunization of llamas. The same general protocol can be adapted for any target antigen in any camelid species, hence the precise identity of “cytokine x” is not material. The process is also illustrated for preparation of Fabs binding IL-1 Beta (Example 15 onwards).
Various publications are cited in the foregoing description and throughout the following examples, each of which is incorporated by reference herein in its entirety.
General Protocol
Example 1
Immunization of Llamas
Immunizations of llamas (Lama glama) and harvesting of peripheral blood lymphocytes as well as the subsequent extraction of RNA and amplification of antibody gene fragments were performed as described by De Haard and colleagues (De Haard et al., J. Bact. 187: 4531-4541 (2005)). One llama was immunized intramuscularly with recombinant human Cytokine x using Freund's complete adjuvant or an appropriate animal-friendly adjuvant Stimune (Cedi Diagnostics BV, The Netherlands). Cytokine x (recombinantly expressed in engineered human cell line) was purchased. Prior to immunization the lyophilized cytokine x was reconstituted in PBS (Dulbecco) at a concentration of 250 μg/ml. The llama received 6 injections at weekly intervals, the first two injections with 100 μg of cytokine per injection, the four last injections with 50 μg for each boost. Four days after the last immunization a blood sample (PBL1) of 150 ml was collected from the animal and serum was prepared. Ten days after the last immunization a second blood sample (PBL2) of 150 ml was taken and serum was prepared. Peripheral blood lymphocytes (PBLs), as the genetic source of the llama immunoglobulins, were isolated from the blood sample using a Ficoll-Paque gradient (Amersham Biosciences) yielding between 1 and 5×108 PBLs. The maximal diversity of antibodies is expected to be equal to the number of sampled B-lymphocytes, which is about 10% (between 9.2-23.2% (De Genst et al., Dev. Comp. Immunol. 30:187-98 (2006)) of the number of PBLs (1−5×107). The fraction of conventional antibodies in llama serum is up to 80% of the amount of total immunoglobulin, which might be extrapolated to a similar fraction of B-lymphocytes that produce the conventional antibodies. Therefore, the maximal diversity of conventional antibodies in the 150 ml blood sample is calculated as 0.8−4×107 different molecules. Total RNA was isolated from PBLs according to the method of Chomczynski et al. Anal. Biochem. 162:156-159 (1987)).
Example 2
Enrichment of Antigen Reactive B Cells by Panning or FACs Sorting (Optional)
In order to reduce the complexity of the sampled B cell repertoire enabling the efficient cloning of the recombinatorial Fab phage display library, antigen reactive B cells were enriched by a FACS sorting (Weitkamp et al., J. Immunol. Meth. (2003) 275: 223-237) using fluorescently labelled antigen and a mAb recognizing camelid conventional antibody specifically (as B cell marker) or by a panning procedure on immobilized antigen (Lightwood et al., J. Immunol. Meth. 316:133-143 (2006)).
PBLs from immunized animals were isolated via a density centrifugation on Ficoll-Paque as described above. Optionally co-purified red blood cells were lysed by resuspending the PBL pellet in 20 ml of lysis buffer (8.29 g/L NH4Cl, 1.09 g/L KHCO3 and 37 mg/L EDTA) at room temperature followed by centrifugation for 10 minutes at 200×g. Optional was also the depletion of monocytes by adhering these to the plastic surface of TI50 culture flask. To achieve this cells were resuspended in 70 ml RPMI (Invitrogen) supplemented with 10% foetal calf serum, Glutamax, 25 mM Hepes, penicillin-streptomycin (Invitrogen) and 0.38% sodium citrate and incubated for 2 hours at 37° C. and 5% CO2 in the flasks. The supernatant fraction containing the B selected was recovered and cells were counted.
Bulk sorting in FACS of (living) B cells displaying target specific conventional antibodies was performed by simultaneous staining with the fluorescently labeled mAb specifically recognizing camelid conventional antibodies and target antigen, labeled with yet another fluorescent dye. Between 1,000 and 100,000 antigen specific cells were sorted and used for RNA extraction by applying the protocol of Gough and colleagues (Gough, Anal. Biochem. 173:93-95 (1988)) or by using the TRIzol kit (Invitrogen). Total RNA was converted into random primed cDNA as template for the amplification of the antibody heavy and light chain variable genes (see Example 3 and further).
Example 3
Amplification and Cloning of Variable Region Genes
Random primed cDNA was prepared from 80 μg of PBL RNA using the superscript III First-Strand Synthesis System for RT-PCR (Invitrogen). RNA was heat-denatured for 5 min at 65° C. in the presence of 2.5 μM of random hexanucleotide primer and 500 μM dNTPs in 8 independent reaction of 20 ul reaction. Subsequently, buffer and dithiothreitol were added according to the supplier's instructions, as well as 640 units of RNasOUT (40 units/μl, Invitrogen), and 3200 units of SuperscriptIII reverse transcriptase (200 units/μl; Invitrogen) in a total final volume of 8×40 μl. After 50 min at 50° C., 5 min at 85° C. and 1 min at 1° C. RNAse H was added ( ̃4U) and incubated for 20 min at 37° C. The pooled cDNA was cleanup using QIAquick PCR Purification Kit according to supplier's recommendation and used for PCR.
Primers annealing to the 3′ end of CH1 and 5′ and 3′ end of VH were designed on the basis of germline sequences from llama and dromedary, for which the deposited sequences could be retrieved from IMGT and other databases following the citations from De Genst and colleagues (De Genst et al, Dev. Comp. Immunol. 30:187-198 (2006)). For design of oligonucleotides for amplification of the light chain the rearranged and somatically mutated dromedary sequences were used that were published in a thesis study (I. Legssyer, Free University Brussels).
All primary PCRs were carried out with separate BACK primers annealing to the 5′ end of the variable region and combined with FOR primers annealing to the 3′ end of CH1, on relatively large amounts of random primed cDNA as template (up to 2.5 μl corresponding to 6 μg of total RNA) to maintain maximal diversity. The heavy chain derived amplicons can be reamplified with a combination of JHFOR primers, annealing to the 3′ end of VH and containing a naturally occurring BstEII site, and SfiI-tagged VHBACK primers annealing to the 5′ end of the VH gene, and subsequently cloned as VH fragments. The light chain V-genes were obtained by PCR with a set of CKFOR or CLFOR primer annealing to the 3′ end of the constant domain and BACK primers priming at the 5′ end of the V-regions. The amplicons from the first PCR reactions were reamplified with extended CH1FOR (containing a NotI site) or CKFOR and CLFOR primers (containing an AscI site) and subsequently cloned as llama Fab fragments. Alternatively, the DNA segments can be reamplified with primers tagged with restriction sites (FOR primers with AscI site and FR4 based BACK primers with XhoI site) and cloned as VL fragments thus creating chimeric Fab's containing llama derived V regions combined with human C regions.
PCR was performed in a volume of 50 μl reactions using Phusion polymerase (Finnzymes) and 500 pM of each primer for 28 cycles (1 min at 96° C., 1 min at 60° C., and 1 min at 72° C. All products were purified from agarose gel with the QIAex-II extraction kit (Qiagen). As input for reamplification to introduce restriction sites, 100-200 ng of purified DNA fragment was used as template in a 100-μl reaction volume. The large amount of input, ensuring the maintenance of variability, was checked by analysis of 4 μl of the “unamplified” PCR mixture on agarose gel.
Example 4
Construction of the Primary and Secondary Camelid Fab Repertoires
For the construction of the primary heavy chain and the two primary light chain repertoires, the PCR products, appended with restriction sites, were gel-purified prior to digestion and the different VH, VK, and VL families combined into three groups. The VHCH1 fragments were digested with SfiI and NotI and the VKCK and VLCL fragments were digested with ApaLI and AscI, and cloned into the phagemid vector pCB3 (similar to vector pCES1 with adapted multiple cloning site). The digested fragment (1 to 2 μg) were ligated to digested and purified PCB3 (2 to 4 μg) using T4-DNA ligase (Fermentas) at room temperature for several hours and then at 37° C. for 1-2 hours. The desalted ligation mixture for light or heavy chain pools was used for electroporation of the E. coli strain TG1, to create the one-chain libraries.
Alternatively, the VH fragments, 1.5 μg in total, may be digested with SfiI and BstEII (present in the VH) and ligated in a 100-200-μl reaction mixture with 9 units of T4-DNA ligase at room temperature to 4 μg, gel-purified vector PCB4 (similar to vector PCB3, but with the pill gene deleted). In addition, the VH gene segments may be cloned via SfiI and BstEII and the VK/VL gene segments via ApaLI and XhoI, yielding the chimeric Fd and VKCK and VLCL.
The Fab library was obtained by cloning of light chain fragments, digested from plasmid DNA prepared from the light chain repertoires, into the plasmid collection containing the heavy chain repertoires. Plasmid DNA, isolated from at least 3×109 bacteria of the VL library (the donor vector), was digested with ApaLI and AscI for cloning of the gel purified DNA fragments in the acceptor vector that already contained the heavy chain libraries, thus creating a separate Fab library with kappa light chains and another library consisting of Fabs with a lambda light chain with a size of 1-10×109 clones. Similarly, the VLCL or VKCK from the single chain library can be extracted from agarose gel using ApaLI/AscI and cloned into the VHCH library vector using the same restriction site.
Example 5
Selection of the Library
The rescue of phagemid particles with helper phage M13-KO7 or VCSM-13 was performed on 2-liter scale, using representative numbers of bacteria from the library for inoculation, to ensure the presence of at least 10 bacteria from each clone in the start inoculum. For selections, 1013 colony-forming units were used with antigens immobilized in immunotubes (Maxisorp tubes, Nunc) or in 96 wells microtiterplates (Maxisorp, Nunc) or with soluble biotinylated antigens. The amount of the immobilized antigens was reduced 10-100 fold during subsequent selection rounds, starting at 10 μg/ml at round 1. Antigens were biotinylated at a ratio of 3 to 10 molecules of NHS-Biotin (Pierce) per molecule of antigen according to the supplier's recommendations and tested for their bioactivity in a bioassay. Unless stated otherwise, the antigens were used for selection at concentrations of 1 to 10 nM during round 1 and 10 pM to 1 nM during subsequent rounds.
Example 6
Screening for Antagonistic Cytokine x Specific Fab's
Soluble Fab was produced from individual clones as described in Marks et al. (Marks et al., J. Mol. Biol. 222:581-597 (1991)), but preferably as monoclonal phage (Lee et al., Blood 108:3103-3111 (2006)) to boost the sensitivity. Culture supernatants containing soluble Fab or Fab displaying phage were tested in ELISA with directly coated antigen or captured via immobilized streptavidin. Recombinant human cytokine x and streptavidin were coated at 10 μg/ml in 0.1 M NaHCO3, pH 9.6, for 16 h at 4° C. Following 3 washes with PBS, 0.1% (v/v) Tween 20, biotinylated antigen was added for 30 to 60 minutes at room temperature at a concentration of 0.5 μg/ml. The plates were blocked during 30 min at room temperature with 2% (w/v) semi-skim milk powder (Marvel) in PBS or with 1% casein solution (in PBS). The culture supernatant was diluted 1- or 5-fold in 2% (w/v) Marvel/PBS and incubated 2 h; bound Fab was detected with anti-myc antibody 9E10 (5 μg/ml) recognizing the myc-peptide tag at the carboxyl terminus of the heavy Fd chain, and rabbit anti-mouse-HRP conjugate (Dako). Following the last incubation, staining was performed with tetramethylbenzidine and H2O2 as substrate and stopped by adding 0.5 volume of 1M H2SO4; the optical density was measured at 450 nm. Clones giving a positive signal in ELISA (over 2 times background), were analyzed by BstNI or HinfI fingerprinting of the PCR products obtained by amplification with the oligonucleotide primers M13-reverse and geneIII-forward (4) or of the separate Fd and VKCK or VLCL amplicons.
Screening for the Fab's capacity to interfere with binding of cytokine x to its receptor was performed in an appropriate receptor—ligand binding ELISA. For this, low amounts of biotinylated cytokine x were incubated with Fab in culture supernatant on cytokine x-Receptor coated plates and bound cytokine x was subsequently detected with streptavidin-HRP conjugate. Positive hits were sequenced and Fab purified for determining their potency (IC50) in the in vitro receptor—ligand assay and to assess their affinity in BIAcore on immobilized cytokine x.
Large scale induction of soluble Fab fragments from individual clones was performed on a 50-ml or 250-ml scale in 2×TY containing 100 μg/ml carbenicillin and 2% glucose. After growth at 37° C. to an OD600 of 0.9, the cells were pelleted (10 min at 2,934×g) and resuspended in 2×TY with carbenicillin and 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG). Alternative the De Bellis procedure (De Bellis and Schwartz, NAR (1990) 18(5): 1311) was followed using 0.2% in stead of 2% glucose, thus permitting the direct addition of IPTG to the medium of the late log phase cells. Bacteria were harvested after 3.5 h of growth at 30° C. by centrifugation (as before); periplasmic fractions were prepared by resuspending the cell pellet in 1 ml of ice-cold PBS. After 2-16 h of rotating head-over-head at 4° C., the spheroplasts were removed by two centrifugation steps; after spinning during 10 min at 3,400×g, the supernatant was clarified by an additional centrifugation step during 10 min at 13,000×g in an Eppendorf centrifuge. The periplasmic fraction obtained was directly used in the different functional assays (target binding ELISA, in vitro receptor—ligand binding assays and Biacore).
For sequencing, plasmid DNA was prepared from 5-ml cultures grown at 30° C. in LB-medium, containing 100 μg/ml carbenicillin and 2% glucose, using the Qiagen Mini-kit (Qiagen) or on amplicons with vector primers M13-reverse and geneIII-forward, which anneal at the borders of the Fab insert.
Example 7
Large Scale Production and Purification of Lead Fab's
Fab inserts from 3 to 6 different leads were recloned via ApaLI—NotI in an expression vector (coded pCB5) identical to pCB3 including the hexahistidine and C-MYC tags fused to the carboxyterminus of the Fd, but lacking the bacteriophage M13 gene3. In parallel the V regions were recloned with the appropriate combination of restriction enzymes and sequentially cloned in gene3 deleted vectors containing human CH1 and CK or CL for the expression of chimeric Fabs. After fingerprint analysis, individual clones obtained after recloning were grown on 50-ml or 250-ml scale and periplasmic fractions were prepared as described above. Fab fragment was IMAC purified and the correctly formed Fab was further purified via Size Exclusion Chromatography using a Superdex 75HR column (Amersham Pharmacia Biotech). Depending on the cell based assay endotoxin was removed by passage over an anion exchange column (Source30Q, GE Healthcare), which was sensitized overnight in 1 M NaOH and subsequently equilibrated in D-PBS. The yield was determined by measuring the optical density at 280 nm using a molar extinction coefficient of 13 for Fabs.
The purified Fab's were tested in the in vitro receptor—ligand binding assay and Biacore to confirm the observations made with the Fab fragment as produced by the gene3 containing pCB3 vector. Finally the potency of the Fab was determined in the bioassay.
Example 8
In this example the llama derived lead Fabs against cytokine x were humanized by using a soft randomization procedure targeting a small set of framework residues and by monovalent display of the resulting Fab library on the surface of filamentous phage in order to identify high affinity framework sequences via affinity based selection (US2003/0190317 A1, incorporated herein by reference). For instance, for dromedary derived germline VH (IGHV1S20) a small library was generated for positions 5 (Val, Leu), 55 (Gly, Ala), 83 (Ala, Ser), 95 (Lys, Arg), 96 (Ser, Ala) and 101 (Met, Val) maintaining 70% of the wild type residues (IMGT numbering). Amino acids in the hypervariable loops could be addressed in a similar way.
Site-directed mutagenesis to correct PCR errors or to introduce additional specific single codon changes was performed essentially as described by Kunkel et al. Curr. Protoc. Mol. Biol. CH8U8.1 (2001) or alternatively Synthetic genes encoding the variants ordered from GeneArt. The template for site-directed experiments was single-stranded DNA from a humanized Fab clone.
Site directed mutagenesis was also used to directly change a limited number of amino acid codons for humanization or modification purposes in the DNA encoding the wild type or humanized Fabs.
After selection the individual leads were tested on affinity and potency and the best leads were chosen for reformatting into human Fab/IgGs.
Example 9
Expression of Human Fab Fragments and Human Monoclonal Antibodies
Starting from the humanized VH and VL regions expression of humanized Fabs was performed as described in Rauchenberger et al. J. Biol. Chem. 278:38194-204 (2003). For the expression of human monoclonal antibodies two separate expressions vectors, one for the light chain and one for the heavy chain construct were constructed based on the pcDNA 3.1 vector. The expression vector for the light chain contained either the human C kappa or human C lambda sequence downstream of a CMV promoter as well as restriction sites allowing the cloning of the light chain construct as KPN1 BsmB1 fragments downstream of the CMV promoter and in frame with the light chain constant domain. The expression vector for the heavy chain contained then human CH1-hinge-CH2-CH3 sequence downstream of a CMV promoter as well as restriction sites allowing the cloning of the VH construct as KPN1 BsmB1 fragments downstream of the CMV promoter and in frame with the heavy chain constant domains.
The VL and VH fragments were cloned into the appropriate expression vectors as KPN1 BsmB1 fragments containing the Kozak sequence followed by the mouse IgG kappa leader sequences in frame with the respective VL or VH sequence. These sequences were obtained by gene synthesis and optimized for expression in mammalian cells (Geneart).
For full length IgG production VH and VL expression vectors constructs were co-transfected into mammalian cells (HEK-293 (transient) or CHO(stable)). Supernatant from transiently transfected cells or from stably transfected cells was purified via protein A chromatography.
Monoclonal antibodies or Fabs were tested in receptor binding assays and in bioassays and the best leads were selected for further development.
Example 10
Camelid vs Human Homology Analysis
Methodology
Sequences of germline llama and dromedary J regions, which encode for FR4 were compared with human sequences and were completely identical (10 out of 10 residues match); the only exception is IGHJ4, which contains Glutamine (instead of Leucine or Methionine) on position 6 in FR4 (alignments shown below). For somatically mutated VLambda FR4 from dromedary 9 out of 10 residues match (90% homology), since most of the available sequences have Histidine in stead of Lysine or Glutamate or Glutamine on position 6 (alignment shown below). Finally there is again 90% identity (9 out of 10 residues) in FR4 of the set of six available somatically mutated dromedary VKappa sequences, because position 3 residue Serine deviates from what is found in the human germline JK segments, i.e. Glutamine, Proline and Glycine (alignment shown below).
For VH, VLambda and VKappa the analysis is supported by alignments (see below). Sequence alignment was done with closest human germline sequence, having identical H1 and H2 canonical folds.
Residues which don't align, but which appear in another family member (or subclass) of the same germline are considered as homologous, based on the assumption that it is feasible to mutate them back to said closest human germline sequence.
Canonical structures are compared using the following programs: www.bioinf.ora.uk/abs/chothia and www.bioc.unizh ch/antibody/Sequences/GermlinesNBase_hVK. Residues of analyzed camelid antibodies (or from other species) which do not fit exactly the canonical fold algorithm are checked for their appearance in the sequence of members of the matching human germline family with the same combination of canonical folds, or mentioned residues allowing the folds are checked for their appearance within the family of camelid antibodies to which the analyzed antibody belongs.
Results are presented in the following sections:
10.1—Dromedary VH
10.2—Lama glama VH
10.3—VL 1-40
10.4—VL 2-18
10.5—VL 3-1
10.6—VL 3-12
10.7—VKappa 2-40
10.8—J(H) region comparisons of llama and human
10.9—Comparison of light chain J regions
10.10—Lama pacos VH germline homology
10.11—Lama glama derived VH homology analysis
10.12—Lama glama derived VL analysis










10.1 Dromedary VH (SEQ ID NOS: 1-20)
















IGHV
         FR1-IMGT          CDR1-IMGT 


gene
          (1-26)            (27-38) 






1       10        20         30



.........|.........|...... ...|........


 


M99679, IGHV3-53
EVQLVESGG.GLIQPGGSLRLSCAAS GFTVSSNY....


AF000603, IGHV1S1
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245151, IGHV1S2
QVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245152, IGHV1S3
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245153, IGHV1S4
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245154, IGHV1S5
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245155, IGHV1S6
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245157, IGHV1S7
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYD....


AJ245158, IGHV1S8
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245159, IGHV1S9
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245160, IGHV1S10
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSGYY....


AJ245164, IGHV1S11
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245165, IGHV1S12
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....


AJ245167, IGHV1S13
AVQLVESGG.GSVQAGGSLRLSCAAS GFTFSSYY....


AJ245168, IGHV1S14
QVQLVESGG.GSVQAGGSLRLSCAAS GFTFSSYY....


AJ245170, IGHV1S15
AVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW....


AJ245171, IGHV1S16
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW....


AJ245173, IGHV1S17
QVQLVESGG.GSVQAGGSLRLSCAAS GFTFSSYD....


AJ245174, IGHV1S18
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYA....


AJ245156, IGHV1S19
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY....





IGHV
    FR2-IMGT      CDR2-IMGT    FR3-IMGT


gene
    (39-55)        (56-65)     (66-104)






40        50         60         70 



.|.........|..... ....|..... ....|.....


 


M99679, IGHV3-53
MSWVRQAPGKGLEWVSV IYSGGST... YYADSVK.GR


AF000603, IGHV1S1
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245151, IGHV1S2
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245152, IGHV1S3
MSWARQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245153, IGHV1S4
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245154, IGHV1S5
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245155, IGHV1S6
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245157, IGHV1S7
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245158, IGHV1S8
MSWVRKAQGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245159, IGHV1S9
MSWVRQAPGKGLEWVSS NTSDGST... YYGDSVK.GR


AJ245160, IGHV1S10
MSWVRQAPGRGLEWVSG IYSDGGT... YYGDSVR.GR


AJ245164, IGHV1S11
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245165, IGHV1S12
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245167, IGHV1S13
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245168, IGHV1S14
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245170, IGHV1S15
MYWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245171, IGHV1S16
MYWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR


AJ245173, IGHV1S17
MSWVRQAPGKGLEWVSA IYSDGST... NYADSVK.GR


AJ245174, IGHV1S18
MSWVRQAPGKGLEWVSA INSRGST... HYADSMK.GR


AJ245156, IGHV1S19
MSWVRQAPGKGLEWVSG IYSDGST... YYGDSVK.GR





ICHV
      FR3-IMGT                 CDR3-IMGT


gene
      (66-104)                 (105-115)






   80        90        100       110



....|.........|.........|.... .....|.....


 


M99679, IGHV3-53
FTISRDNSKNTLYLQMNSLRAEDTAVYYC AR.........


AF000603, IGHV1S1
FTISRDNAKNMLYLQMNSLKPEDTAVYYC AG.........


AJ245151, IGHV1S2
FTISRDNAKNMLYLQMNSLKPEDTAMYYC


AJ245152, IGHV1S3
FTISRDNAKNMLYLQMNSLKPEDTAMYYC


AJ245153, IGHV1S4
FTISRDNAKNTLYLQMNSLKPEDTAMYYC


AJ245154, IGHV1S5
FTISRDNAKNMLYLQVNSLKPEDTAVYYC


AJ245155, IGHV1S6
FTISRDNAKHMLYLQMHSLKPEDTAMYYC


AJ245157, IGHV1S7
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245158, IGHV1S8
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245159, IGHV1S9
FTISRDNAKNMLYLQMNSLKPEDTAMYYC


AJ245160, IGHV1S10
FTISRDNAKNMLYLQMNSLKPEDTAMCYC


AJ245164, IGHV1S11
FTISRDKAKNMLYLQMNSLKPEDTSMYYC


AJ245165, IGHV1S12
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245167, IGHV1S13
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245168, IGHV1S14
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245170, IGHV1S15
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245171, IGHV1S16
FTISRDKAKNMLYLQMNSLKPEDTAMYYC


AJ245173, IGHV1S17
FTISRDNAKNTVYLQMNSLKPEDTAMYYC


AJ245174, IGHV1S18
FTISRDNAKNVLYLQMNSLKPEDTAMYYC


AJ245156, IGHV1S19
FTISQDNAKNTVYLQMNSLKPEDTAMYYC










A) Sequence comparisons


Sequences in comparison to human IGHV3-23 and other human germlines:








 55 G/S/A
can be considered more variable/beginning of CDR2


 68 G
also human A exist in the same context (IGHV1S17/18) ->



should be replacebale by A


 83 A
present in many other human VH3 class germlines


 86 M/V
also human T exist in the same context -> should be



replacebale by T


 95 K
also in human germlines 3-15/49/72/73


 96 P
also in human germline 3-19


101 M
not found in human IGHV3 class


 







Sequence homology: 26/26 (FR1) + 17/17 (FR2) + 38/39 (FR3) = 81/82 = 99%


 


B) Canonical folds analysis CDR H1 and H2


 


1) Analysis of germline Dromedary VH sequences IGHV1S1 to IGHV1S19


reveals a canonical fold 1 for CDR1 and fold 1 for CDR2, so identical


to the folds of human germline VH3-13 and VH3-53, confirming the


data published by Nguyen and colleagues (EMBO J (2000), 19(5),


p 921-930). The analysis for dromedary IGHV1S1 and human IGHV3-53


are shown below as examples using auto-generated SDR templates:


 


IGHV1S1


CDR H1 Class ?


! Similar to class 1/10A, but:


! H94 (Chothia Numbering) is deleted.


CDR H2 Class 1/9A [1 gig]


 


IGHV3-53


CDR H1 Class ?


! Similar to class 1, but:


! H94 (Kabat Numbering) is deleted.


CDR H2 Class 1 chothia:human [1 gig]


(SEQ ID NOS: 21-42)











IGHV
        FR1-IMGT           CDR1-IMGT


gene
         (1-26)              (27-38)






1       10        20         30



.........|.........|...... ...|.......


M99660, IGHV3-23
EVQLLESGG.GLVQPGGSLRLSCAAS GFTFSSYA...


AJ245177, IGHV1S20
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY...


AJ245178, IGHV1S21
AVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYY...


AJ245183, IGHV1S22
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245185, IGHV1S23
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245186, IGHV1S24
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245187, IGHV1S25
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245189, IGHV1S26
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245191, IGHV1S27
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYD...


AJ245192, IGHV1S28
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYD...


AJ245193, IGHV1S29
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYA...


AJ245194, IGHV1S30
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYA...


AJ245195, IGHV1S31
AVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYA...


AJ245179, IGHV1S32
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245180, IGHV1S33
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245182, IGHV1S34
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245190, IGHV1S35
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYW...


AJ245196, IGHV1S36
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYA...


AJ245197, IGHV1S37
EVQLVESGG.GSVQAGGSLRLSCAAS GFTFSSYD...


AJ245181, IGHV1S38
EVQLVESGG.GLVQPGGSLRLSCAAS GFTSSSYW...


AJ245198, IGHV1S39
EVQLVESGG.GLVQPGGSLRLSCAAS AFTYSSCC...


AJ245199, IGHV1S40P
EVQLVESGG.GLVQPGGSLRLSCAAS *FTFSSYA...





IGHV
    FR2-IMGT      CDR2-IMGT    FR3-IMGT


gene
    (39-55)        (56-65)     (66-104)






40        50         60         70



.|.........|..... ....|..... ....|.....


M99660, IGHV3-23
MSWVRQAPGKGLEWVSA ISGSGGST.. YYADSVK.GR


AJ245177, IGHV1S20
MSWVRQAPGKGLEWVSG INSDGSNT.. YYADSVK.GR


AJ245178, IGHV1S21
MSWVRQAPGKGLEWVSG IYTGGGST.. YYADSVK.GR


AJ245183, IGHV1S22
MYWVRQAPGKGLEWVST INSGGGST.. YYADSVK.GR


AJ245185, IGHV1S23
MYWVRQAPGKGLEWVST INSGGGST.. YYADSVK.GR


AJ245186, IGHV1S24
MYWVRQAPGKGPEWVST INSGGGST.. YYADSVK.GR


AJ245187, IGHV1S25
MYWVRQAPRKGLEWVST INSAGGST.. YYADSVK.GR


AJ245189, IGHV1S26
MYWVRQAPGKGLEWVST INSAGGST.. YYADSVK.GR


AJ245191, IGHV1S27
MSWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR


AJ245192, IGHV1S28
MSWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GQ


AJ245193, IGHV1S29
ISWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR


AJ245194, IGHV1S30
MSWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR


AJ245195, IGHV1S31
ISWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR


AJ245179, IGHV1S32
VYWVRQAPGKGLEWVSS IYTGGGST.. YYADSVK.GR


AJ245180, IGHV1S33
MYWVRQAPGKGLEWVSS IYTGGGST.. YYADSVK.GR


AJ245182, IGHV1S34
MSWVRQAPGKALQWVSS IYTGGGST.. YYADSVK.GP


AJ245190, IGHV1S35
MYWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR


AJ245196, IGHV1S36
MSWVRQAPGKGLEWVSA IYTGGGST.. YYADSVK.GR


AJ245197, IGHV1S37
MSWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR


AJ245181, IGHV1S38
MYWVRQAPGKGLEWVSS IYTGGGST.. YYADSVK.GR


AJ245198, IGHV1S39
MYWVRQAPGKGFEWVSA INSGGGST.. YYADSVK.GR


AJ245199, IGHV1S40P
ISWVRQAPGKGLEWVSA INSGGGST.. YYADSVK.GR





IGHV
         FR3-IMGT              CDR3-IMGT


gene
         (66-104)              (105-115)






   80        90        100       110



....|.........|.........|.... .....|.....


M99660, IGHV3-23
FTISRDNSKNTLYLQMNSLRAEDTAVYYC AK.........


AJ245177, IGHV1S20
FTISRDNAKNTLYLQMNSLKSEDTAMYYC


AJ245178, IGHV1S21
FTISRDNAKNVLYLKLSSLKPEDTAMYYC


AJ245183, IGHV1S22
FTISRDNAKNMLYLQMNSLKPEDTAMYYC


AJ245185, IGHV1S23
FTISRDNAKNMLYLQMNSLKPEDTAVYYC


AJ245186, IGHV1S24
FTISRDNAKNMLYLQMNSLKPEDTAMYYC


AJ245187, IGHV1S25
FTISRDNAKNTVYLQMNSLKPEDTAMYYC


AJ245189, IGHV1S26
FTISRDNAKNTVYLQMNSLKPEDTAMYYC


AJ245191, IGHV1S27
FTISRDNAKNTLYLQMNSLKPEDTAMYYC


AJ245192, IGHV1S28
FTISRDNAKNTLYLQMNSLKPEDTAMYYC


AJ245193, IGHV1S29
FTISRDNAKNTVYLQLNSLKPEDTAMYYC


AJ245194, IGHV1S30
FTISRDNAKNTLYLQLNSLKTEDTAMYYC


AJ245195, IGHV1S31
FTISRDNAKNTVYLQLNSLKTEDTAMYYC


AJ245179, IGHV1S32
FTISKDNAKNTLYLQMNSLKPEDTAMYYC


AJ245180, IGHV1S33
FTISKDNAKNTLYLQMNSLKPEDTAMYYC


AJ245182, IGHV1S34
LTISKDNAKNTLYLQMNSLKPEDTAMYYC


AJ245190, IGHV1S35
FTISQDNAKNTRYLQMNSLKPEDTAMYYC


AJ245196, IGHV1S36
FTISQDNAKNTVYLQMNSLKTEDTAMYYC


AJ245197, IGHV1S37
FTISQDNAKNMLYLQMNSLKPEDTAMYYC


AJ245181, IGHV1S38
FTISKDNAKNTLYLQMNSLKPEDTAMYYC


AJ245198, IGHV1S39
FTISQDNAKNTRYLQMNSLKPEDTAMYYC


AJ245199, IGHV1S40P
FTISQDNAKNTRYLQMNSLKPEDTAMYYC










A) Sequence comparisons


Sequences in comparison to human IGHV3-23 and other human germlines:








  5 V
exist in all other VH3 germlines


 55 G/T/S
can be considered more variable/beginning of CDR2


 83 A
present in many other human VH3 germlines


 86 M/V
majority is human T in the same context -> should be



replaceable by T


 95 K
also in human germlines 3-15/49/72/73


 96 P
also in human germline 3-19


101 M
not found in human IGHV3 class


 







Sequence homology: 26/26 (FR1) + 17/17 (FR2) + 38/39 (FR3) = 81/82 = 99%


 


B) Canonical folds analysis CDR H1 and H2


2) Analysis of the germline Dromedary VH sequences IGHV1S20 and IGH1S22


to IGH1S24 shows the presence of canonical fold 1 for CDR1 and fold 3


for CDR2, so identical to the canonical folds found in human germline


VH3-23, confirming the data published by Nguyen and colleagues (EMBO J


(2000), 19(5), p 921-930). The analysis for dromedary IGHV1S20 and human


IGHV are shown below as examples, where it should be mentioned that


residue H57 Asparagine is found back in VH3-21 that also have a class


3 fold for CDR2 in combination with class 1 fold of CDR1 (deletions are


D- and/or J-region encoded):


 


IGHV1S20:


CDR H1 Class ?


! Similar to class 1/10A, but:


! H94 (Chothia Numbering) is deleted.


! H102 (Chothia Numbering) = - (allows: YHVISDG)


CDR H2 Class ?


! Similar to class 3/10B, but:


! H52 (Chothia Numbering) = N (allows: SFWH)


 


IGHV3-21


CDR H1 Class ?


! Similar to class 1, but:


! H94 (Chothia Numbering) is deleted.


CDR H2 Class 3 chothia:human [1igc]


 


3) Germline Dromedary VH sequences IGH1S21 and IGHV1S25 to IGHV1S39


have canonical fold 1 for CDR1 and fold 2 for CDR2, identical to the


folds of human germline VH5, thereby confirming the data published by


Nguyen and colleagues (EMBO J (2000), 19(5), p 921-930). The analysis


for IGHV1S32 is shown below as an example using auto-generated SDR


templates. Serine (S) in position H55 is not found nor Lysine (K)


in human germline VH with fold 2 of CDR2:


 


IGHV1S32:


CDR H1 Class ?


! Similar to class 1/10A, but:


! H94 (Chothia Numbering) is deleted.


! H102 (Chothia Numbering) = - (allows: YHVISDG)


CDR H2 Class ?


! Similar to class 2/10A, but:


! H50 (Chothia Numbering) = S (allows: REWYGQVLNKA)


! H71 (Chothia Numbering) = K (allows: VAL)


 


Compared to results for IGHV3-23:


CDR H1 Class ?


! Similar to class 1/10A, but:


! H94 (Chothia Numbering) is deleted.


! H102 (Chothia Numbering) = K (allows: YHVISDG)


CDR H2 Class ?


! Similar to class 2/10A, but:


! H71 (Chothia Numbering) = R (allows: VAL)


 


Conclusions:


Canonical fold 1 for CDR1-and fold 1 for CDR2 were predicted for a


large group of germline dromedary VH (similar as in human germline


VH3-13), another large group used canonical fold 1 for CDR1 and fold


3 for CDR2 (as in human germline VH321) and another group used


canonical fold 1 for CDR1 and fold 2 for CDR2 (as found in human


germline VH3-21)





Note:


Residues 50, 52, 71, 94, 102 according to Chothia numbering compare with residues 55, 57, 80, 107, 117 in IMGT numbering system, germline VH3-21) respectively.
















10.2 Llama VH (SEQ ID NO: 21 AND 23)
















IGHV
         FR1-IMGT           CDR1-IMGT      FR2-IMGT


gene
          (1-26)             (27-38)       (39-55)






1       10        20         30        40        50



.........|.........|...... ...|.........|.........|.....


M99660, IGHV3-23
EVQLLESGG.GLVQPGGSLRLSCAAS GFTFSSYA....MSWVRQAPGKGLEWVSA


AF305949, IGHV1S6
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSSA....MSWVRQAPGKGLEWVSS





IGHV
CDR2-IMGT                  FR3-IMGT                 CDR3-IMGT


gene
 (56-65)                   (66-104)                 (105-115)   






   60         70        80        90        100        110



....|..... ....|.........|.........|.........|.... .....|.....


M99660, IGHV3-23
ISGSGGST.. YYADSVK.GRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AK.........


AF305949, IGHV1S6
IYSYSSNT.. YYADSVK.SRFTISTDNAKNTLYLQMNSLKPEDTAVYYC AA.........










A) Sequence comparisons:


Sequences in comparison to human IGHV3-23 and other human germlines:








 5 V
exist in all other VH3 germlines


55 S
in 3-21/38; can be considered more variable/beginning of CDR2


74 S
not in huam gemline class 3 but in 4 and 6


80 T
not present in any other human VH3 germlines


83 A
in many othe human class 3 germlines


95 L
not present in any other human VH germlines


96 P
not present in class 3 but in 2 and 6


 







Sequence homology: 26/26 (FR1) + 17/17 (FR2) + 35/39 (FR3) = 78/82 = 95%


 


B) Canonical folds analysis:


M99660, IGHV3-23 Results using auto-generated SDR templates:


CDR H1 Class ?


! Similar to class 1/10A, but:


! H94 (Chothia Numbering) is deleted.


! H102 (Chothia Numbering) = K (allows: YHVISDG)


CDR H2 Class ?


! Similar to class 2/10A, but:


! H71 (Chothia Numbering) = R (allows: VAL)


 


AF305949, IGHV1S6 Results using auto-generated SDR templates:


CDR H1 Class ?


! Similar to class 1/10A, but:


! H32 (Chothia Numbering) = S (allows: IHYFTNCED)


! H94 (Chothia Numbering) is deleted.


! H102 (Chothia Numbering) = A (allows: YHVISDG)


CDR H2 Class ?


! Similar to class 2/10A, but:


! H50 (Chothia Numbering) = S (allows: REWYGQVLNKA)


! H56 (Chothia Numbering) = N (allows: YREDGVSA)


! H71 (Chothia Numbering) = T (allows: VAL)


 


(B) Canonical folds CDR H1 and H2


 


Analysis of the only available germline Llama VH sequence aligning to human


germline IGHV3-23 reveals a canonical fold 1 for CDR1 and fold 2 for CDR2


identical to the folds of CDR1 and 2 of some human germline VH2 members and


all VH5 and VH7 members. The analysis for IGHV1S6 is shown below:


 


Discussion analysis:


1) Position 32 Serine is also found in human germline VH2-8, VH3-20 and


VH3-22, which all have a canonical fold 1 for CDR1


2) Position 94 is deleted, position 102 is A; these residues are encoded


by the D and/or J region


3) Position 50 Serine (S) for canonical fold 2 for CDR2 is not found in


human germline VH with the same fold


4) Position 56 Asparagine (N) is found in VH2-9 and VH2-10 that share


canonical fold 2 for CDR2


5) Position 71 Threonine (T) is found in almost all human germline VH


with canonical fold 2 for CDR2


 


Conclusion:


Llama germline sequence IGHV1S6 is most likely adopting canonical folds


1/10A for CDR1 and 2/10A for CDR2 just as found for the human IGHV3-23


germline sequence.





Note:


Chothia numbering 32, 50, 56, 71, 94 and 102 compare to numbers 33, 55, 62, 77, 107 and 115 in IMGT numbering scheme, respectively.
















10.3 VL 1-40 (SEQ ID NOS: 44 AND 45)
















IGLV
         FR1-IMGT           CDR1-IMGT 


gene
          (1-26)             (27-38)






1       10        20         30         40



.........|.........|...... ...|........ .|..


M94116, IGLV1-40
QSVLTQPPS.VSGAPGQRVTISCTGS SSNIGAGYD... VHWY


Camv144
QSVLTQPPS.MSGSLGQRVTISCTGS SSNIGGGSG... VQWF





IGLV
FR2-IMGT      CDR2-IMGT           FR3-IMGT


gene
(39-55)        (56-65)            (66-104)






      50         60         70        80



.......|..... ....|..... ....|.........|....


M94116, IGLV1-40
QQLPGTAPKLLIY GNS....... NRPSGVP.DRFSGSK..SG


Camv144
QQLPGTAPKLLIY GNS....... NRASGIP.DRFSESK..SG





IGLV
  FR3-IMGT            CDR3-IMGT      


gene
  (66-104)            (105-115)      FR4






    90       100        110



.....|.........|.... .....|......


M94116, IGLV1-40
TSASLAITGLQAEDEADYYC QSYDSSLSG...


Camv144
SSASLTITGLQADDEADYYC ASYDNRLSG--PVFGGGTKLTVLG










A) Sequence comparisons:








11 M:
not found in any human sequence


14 S:
not in human VL1 sequences but in almost all other VL types


15 L:
not in human VL1 but in VL 3,4 9, 10 classes


40 Q:
not in human VL1 but in VL6-57


42 F:
in 3-27 and V17 but not in class 1


68 A:
not in any human VL


78 E:
not in any human VL


85 5:
not in any human VL


90 T:
not in human VL1 but in classes 2-4 and 6-8


97 D:
not in VL1 but in 4-3 and 8-61


 







Sequence homology: 23/26 (FR1) + 15/17 (FR2) + 34/39 (FR3) = 72/82 = 88% homology


 


B) Canonical folds analysis:


 


M94116, IGLV1-40: Results using auto-generated SDR templates


 


CDR L1 Class ?


! Similar to class 6/14A, but:


! L31 (Chothia Numbering) = Y (allows: H)


! L32 (Chothia Numbering) = D (allows: N)


! L93 (Chothia Numbering) = S (allows: R)


CDR L2 Class 1/7A [1lmk]


 


Camv144: Results using auto-generated SDR templates


 


CDR L1 Class ?


! Similar to class 6/14A, but:


! L31 (Chothia Numbering) = S (allows: H)


! L32 (Chothia Numbering) = G (allows: N)


! L93 (Chothia Numbering) = N (allows: R)


CDR L2 Class 1/7A [1lmk]


 


CDR L2 gives a perfect match for canonical fold 1/7A, while for CDR L1 three


key residues are questionable for giving a perfect match with canonical fold


6/14A, which now will be discussed individually.


1) Position L31 Serine (S, in CDR1) and L32 Glycine (G, in CDR1) should be


Histidine (H) and Asparagine (N), respectively; both residues were not found


in sequences with a canonical fold 14A; no other camelid lambda sequences,


which align with human germline VL1 family, were identified, therefore


making the analysis rather difficult


2) Position L93 Asparagine (N, in CDR3) should be Arginine (R), but


Asparagine (N) also occurs in two human germline VL4 family members, which


share the canonical fold 14A with human germline VL1-2


 


Conclusions:


1) Canonical fold 1/7(A) for CDR2 expected and probably fold number 6/14A


for CDR1, i.e. identical to what is found in human germline VL1 member 1-40.





NOTE:


Positions 31, 32 and 93 (Chothia) compare to 34, 35, and 109 in IMGT nomenclature used for the sequence comparison.
















10.4 VL 2-18 (SEQ ID NOS: 46-59)
















IGLV
                             FR1-IMGT     CDR1-IMGT


gene
leader                        (1-26)       (27-38)






                    1       10        20         30



                    .........|.........|...... ...|


Z73642, IGLV2-18               
                    QSALTQPPS.VSGSPGQSVTISCTGT SSDV


Camv117
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv133
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTITCTGT RDDV


Camv136
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv159
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv130
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv132
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNGV


Camv157
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv15
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv165
                    QAVLTQPSS.VSGTPGQTVTISCTGT SNDV


Camv151
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV


Camv131
MAWALLLLTLLTQGTGSWA QSALAQPSS.VSGTPGQTVTISCTGT SNDV


Camv160
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT RDDV


Camv152
MAWALLLLTLLTQGTGSWA QSALTQPSS.VSGTPGQTVTISCTGT SNDV





IGLV
CDR1-IMGT   FR2-IMGT     CDR2-IMGT      FR3-IMGT


gene
(27-38)     (39-55)       (56-65)       (66-104)






         40        50         60         70



........ .|.........|..... ....|..... ....|........ 


Z73642, IGLV2-18
GSYNR... VSWYQQPPGTAPKLMIY EVS....... NRPSGVP.DRFSG


Camv117
GGYNY... VSWYQQLPGTAPKLLIY QDS....... KRNSGIP.DRFSG


Camv133
GGYNY... VSWYQQLPGTAPKLLIY QIN....... KRLSGIP.DRFSG


Camv136
GGYNY... VSRYQQLPGTAPKLLIY QIN....... KRASGIP.DRFSG


Camv159
GRYNY... VSWYQQLPGTAPKFLIY QVN....... KRASGIP.DRFSG


Camv130
GRYNY... VSWYQQFPGTAPKLLIY QVN....... KRASGIP.DRFSG


Camv132
GGYNY... VSWYRQLPGTAPKLLIY QVN....... KRASGIP.DRFSG


Camv157
GGYNY... VSWYQQLPGTAPKLLIY QVN....... KRASGIP.DRFSS


Camv15
GRYNY... VSWYQQLPETAPKLLIY DVD....... KRASGIP.DRFSG


Camv165
GRYNY... VSWYQQFPGTAPKLLIY QVN....... KRGSG1P.DRFSG


Camv151
GGYNY... VSWHQQVPGTAPKLILY QVK....... ERPSGIP.DRFSG


Camv131
GRYNY... VSWYQQLPGTAPKLLIY QVN....... KRPSGIP.DRFSG


Camv160
GKYNY... VSWYQQLPGTAPKLLIY QVN....... KRASGIP.DRFSG


Camv152
GRYAY... VSWYQHLPGTAPKLLIY QVN....... KRASGTP.DRFSG





IGLV
   FR3-IMGT                 CDR3-IMGT


gene
   (66-104)                 (105-115)       FR4






80        90       100        110



.|.........|.........|.... .....|...... 


Z73642, IGLV2-18
SK..SGNTASLTISGLQAEDEADYYC SLYTSSSTF...


Camv117
SK..SDNTASMTISGLQSADEADYYC ASYRSTYH---SL FGGGTHLTVLG


Camv133
SK..SGNTASMTISGLQSADEADYYC ASYRDLNT---LV FGGGTHLTVLG


Camv136
SR..SGNTASMTISGLQSADEADYYC ASYRATNS---IV FGGGTHLTVLG


Camv159
SK..SGNTASMTISGLQSADEADYYC ASLPSSGN---AV FGGGTHLTVLG


Camv130
SK..SGNTASMTISGLQSADEADYYC ASYRNWAN---LP FGGGTHLTVLG


Camv132
SK..SGNTASMTISGLQSADEADYYC ASYRNGNN---AV FGGGTHLTVLG


Camv157
SK..SDNTASMTISGLQSADEADYYC ASYRSRDN---AV FGGGTHLTVLG


Camv15
SK..SGNTASMTISGLQSADEADYYC ASYRSGDN---AA FGGGTRLTVLG


Camv165
SK..SGNTASMTISGLQSADEADYYC ASLSSGNN---AV FGGGTHLTVLG


Camv151
SK..FGNTASMTISGLQSADEADYYC ASYSSPNN---VL FGGGTHLTVLG


Camv131
SK..SGNTVSLTISGLQSADEADYTC ASYKHTYN---AV FGGGTHLTVLG


Camv160
SK..SGNTASMTISGLQSADEADYYC ASVRDYDNNEFVV FGGGTHLTVLG


Camv152
SK..SGNTASMTTSGLQSADEADYYC SAYRSNDGP---V FGGGTHLTVLG










A) Sequence comparisons:


 








 8 S
not in class 2 but also in 3-27 and 4-60, 5-52


14 T
not in class 2 but also in 1-44/47


18 T
not in class 2 but in many other germlines of class 3 and in many



other germline classes as well


45 L
not in class 2, only in class 1


53 L
in 2-33, as well as in classes 1, 4, 5, 7, 8, 10


66 K
in classes 1, 2, 3


68 N/L/A/G
somatic mutation and also human residue P is found in Camv151 and



Camv131


71 I
in other class 2 members and in class 1-41/51 and classes 3, 4, 9, 10


89 M
somatic mutation (?) as also human residue L is fund in Camv131


96 S
in classes 1, 2, 4, 5


97 A
not found in human germline.


 







Sequence homology: 23/26 (FR1) + 16/17 (FR2) + 38/39 (FR3) = 78/82 = 94% homology


 


B) Canonical folds analysis:


 


Z73642, IGLV2-18: Results using auto-generated SDR templates


 


CDR L1 Class ?


! Similar to class ?/14C, but:


! L32 (Chothia Numbering) = R (allows: Y)


! L90 (Chothia Numbering) = L (allows: S)


! L93 (Chothia Numbering) = S (allows: G)


CDR L2 Class 1/7A [1lmk]


 


Camv159 Results using auto-generated SDR templates


 


CDR L1 Class ?


! Similar to class ?/14C, but:


! L28 (Chothia Numbering) = N (allows: S)


! L93 (Chothia Numbering) = S (allows: G)


CDR L2 Class 1/7A [1lmk]


 


Analysis of the camelid lambda light chain variable sequences aligning to human


germline IGLV2-18 reveals a canonical fold 2/14 for CDR1 and fold 1/7A for CDR2,


so identical to the folds of CDR1 and 2 of human germline VL2 family. The


analysis for Camv159 is shown as an example:


 


CDR L2 gives a perfect match for canonical fold 1/7A, while for CDR L1 only two


key residues are questionable for giving a perfect match with canonical fold


2/14C, which now will be discussed individually.


1) Position L28 Asparagine (N, in CDR1) should be Serine (S), but Aspartate (D)


found in Camv133 is the most often found residue in human germline VL2 sequences


2) Position L93 Serine (S, in CDR3) should be Glycine (G), but Serine present


in three of the 8 aligned camelid VLs is the most often found residue in human


germline VL2, as in the human IGLV2-18 used for comparison


 


Conclusions:


Canonical fold number 2/14 for CDR1 expected and fold 1/7(A) for CDR2, i.e.


identical to what is found in human germline VL2.





NOTE:


Position 93 (Chothia) compares to 109 in IMGT nomenclature used for the sequence comparison.
















10.5 VL 3-1 (SEQ ID NOS: 60-65)
















IGLV
            FR1-IMGT           CDR1-IMGT 


gene
             (1-26)             (27-38) 






1       10        20         30         40



.........|.........|...... ...|..........|...


X57826, IGLV3-1
SYELTQPPS.VSVSPGQTASITCSGD KLGDKY...... ACWYQ


Camv119
QSVLTQPSA.VSVSLGETARITCQGG NFGSYY...... ANWYQ


Camv120
QSVLTQPSA.VSVPLGETARITCQGG DFGDYY...... VSWYQ


Camv18
 TALTQPSA.VSVSLGETARITCQGG NFGSYY...... TSWYQ


Camv118
QAVLSQPSA.VSVSLGETARITCQGD NFGSYY...... FSWYQ


Camv123
QSVLTQPSA.VSVSLGQTARITCQGG ILGSKK...... TNWYQ





IGLV
   FR2-IMGT    CDR2-IMGT       FR3-IMGT


gene
   (39-55)      (56-65)        (66-104)






     50         60         70        80



......|..... ....|..... ....|.........|......


X57826, IGLV3-1
QKPGQSPVLVIY QDS....... KRPSGIP.ERFSGSN..SGNT


Camv119
QKPGQAPVLVLY KDS....... ARPSGIP ERFSGSS  SGGT


Camv120
QKPGQSPVLVIY KDT....... LRPSGIP ERFTGSS  SGGA


Camv18
QKPEEAPVVVIY KDT....... ERPSGIP ERFSASS  SGDT


Camv118
QKPGQAPVLVIY RNS....... NRPSGIP ERFSASS  SGGT


Camv123
QKPGQAPVLVIY GDD....... SRPSGIP ERFSGSR  SGGT





IGLV
  FR3-IMGT            CDR3-IMGT


gene
  (66-104)            (105-115)






  90       100        110



...|.........|.... .....|......


X57826, IGLV3-1
ATLTISGTQAMDEADYYC QAWDSSTA....


Camv119
ATLTISGAQAEDEADYYC QSGSSSA-SA--V FGGGTHLTVLG


Camv120
ATLTISGAQAEDEADYYC QSETSSA-T---V FGGGTHLTVLG


Camv18
ATLTISGAQAEDEADYYC QSGSSSA-NAP-V FGGGTKLTVLG


Camv118
ATLTISGAQAEDEADYYC QSADSSGRNAR-A FGGGTKLTVLG


Camv123
ATLTISGAQAEDEADYYC QLLDSTDSSSYWV FGGGTHLTVLG










C) Sequence comparisons:








 1 Q
primer encoded


 2 S/T
primer encoded


 3 V/A
primer encoded


 5 S
primer encoded


 8 S
also in 3-27 and 4-60


 9 A
also in 3-19/32


15 L
in 3-9/16/19/32


17 E
not in human class 3 but human Q exists in Camv123 in same context


20 R
in all other human class 3 sequences and others


24 Q
in 3-19/32


26 G
somatic Mutation/part of CDR; human D exists in Camv118 in same context


39 V/T/F
somatic mutation/part of CDR


40 N/S
somatic mutation/part of CDR


49 A
in many other class 3


66 A/L/N/S
somatic mutation/part of CDR


80 S
in 3-16/19/10/25/27


85 G
not in class 3 but in classes 6 and 7


94 A
in 3-19/10/9


97 E
in 3-10/16/19


 







Sequence homology: 26/26 (FR1) + 17/17 (FR2) + 38/39 (FR3) + 81/82 = 99% homology


 


D) Canonical folds analysis:


 


Analysis of the above listed camelid lambda light chain variable sequences on the


UCL webpage http://www.bioinf.org.uk/abs/chothia.html shows that CDR-L1 adopts


canonical fold 11, while CDR-L2 has canonical fold 7. This corresponds with the


canonical folds found in all human germline IGLV3 family members (see Pluckthun


homepage http://www.bioc.unizh.ch/antibody/Sequences/Germlines/VBase_hVK.html). The


canonical fold is determined by the length of the CDRs and certain key residues


within and outside of the CDR. The analysis of e.g. Camv120 is shown below:


 


CDR L1 Class ?


! Similar to class 2/11A, but:


! L2 (Chothia Numbering = S (allows: I)


! L25 (Chothia Numbering = G (allows: A)


! L26 (Chothia Numbering = G (allows: S)


! L28 (Chothia Numbering = F (allows: NSDE)


! L29 (Chothia Numbering = G (allows: IV)


! L51 (Chothia Numbering = D (allows: ATGV)


! L71 (Chothia Numbering = A (allows: YF)


! L90 (Chothia Numbering = S (allows: HQ)


CDR L2 Class 1/7A [1lmk]


 


CDR L2 gives a perfect match for canonical fold 1/7A, while for CDR L1 certain key


residues are questionable for giving a perfect match with canonical fold 2/11A,


which now will be discussed individually.


1) Position L2 Serine (S) should be Isoleucine (I), but human IGLV3-5 (which also


has fold 11) has Serine (S) residue found in these camelid VLs.


2) L25 Glycine (G) is found in all human VL3 family members


3) L26 Glycine (G) should be Serine (S), but Aspartate (D) found in Camv118 is


most often used in human VL3 members


4) L28 Phenylalanine (F, in CDR1) should be Asparagine (N), Serine (S), Aspartate


(D) or Glutamate (E), but Leucine(L) found in Camv123 is the most often used


residue in human VL3


5) L29 Glycine (G, in CDR1) is found in 4 of the 9 human VL3 germlines


6) L51 Aspartate (D, in CDR2) is most often used in human VL3


7) L71 Alanine (A, FR3) is most often used in human VL3


8) L90 Serine (S, CDR3) is most used residue in human VL3


 


Conclusions:


2) Canonical fold number 11 for CDR1 is expected and fold 7 for CDR2, i.e.


identical to what is found in human germline VL3





Note:


Chothia Numbering 51, 71, and 90 compares to IMGT numbering 57, 87, and 106
















10.6 VL 3-12 (SEQ ID NOS: 66 and 67)
















IGLV
                 FR1-IMGT          CDR1-IMGT


gene
leader            (1-26)            (27-38)






        1       10        20         30         40



        .........|.........|...... ...|........ .|...


273658, IGLV3-12
        SYELTQPHS.VSVATAQMARITCGGN NIGSKA...... VHWYQ


Camvlll
        QSVLTQPST.ASMSLGQTAKITCQGG SLRNYA...... AHWYQ





IGLV
          FR2-IMGT    CDR2-IMGT          FR3-IMGT 


gene
leader    (39-55)      (56-65)           (66-104)






             50         60         70        80



        ......|..... ....|..... ....|.........|......


273658, IGLV3-12
        QKPGQDPVLVIY SDS....... NRPSGIP.ERFSGSN..PGNT


Camvlll
        QKPGAAPVLVIY NDN....... NRPSGIP.ERFSGSK..SGGT





IGLV
         FR3-IMGT      CDR3-IMGT


gene
leader   (66-104)      (105-115)             FR4






          90       100        110           



        ...|.........|.... .....|......


273658, IGLV3-12
        TTLTISRIEAGDEADYYC QVWDSSSDH...


Camvlll
        ATLTISRTKAEDEADYYC LSRDMSDSN-RVV FGGGTHLTVLG










A) Sequence comparisons:








 1 Q
primer encoded


 2 S
primer encoded


 3 V
primer encoded


 5 S
primer encoded


 8 S
also in 3-27 and 4-60


 9 T
not in any human germline


11 A
not in class 3 but in classes 1, 2, 4, and 9


13 M
not in any human germline


14 S
in many other germlines of class 3 and in many other germline classes as well


15 L
in 3-16/19/32 and in many other classes


16 G
almost everywhere other than in this particular germline


18 T
in many other germlines of class 3 and in many other germline classes as well


20 K
not in human class 3 sequences but in class 4


24 Q
in 3-19/32


26 G
somatic mutation/part of CDR


39 A
in many other germlines of class 3


48 A
not in any human germline


49 A
in many other germlines of class 3 and in many other germline classes as well


80 K
in 3-32 and many other germeline classes


85 G
not in class 3 but in class 7


87 A
in many other germlines of class 3 and in many other germline classes as well


94 T
in 3-1


95 K
not in class 3 but in 2-33 and:6-57


97 E
in 3-10/16/19 and in many other germline classes


 







Sequence homology: 22/26 (FR1) + 16/17 (FR2) + 37/39 (FR3) + 75/82 = 91% homology


Most likely homology underestimated due to somatic mutations and because only one


family member is found.


 


B) Canonical folds analysis:


 


Z73658, IGLV3-12: Results using auto-generated SDR templates


 


CDR L1 Class ?


! Similar to class 2/11A, but:


! L2 (Chothia Numbering) = Y (allows: I)


! L25 (Chothia Numbering) = G (allows: A)


! L26 (Chothia Numbering) = N (allows: S)


! L28 (Chothia Numbering) = I (allows: NSDE)


! L29 (Chothia Numbering) = G (allows: IV)


! L51 (Chothia Numbering) = D (allows: ATGV)


! L71 (Chothia Numbering) = T (allows: YF)


! L90 (Chothia Numbering) = V (allows: HQ)


CDR L2 Class 1/7A [1lmk]


 


Camvlll: Results using auto-generated SDR templates


CDR L1 Class ?


! Similar to class 2/11B, but:


! L25 (Chothia Numbering) = G (allows: A)


! L26 (Chothia Numbering) = G (allows: N)


! L29 (Chothia Numbering) = R (allows: P)


! L34 (Chothia Numbering) = H (allows: Y)


! L46 (Chothia Numbering) = L (allows: M)


! L71 (Chothia Numbering) = A (allows: V)


! L90 (Chothia Numbering) = S (allows: A)


! L93 (Chothia Numbering) = M (allows: N)


CDR L2 Class 1/7A [1lmk]


 


Remarks: more difficult to align, especially FR1. These are somatically mutated


sequences, meaning that variations in FR can be expected as well. Deviations from


canonical fold analyis are very comparable in IGLV3-12, so most likely adopts


comparable canonical folds. For CDR L2 fold 1-7A shows a perfect match, CDR L2


will adopt fold 2-11 just as in human counterpart.


 


Conclusion:


Adopts canonical fold 2/11 for CDR1 and fold 1/7A for CDR2, so identical to human


germline VL3. Only one family member found, which is somatically mutated and


therefore it is difficult to draw conclusions.



















10.7 VKappa 2-40 (SEQ ID NOS: 68-75)
















IGKV
       FR1-IMGT             CDR1-IMGT      FR2-IMGT      CDR2-IMGT


gene
        (1-26)              (27-38)        (39-55)        (56-65)






1       10        20         30         40        50         60



.........|.........|...... ...|........ .|.........|..... ....|..


X59314, IGKV2-40
DIVMTQTPLSLPVTPGEPASISCRSS QSLLDSDDGNTY LDWYLQKPGQSPQLLIY TLS....


Kp6
DIVMTQSPSSVTASVGEKVTINCKSS QSVFDTSRQKSF LNWHRQRPGQSPRRLIY YAS....


Kp48
DIVMTQSPSSVTASVGEKVTINCKSS QSVFSSSSQKSL LDWHQQRPGQSPRRLIY YAS....


Kp3
DIVMTQSPSSVTASVGEKVTINCKSS QHVISVSNQKSY LNWYQQRPGQSPRLLIY YAS....


Kp20
DIVMTQSPSSVTASVGEKVTINCKSS QSVLSSSNQKSY LNWYQQRPGQSPRLLIY YAS....


Kp7
DIVMTQSPSSVLASVGEKVTINCKSS QSVLSSSNQKSY LNWYQQRPGQSPRLLIT YAS....


Kp10
DIVMTQSPTSVTASVGEKVTINCKSS QSVFASSSQKSQ LAWHQQRPGQSPRRLIY YAS....


Kp1
DIVMTQSPSSVTASVGEKVTINCKSS QNLVSDSNQRSL LAWHQQRPGQSPRKLIY YAS....





IGKV
                   FR3-IMGT                 CDR3-IMGT


gene
                   (66-104)                 (105-115)






       70        80        90        100       110



... ....|.........|.........|.........|.... .....|.....


X59314, IGKV2-40
... YRASGVP.DRFSGSG..SGTDFTLKISRVEAEDVGVYYC MQRIEFP....


Kp6
... TRQSGVP.DRFSGSG..STTDFTLTISSVQPEDAAVYYC QQAFNVQPS FGSGTRLEIKR


Kp48
... ARASGVP.DRFSGSG..STTDFTLTISSVQPEDAAVYYC QQYSGSPPT FGSGTRLEIKR


Kp3
... TRESGIP.DRFSGSG..STTDFALTISSVQPEDAAVYYC QQAYSTPYS FGSGTRLEIKR


Kp20
... TRESGIP.DRFSGSG..STTDFTLTISSVQPEDAAVFYC QQAYSAPYS FGSGTRLEIKR


Kp7
... TRESGIP.DRFSGSG..STTDFTLTISSVQPEDAVVYYC QQAYSKPYN FGNGTRLEIKR


Kp10
... TRESGVP.DRFSGSG..STTDFTLTISSVQPEDAAVYYC QHLYSAPYS FGSGTRLEIKR


Kp1
... TRISGTP.DRFSGSG..STTDFTLTISSVQPEDAAVYYC QQGKKDPLS FGSGTRLEIKR










A) Sequence comparisons:








  7 S
primer encoded


  9 S
only in human kappa 1 not kappa 2 family


 11 V
only in human kappa 1-12 not kappa 2 family


 12 T/L
not in human kappa germline


 13 A
not in class 2 but in class 1 and 5


 14 S
not in class 2 but in class 1, 3, 4, 7


 15 V
only in class 1


 19 V
not in class 2 but in class 1, 5, 6


 20 T
not in class 2 but in class 1, 3, 4, 6, 7


 22 N
not in class 2 but in class 4


 24 K
in classes 2, 4, 5


 40 N/A
somatic mutation, human D also exists in KP48


 42 H
somatic mutation, human Y also exists in KP3/20/7


 43 Q/R 
Q also found in classes 1, 2, 3, 4, 5, 6 and 7; R is somatic mutation


 51 R
in 2-24 and 2-30 as well as is class 3


 52 R/K
R in 2-30 and 1-17; human L also exits


 66 T/A
in classes 1, 3, 4 but not in 2; somatic mutation/part of CDR


 68 Q/E
somatic mutation, human A also exists in KP48


 71 I
somatic mutation; human V also exists in same context in various dromedary



kappa chains


 84 T
not in any human kappa germline


 90 T
not in class 2 but in classes 1, 3, 4, 5, 6, 7


 93 S
not in class 2 but in classes 1, 3, 4, 6


 95 Q
not in class 2 but in classes 1, 3, 4


 96 P
not in class 2 but in classes 1, 3


 99 A
not in class 2 but in classes 5, 6


100 A/V
not in class 2 but in classes 1, 3, 4, 5, 6, 7


 







Sequence homology: 17/26 (FR1) + 17/17 (FR2) + 31/39 (FR3) = 66/82 = 80% homology


Most likely homology underestimated due to somatic mutations and because all sequences seem 


to belong to the same class.


 


B) Canonical folds analysis:


X59314, IGKV2-40 Results using auto-generated SDR templates 


CDR L1 Class ?


! Similar to class 3/17A, but:


! L90 (Chothia Numbering) = Q (allows: N)


 


CDR L2 Class 1/7A [1lmk]


 


Kp6 Results uing auto-generated SDR templates


 


CDR L1 Class ?


! Similar to class 3/17A, but: 


! L29 (Chothia Numbering) = V (allows: L)


! L90 (Chothia Numbering) = Q (allows: N)


CDR L2 Class 1/7 [1lmk]


 


Analysis of the camelid kappa light chain variable sequences aligning to human germline


IGLV2-40 reveals a canonical fold 3/17A for CDR1 and fold 1/7A for CDR2, so identical to


the folds of CDR1 and 2 of human germline IGKV2-40. Dromedary Kp6 was analyzed as an


example. CDR2 gives a perfect match for canonical fold 1, while for CDR1 a number of


residues are questionable for giving a perfect match with canonical fold 3/17A, which


now will be discussed individually.


1) Positiion L29 Valine (V, in CDR1) should be Leucine (L) for having canonical fold 3


for CDR1, but this residue is present in dromedary Kp1 sequence


2) Position L90 Glutamine (Q, in CDR3) occurs as well in human germline VBase_VK4_1,


which also has canonical folds 3 for CDR1 (in combination with fold 1 for CDR2)





Conclusions:


Canonical fold 1 for CDR2 expected and most probably fold number 3/17A for CDR1 and fold 1 for CDR2, i.e. identical to what is found in human germline


NOTE:


Postitions 90 (Chothia) compares to position 107 in IMGT nomeclature used for the sequence comparison.
















10.8 J(H) region comparisons of human 


SEQ ID NOS: 76-81) and llama (SEQ ID NOS: 82-86)















Human








IGHJ



Genes
---CDR3--- ----FR4----






 1        10        20



 ......... |.........|


 


J00256, IGHJ1
 ...AEYFQH WGQGTLVTVSS


J00256, IGHJ2
 ...YWYFDL WGRGTLVTVSS


J00256, IGHJ3
 .....AFDV WGQGTMVTVSS


J00256, IGHJ4
 .....YFDY WGQGTLVTVSS


J00256, IGHJ5
 ....NWFDS WGQGTLVTVSS


J00256, IGHJ6
 YYYYYGMDV WGQGTTVTVSS










Llama:








IGHJ



Genes
--CDR3--- ----FR4----






  1        10



  ....... ..|........


AF305952, IGHJ2
  GYRYLEV WGQGTLVTVSS


AF305952, IGHJ3
    NALDA WGQGTLVTVSS


AF305952, IGHJ4
     EYDY WGQGTQVTVSS


AF305952, IGHJ5
    PQFEY WGQGTLVTVS


AF305952, IGHJ6 (1)
     DFGS WGQGTLVTVS


 







Sequence analysis:


The J(H) regions derived from llama show a perfect


homology to their human counterparts. There is a


100% sequence identity. The only exception is the


6th residue of FR4 in llama IGHJ4 being Gln (Q).


This residue is not found in human J(H) regions


at this position.



















10.9 Comparison of lambda (SEQ ID NOS: 87-96)


and kappa (SEQ ID NOS: 97-103) light chain J regions















Lambda J:


Kabat numbering ..97 98......108


                      ---FR4----


          -- CDR3 --  -J-lambda-





                  ..  ..........


X04457, IGLJ1     YV  FGTGTKVTVL


M15641, IGLJ2     VV  FGGGTKLTVL


M15642, IGLJ3     VV  FGGGTKLTVL


X51755, IGLJ4     FV  FGGGTQLIIL


X51755, IGLJ5     WV  FGEGTELTVL


M18338, IGLJ6     NV  FGSGTKVTVL


X51755, IGLJ7     AV  FGGGTQLTVL


 


Camv119 etc.      ..  FGGGTHLTVLG (38/44 anaylzed sequences)


Camv18/18/4       ..  FGGGTKLTVLG (3/44 analyzed sequences)


Camv158/28/5      ..  FGGGTRLTVLG (3/44 analyzed sequences)


 


Sequence analysis:


The first 2 residues of the human germline J are considered part of the CDR3.


They are often changed during the joining process. The best match of dromedary


J-lambda regions is with IGLJ2 and 3. 9/10 amino acids are identical: 90%


sequence identity. Only His or Arg in position 103 (Kabat) do not match. Arg


is positively charged (as Lys) and even His can be considered somewhat positively


charged. Therefore exchange to the human Lys should be possible.





Kappa J:


Kabat numbering ..97 98......108


                      ---FR4----


          -- CDR3 --    Kappa





                  ..  ..........


J00242, IGKJ1     WT  FGQGTKVEIK


J00242, IGKJ2     YT  FGQGTKLEIK


J00242, IGKJ3     FT  FGPGTKVDIK


J00242, IGKJ4     LT  FGGGTKVEIK


J00242, IGKJ5     IT  FGQGTRLEIK


Kp6/48/3/20/10/1      FGSGTRLEIKR (6/7 analyzed sequences)


Kp7                   FGSGTRLEIKR (1/7 analyzed sequences)


 


Sequence analysis:


The first 2 residues of the human germline J regions are considered part of the


CDR3. They are often changed during the joining process. Best match of dromedary


J-kappa is with human IGKJ5. 9/10 amino acids match: 90% sequence identity.



















10.10 Lama pacos VH germline analysis (SEQ ID NOS: 269-325)



















%
%
                       FR1


Name
Ident
Homol
 1  2  3  4  5  6  7  8  9 10 11 12 13 14 15





X92343|IGHV1-46*01


 Q  V  Q  L  V  Q  S  G  A  E  V  K  K  P  G


LpVH1-s6 (AM939701)
89.2%
91.9%
 E  V  Q  L  V  Q  P  G  A  E  L  R  N  P  G


LpVH1-s2 (AM939697)
89.2%
91.9%
 E  V  Q  L  V  Q  P  G  A  E  L  R  N  P  G


LpVH1-s3 (AM939698)
87.8%
90.5%
 E  V  Q  L  V  Q  P  G  A  E  L  R  N  P  G


LpVH1-s4 (AM939699)
89.2%
91.9%
 E  V  Q  L  V  Q  P  G  A  E  L  R  N  P  G


LpVH1-s5 Ps (AM939700)
89.2%
91.9%
 E  V  Q  L  V  Q  P  G  A  E  L  R  N  P  G


 


M99660|IGHV3-23*01


 E  V  Q  L  L  E  S  G  G  G  L  V  Q  P  G


AM939712
94.6%
98.6%
 E  V  Q  V  V  E  S  G  G  G  L  V  Q  P  G


AM939713
89.2%
94.6%
 Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939730
93.2%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939731
91.9%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939744
86.5%
93.2%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939726
93.2%
97.3%
 Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939727
93.2%
97.3%
 Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939739
94.6%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939740
94.6%
98.6%
 Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939741
94.6%
98.6%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939742
90.5%
95.9%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939743
93.2%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G












    FR1                                        CDR1









Name
16 17 18 19  
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35  





x92343|IGHV1-46*01
A   S  V  K  
 V  S  C  K  A  S  G  Y  T  F  T     


LpVH1-s6 (AM939701)
A   S  V  K
 V  S  C  K  A  S  G  Y  T  F  T  S  Y  Y  I  D


LpVH1-s2 (AM939697)
A   S  V  K
 V  S  C  K  A  S  G  Y  T  F  T  S  Y  Y  I  D


LpVH1-s3 (AM939698)
A   S  L  K
 V  S  C  K  A  S  G  Y  T  F  T  S  Y  Y  I  D


LpVH1-s4 (AM939699)
A   S  L  K
 V  S  C  K  A  S  G  Y  T  F  T  S  Y  Y  I  D


LpVH1-s5 Ps (AM939700)
A   S  V  K
 V  S  C  K  A  S  G  Y  T  F  T  S  Y  Y  I  D


 


M99660|IGHV3-23*01
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S   


AM939712
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  D  Y  A  M  S  


AM939713
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  D  D  Y  G  M  S  


AM939730
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S  


AM939731
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  G  S  Y  D  M  S  


AM939744
G   S  L  K
 H  S  C  A  A  S  G  L  T  F  G  S  Y  D  M  S  


AM939726
G   S  L  R
 V  S  C  A  A  S  G  F  T  F  S  S  Y  Y  M  S 


AM939727
G   S  L  R
 V  S  C  A  A  S  G  F  T  F  S  S  Y  Y  M  S 


AM939739
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  S  Y  D  M  S  


AM939740
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S  


AM939741
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S  


AM939742
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S  


AM939743
G   S  L  R
 L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S  












   CDR1                           FR2









Name
35a 35b 35c
 36 37 38 39 40 41 42 43 44 45 46 47 48 49





X92343|IGHV1-46*01

  W  V  R  Q  A  P  G  Q  G  L  E  W  M  G


LpVH1-s6 (AM939701)

  W  V  R  Q  A  P  G  Q  G  L  E  W  M  G


LpVH1-s2 (AM939697)

  W  V  R  Q  A  P  G  Q  G  L  E  W  M  G


LpVH1-s3 (AM939698)

  W  V  R  Q  A  P  G  Q  G  L  E  W  M  G


LpVH1-s4 (AM939699)

  W  V  R  Q  A  P  G  Q  G  L  E  W  M  G


LpVH1-s5 PS (AM939700)

  W  V  *  Q  A  P  G  Q  G  L  E  W  M  G


 


M99660|IGHV3-23*01

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939712

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939713

  W  V  R  H  S  P  G  K  G  L  E  W  V  S


AM939730

  W  V  R  Q  A  P  G  K  G  P  E  W  V  S


AM939731

  W  V  R  Q  A  P  G  K  G  P  E  W  V  S


AM939744

  W  V  R  Q  A  P  G  K  G  P  E  W  V  S


AM939726

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939727

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939739

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939740

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939741

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939742

  W  V  R  H  S  P  G  K  G  L  E  W  V  S


AM939743

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S














%
%
                               CDR2


Name
Ident
Homol
 50 51 52 52a 52b 52C 53 54 55 56 57 58 59 60 61 62 63 64 65  





X92343|IGHV1-46*01


                   


LpVH1-s6 (
89.2%
91.9%
 R  I  D  P            E  D  G  G  T  K  Y  A  Q  K  F  Q  G


LpvH1-S2 (
89.2%
91.9%
 R  I  D  P            E  D  G  G  T  K  Y  A  Q  K  F  Q  G


LpVH1-s3 (
87.8%
90.5%
 R  I  D  P            E  D  G  G  T  K  Y  A  Q  K  F  Q  G


LpVH1-s4 (
89.2%
91.9%
 R  I  D  P            E  D  G  G  T  K  Y  A  Q  K  F  Q  G


LpVH1-s5 Ps
89.2%
91.9%
 R  I  D  P            E  D  G  G  T  N  Y  A  Q  K  F  Q  G


 


M99660|IGHV3-23*01


                


AM939712
94.6%
98.6%
A  I  S  W             N  G  G  S  T  Y  Y  A  E  S  M  K  G


AM939713
89.2%
94.6%
A  I  S  W             N  G  G  S  T  Y  Y  A  E  S  M  K  G


AM939730
93.2%
97.3%
A  I  N  S             G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939731
91.9%
97.3%
A  I  N  S             G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939744
86.5%
93.2%
A  I  N  S             G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939726
93.2%
97.3%
A  I  N  T             G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939727
93.2%
97.3%
T  I  N  T             G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939739
94.6%
97.3%
A  I  N  S             G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939740
94.6%
98.6%
A  I  N  S             G  G  G  S  T  S  Y  A  D  S  V  K  G


AM939741
94.6%
98.6%
A  I  N  S             G  G  G  S  T  S  Y  A  D  S  V  K  G


AM939742
90.5%
95.9%
A  I  N  S             G  G  G  S  T  S  Y  A  D  S  M  K  G


AM939743
93.2%
97.3%
A  I  N  G             G  D  G  S  T  S  Y  A  D  S  V  K  G












                        FR3



 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82a 82b












X92343|IGHV1-46*01
 R  V  T  M
T  R  D  T  S  T  S  T  V  Y  M  E  L  S   S


LpVH1-s6 (
 R  V  T  F 
T  A  D  T  S  T  S  T  A  Y  V  E  L  S   S


Lpvh1-S2 (
 R  V  T  F
T  A  D  T  S  T  S  T  A  Y  V  E  L  S   S


LpVH1-s3 (
 R  V  T  F  
T  A  D  T  S  T  R  T  A  Y  V  E  L  S   S


LpVH1-s4 (
 R  V  T  F
T  A  D  T  S  T  S  T  A  Y  V  E  L  S   S


LpVH1-s5 Ps
 R  V  T  F
T  A  D  T  S  T  S  T  A  Y  V  E  L  S   S


 


M99660|IGHV3-23*01
 R  F  T  I
S  R  D  N  S  K  N  T  L  Y  L  Q  M  N   S





AM939712
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939713
 R  F  T  I  
S  R  D  N  A  K  N  T  V  Y  L  Q  M  N   S


AM939730
 R  F  T  I 
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939731
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939744
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939726
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939727    
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939739
 R  F  T  I
S  R  D  N  A  K  N  T  V  Y  L  Q  M  N   S


AM939740
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939741
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939742
 Q  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939743
 R  S  T  I  
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939730
 R  F  T  I 
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939731
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939744
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939726
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939727
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939739
 R  F  T  I
S  R  D  N  A  K  N  T  V  Y  L  Q  M  N   S


AM939740
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939741
 R  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939742
 Q  F  T  I
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S


AM939743
 R  S  T  I  
S  R  D  N  A  K  N  T  L  Y  L  Q  M  N   S












               FR3


Name
82c 83 84 85 86 87 88 89 90 91 92





X92343|IGHV1-46*01
 L  R  S  E  D  T  A  V  Y  Y  C


LpVH1-s6 (
 L  R  S  E  G  T  A  V  Y  Y  C


Lpvh1-S2 (
 L  R  S  E  G  T  P  V  Y  Y  C


LpVH1-s3 (
 L  R  S  E  G  T  A  V  Y  Y  C


LpVH1-s4 (
 L  R  S  E  G  T  A  V  Y  Y  C


LpVH1-s5 Ps
 L  R  S  E  G  T  A  V  Y  Y  C


 


M99660|IGHV3-23*01
 L  R  A  E  D  T  A  V  Y  Y  C


AM939712
 L  K  S  E  G  T  A  V  Y  Y  C


AM939713
 L  K  P  E  G  T  A  V  Y  Y  C


AM939730
 L  K  P  E  G  T  A  V  Y  Y  C


AM939731
 L  K  P  E  G  T  A  V  Y  Y  C


AM939744
 L  K  P  E  G  T  A  V  Y  Y  C


AM939726
 L  K  P  E  G  T  A  V  Y  Y  C


AM939727
 L  K  P  E  G  T  A  V  Y  Y  C


AM939739
 L  K  P  E  D  T  A  V  Y  Y  C


AM939740
 L  K  P  E  G  T  A  V  Y  Y  C


AM939741
 L  K  P  E  G  T  A  V  Y  Y  C


AM939742
 L  K  P  E  G  T  A  V  Y  Y  C


AM939743
 L  K  P  E  G  T  A  V  Y  Y  C














%
%
                     FR1


Name
Ident
Homol
 1  2  3  4  5  6  7  8  9 10 11 12 13 14 15





U29841|IGHV3-23*03


 E  V  Q  L  L  E  S  G  G  G  L  V  Q  P  G


AM939716
94.6%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939728
90.5%
94.6%
 E  V  R  L  V  E  S  G  G  G  L  V  Q  P  G


AM939738
91.9%
95.9%
 Q  V  Q  L  V  E  S  V  G  G  L  V  Q  D  G


AM939710
89.2%
93.2%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  A  G


AM939748
93.2%
97.3%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939750
94.6%
98.6%
 Q  V  Q  L  V  E  T  G  G  G  L  V  Q  P  G


AM939751
91.9%
95.9%
 Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939767
90.5%
94.6%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939768
93.2%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939707
93.2%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939708
93.2%
97.3%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939709
91.9%
95.9%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939732
93.2%
97.3%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939733
89.2%
94.6%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939717
90.5%
95.9%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939734
94.6%
97.3%
 E  V  Q  V  V  E  S  G  G  G  L  V  Q  P  G


AM939735
91.9%
97.3%
 E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939736
93.2%
97.3%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G


AM939737
94.6%
98.6%
 Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G












    FR1                                           CDR1









Name
 16 17 18 19
 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35     





U29481|IGHV3-23*03
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S   


AM939716
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  S  A  M  S


AM939728
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  S  A  M  S


AM939738
  G  S  L  R  
  L  S  C  A  A  S  G  R  T  F  S  S  S  A  M  S


AM939710
  G  S  L  R
  L  S  C  A  A  S  G  L  T  F  S  S  Y  A  M  S


AM939748
  G  S  L  R
  L  S  C  A  A  S  G  L  T  F  S  S  Y  Y  M  S


AM939750
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  S  A  M  S


AM939751
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  G


AM939767
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  G


AM939768
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  D  M  S


AM939707
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S


AM939708
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S


AM939709
  G  S  L  R
  L  S  C  A  A  S  G  L  T  F  S  S  Y  Y  M  S


AM939732
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  D  M  S


AM939733
  G  S  L  R
  L  S  C  A  A  S  G  F  T  L  G  S  Y  D  M  S


AM939717
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  G  S  Y  D  M  S


AM939734
  G  S  L  R 
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S


AM939735
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  D  N  Y  A  M  S


AM939736
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S


AM939737
  G  S  L  R
  L  S  C  A  A  S  G  F  T  F  S  S  Y  A  M  S






   CDR1
                     FR2


Name
35a 35b 35c
 36 37 38 39 40 41 42 43 44 45 46 47 48 49





U29481|IGHV3-23*03

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939716

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939728

  R  V  R  Q  V  P  G  K  G  L  E  W  V  S


AM939738

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939710

  W  V  R  Q  A  P  G  K  G  L  E  S  V  S


AM939748

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939750

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939751

  W  A  R  Q  V  P  G  K  G  L  E  W  V  S


AM939767

  W  A  R  Q  V  P  G  K  G  L  E  W  V  S


AM939768

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939707

  W  V  R  Q  A  P  G  K  G  L  E  S  V  S


AM939708

  W  V  R  Q  A  P  G  K  G  L  E  S  V  S


AM939709

  W  V  R  Q  A  P  G  K  G  L  E  S  V  S


AM939732

  W  V  R  Q  A  P  G  K  G  P  E  W  V  S


AM939733

  W  V  R  Q  A  P  G  K  G  P  E  W  V  S


AM939717

  W  V  R  R  A  P  G  K  G  L  E  W  V  S


AM939734

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939735

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939736

  W  V  R  R  A  P  G  K  G  L  E  W  V  S


AM939737

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S














%
%
                               CDR2


Name
Ident
Homol
 50 51 52 52a 52b 52c 53 54 55 56 57 58 59 60 61 62 63 64 65





U29481|IGHV3-23*03


                  


AM939716
94.6%
97.3%
  S  I  Y  S           Y  S  S  N  T  Y  Y  A  D  S  V  K  G


AM939728
90.5%
94.6%
  S  I  Y  S           Y  S  S  N  T  Y  Y  A  D  S  V  K  G


AM939738
91.9%
95.9%
  S  I  Y  S           Y  S  S  N  T  Y  N  A  D  S  V  K  G


AM939710
89.2%
93.2%
  T  I  N  S           D  G  S  N  T  Y  Y  A  D  S  V  K  G


AM939748
93.2%
97.3%
  G  I  Y  S           D  G  S  D  T  Y  Y  A  D  S  V  E  G


AM939750
94.6%
98.6%
  G  I  Y  S           D  G  S  D  T  Y  Y  A  D  S  V  K  G


AM939751
91.9%
95.9%
  G  I  Y  S           D  G  S  —  T  Y  Y  A  D  S  V  K  G


AM939767
90.5%
94.6%
  G  I  Y  S           D  G  S  —  T  Y  Y  A  D  S  V  K  G


AM939768
93.2%
97.3%
  G  I  Y  S           D  G  S  —  T  Y  Y  A  D  S  V  K  G


AM939707
93.2%
97.3%
  S  I  Y  S           Y  S  S  N  T  Y  Y  A  D  S  V  K  G


AM939708
93.2%
97.3%
  S  I  Y  S           Y  S  S  N  T  Y  Y  A  D  S  V  K  G


AM939709
91.9%
95.9%
  T  I  Y  S           Y  G  G  N  T  Y  Y  A  D  S  V  K  G


AM939732
93.2%
97.3%
  D  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939733
89.2%
94.6%
  C  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939717
90.5%
95.9%
  Y  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939737
94.6%
97.3%
  Y  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939735
91.9%
97.3%
  Y  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939736
93.2%
97.3%
  Y  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G


AM939737
94.6%
98.6%
  D  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K  G












                          FR3









Name
 66 67 68 69
 70 71 72 72 74 75 76 77 78 79 80 81 82 





U29481|IGHV3-23*03
  R  F  T  I
  S  R  D  N  S  K  N  T  L  Y  L  Q  M


AM939716
  R  F  T  I
  S  T  D  N  A  K  N  T  L  Y  L  Q  M


AM939728
  R  F  T  I
  S  T  D  N  A  K  N  T  L  Y  L  Q  M


AM939738
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939710
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939748
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939750
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939751
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939767
  R  F  T  I
  S  R  D  N  A  K  N  T  V  Y  L  Q  M


AM939768
  R  F  T  I
  S  R  D  N  A  K  N  T  V  Y  L  Q  M


AM939707
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939708
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939709
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939732
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939733
  R  F  T  I
  S  R  D  N  A  K  N  T  V  Y  L  Q  M


AM939717
  R  F  T  I
  S  R  D  N  A  K  N  T  V  Y  L  Q  M


AM939734
  R  F  T  I
  S  R  D  N  A  K  N  T  V  Y  L  Q  M


AM939735
  R  F  T  I
  S  R  D  N  A  K  N  T  V  Y  L  Q  M


AM939736
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M


AM939737
  R  F  T  I
  S  R  D  N  A  K  N  T  L  Y  L  Q  M












                        FR3









Name
82a   82b  
82c 83 84 85 86 87 88 89 90 91 92





U29481|IGHV3-23*03
  N     S
  L  R  A  E  D  T  A  V  Y  Y  C


AM939716
  N     S
  L  K  S  E  D  T  A  V  Y  Y  C


AM939728
  N     S
  L  K  S  E  G  T  A  V  Y  Y  C


AM939738
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939710
  N     S
  L  K  P  D  G  T  A  V  Y  Y  C


AM939748
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939750
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939751
  N     S
  L  K  S  E  G  T  A  V  Y  Y  C


AM939767
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939768
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939707
  N     S
  L  K  S  E  D  M  A  V  Y  Y  C


AM939708
  N     S
  L  K  S  E  G  T  A  V  Y  Y  C


AM939709
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939732
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939733
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939717
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939734
  N     S
  L  K  P  E  D  T  A  V  Y  Y  C


AM939735
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939736
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C


AM939737
  N     S
  L  K  P  E  G  T  A  V  Y  Y  C














%
%
                      FR1


Name
Ident
Homol
  1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16





L33851|IGHV-74*01


  E  V  Q  L  v  E  S  G  G  G  L  V  Q  P  G  G


AM939749
94.6%
98.6%
  Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G  G


AM939724
93.2%
98.6%
  Q  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G  G


AM939725
89.2%
95.9%
  Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G  G


AM939745
87.8%
93.2%
  E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G  G


AM939723
93.2%
97.3%
  Q  L  Q  L  V  E  S  G  G  G  L  V  Q  P  G  G













     FR1
                                     CDR1


Name
 17 18 19 20
 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 35a





L33851|IGHV-74*01
  S  L  R  L
  S  C  A  A  S  G  F  T  F  S   


AM939749
  S  L  R  L
  S  C  A  A  S  G  F  T  F  S  S  Y  W  M  N


AM939724
  S  L  R  L
  S  C  A  A  S  G  F  T  F  S  S  Y  W  M  N


AM939725
  S  L  R  L
  S  C  A  A  S  G  F  T  F  G  S  Y  W  M  Y


AM939745
  S  L  R  L 
  S  C  A  A  S  G  F  T  F  G  S  Y  V  L  S


AM939723
  S  L  R  L
  S  C  A  A  S  G  F  T  F  S  S  Y  W  M  N






   CDR1
                    FR2


Name
35b  35c
 36 37 38 39 40 41 42 43 44 45 46 47 48 49





L33851|IGHV-74*01

  W  V  R  Q  A  P  G  K  G  L  V  W  V  S


AM939749

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939724

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939725

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S


AM939745

  W  V  C  H  S  P  G  K  G  L  E  W  V  S


AM939723

  W  V  R  Q  A  P  G  K  G  L  E  W  V  S














%
%
                       FR1


Name
Ident
Homol
  1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16





X92229|IGHV4-30-2*03


  Q  L  Q  L  Q  E  S  G  S  G  L  V  K  P  S  Q


LpVH2-s7 (AM939704)
78.4%
81.1%
  Q  V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q












                  FR1                                  CDR1









Name
 17 18 19 20
 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 35a 35b





X92229|IGHV4-30-2*03
  T  L  S  L
  T  C  A  V  S  G  G  S  I  S   


LpVH2-s7 (AM939704)
  T  L  S  L  
  T  C  A  V  Y  G  G  S  I  T  T  S  C  Y  A  W  S






CDR1
                   FR2


Name
35c    36
 37 38 39 40 41 42 43 44 45 46 47 48 49





X92229|IGHV4-30-2*03
        W
  I  R  Q  P  P  G  K  G  L  E  W  I  G


LpVH2-s7 (AM939704)
        C
  I  C  Q  P  P  E  K  G  L  E  W  M  A














%
%
                      FR1


Name
Ident
Homol
  1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16





Z14238|IGHV4-30-4*01


  Q  V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s2 (AM939769)
86.5%
86.5%
  E  V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s3 (AM939770)
82.4%
82.4%
  E  V  Q  V  Q  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s4 (AM939771)
82.4%
82.4%
  Q  V  Q  R  Q  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s5 (AM939772)
87.8%
87.8%
  Q  V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s6 (AM939773)
82.4%
86.5%
  E  V  Q  L  Q  E  S  G  P  G  L  L  K  P  S  Q


LpVH20s11 Ps(AM939703)
82.4%
82.4%
  Q  V  Q  L  Q  E  S  G  P  D  L  V  K  P  S  Q


LpVH2-s8 (AM939705)
82.4%
82.4%
  Q  V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s9 Ps(AM939706)
83.8%
83.8%
  Q  V  Q  L  *  E  S  G  P  G  L  V  K  P  S  Q


LpVH2-s10 (AM939702)
83.8%
83.8%
  E  V  Q  L  Q  E  S  G  P  G  L  V  K  P  S  Q












                  FR1                                  CDR1









Name
 17 18 19 20
 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 35a 35b





Z14238|IGHV4-30-4*01
  T  L  S  L
  T  C  T  V  S  G  G  S  I  S   


LpVH2-s2 (AM939769)
  T  L  S  L
  T  C  T  V  S  G  G  S  I  T  T  S  Y  Y  A  W  S


LpVH2-s3 (AM939770)
  A  L  S  L
  T  C  T  A  S  G  G  S  N  T  T  S  Y  Y  A  W  S


LpVH2-s4 (AM939771)
  M  L  S  L  
  T  C  T  A  S  G  G  S  N  T  T  S  Y  Y  A  W  S


LpVH2-s5 (AM939772)
  T  L  S  L
  T  C  T  V  S  G  G  S  I  T  T  S  Y  Y  Y  W  S


LpVH2-s6 (AM939773)
  T  L  S  L
  T  C  A  V  Y  G  G  S  I  T  T  S  Y  Y  Y  W  S


LpVH20s11 Ps(AM939703)
  M  L  S  L
  T  C  T  V  S  G  G  S  N  T  T  S  Y  Y  A  W  S


LpVH2-s8 (AM939705)
  T  L  S  L
  T  C  T  A  S  G  G  S  N  T  T  S  Y  Y  A  W  S


LpVH2-s9 Ps(AM939706)
  T  L  S  L
  T  C  T  V  S  G  G  S  I  T  T  S  C  Y  A  W  S


LpVH2-s10 (AM939702)
  M  L  S  L
  T  C  T  L  S  G  D  S  I  T  T  S  C  Y  A  W  S












CDR1                          FR2









Name
35c    36
 37 38 39 40 41 42 43 44 45 46 47 48 49 





Z14238|IGHV4-30-4*01
        W 
  I  R  Q  P  P  G  K  G  L  E  W  I  G


LpVH2-s2 (AM939769)
        W
  I  R  Q  P  P  G  K  G  L  E  W  M  G


LpVH2-s3 (AM939770)
        W  
  I  R  Q  P  P  G  K  G  L  E  W  M  G


LpVH2-s4 (AM939771)
        W  
  I  R  Q  P  P  G  K  G  L  E  W  M  G


LpVH2-s5 (AM939772)
        W
  I  R  Q  P  P  G  K  G  L  E  W  M  G


LpVH2-s6 (AM939773)  
        W
  I  R  Q  P  P  G  K  G  L  E  W  M  G


LpVH20s11 Ps(AM939703)
        W
  I  R  Q  P  P  G  K  G  L  E  *  M  G


LpVH2-s8 (AM939705)
        W
  I  R  Q  P  P  G  K  G  L  E  W  M  G


LpVH2-s9 Ps(AM939706)
        W 
  I  H  Q  P  P  G  K  G  L  E  *  M  G


LpVH2-s10 (AM939702)
        W
  I  R  Q  P  P  G  K  G  L  E  W  M  G














%
%
                               CDR2


Name
Ident
Homol
50 51 52 52a 52b 52c 53 54 55 56 57 58 59 60 61 62 63 64 65





L33851|IGHV3-74*01


                   


AM939749
94.6%
98.6%
  G  I  Y  S           D  G  S  D  T  Y  Y  A  D  S  V  K G


AM939724
93.2%
98.6%
  A  I  N  S           G  G  G  S  T  S  Y  A  D  S  M  K G


AM939725
89.2%
95.9%
  A  I  N  S           G  G  G  S  T  S  Y  A  D  S  M  K G


AM939745
87.8%
93.2%
  A  I  N  S           C  G  G  S  T  S  Y  A  D  S  V  K G


AM939723
93.2%
97.3%
  A  I  N  S           G  G  G  S  T  Y  Y  A  D  S  V  K G











                                                  
                            FR3


Name
 66    67           68 69 70 71 72 73 74 75 76 77 78 79 80












L33851|IGHV3-74*01
  R     F
  T  I  S  R  D  N  A  K  N  T  L  Y  L


AM939749
  R     F
  T  I  S  R  D  N  A  K  N  T  L  Y  L


AM939724
  Q     F
  T  I  S  R  D  N  A  K  N  T  L  Y  L


AM939725
  Q     F
  T  I  S  S  D  N  A  R  N  T  L  Y  L


AM939745
  R     F
  T  I  S  R  D  N  A  K  N  T  V  Y  L


AM939723
  R     F
  T  I  S  R  D  N  A  K  N  T  V  Y  L












                             FR3









Name
 81    82
82a 82b 83c 83 84 85 86 87 88 89 90 91 92





L33851|IGHV3-74*01
  Q     M
  N  S   L   R  A  E  D  T  A  V  Y  Y  C


AM939749
  Q     M
  N  S   L   K  P  E  G  T  A  V  Y  Y  C


AM939724
  Q     M
  N  S   L   K  P  E  G  T  A  V  Y  Y  C


AM939725
  Q     M
  N  S   L   K  P  E  G  T  A  V  Y  Y  C


AM939745
  Q     M
  N  S   L   K  P  E  G  T  A  V  Y  Y  C


AM939723
  Q     M
  N  S   L   K  P  E  G  T  A  V  Y  Y  C














%
%
                               CDR2


Name
Ident
Homol
50 51 52 52a 52b 52c 53 54 55 56 57 58 59 60 61 62 63 64 65





X92229|IGHV4-30-2*03


                     


LpVH2-s7 (AM939704)
78.4%
81.1%
  A  I  —             Y  S  G  S  T  Y  Y  S  P  S  L  K  S












                            FR3









Name
 66    67
 68 69 70 71 72 73 74 75 76 77 78 79 80





X92229|IGHV4-30-2*03
  R     V
  T  I  S  V  D  T  S  K  N  Q  F  S  L


LpVH2-s7 (AM939704)
  H     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L












                             FR3









Name
 81    82
82a 82b 82c 83 84 85 86 87 88 89 90 91 92





X92229|IGHV4-30-2*03
  K     L
  S  S   V   T  A  A  D  T  A  V  Y  Y  C


LpVH2-s7 (AM939704)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C














%
%
                               CDR2


Name
Ident
Homol
50 51 52 52a 52b 52c 53 54 55 56 57 58 59 60 61 62 63 64 64





Z14238|IGHV4-30-4*01


                  


LpVH2-s2 (AM939769)
86.5%
86.5%
  A  I  A             Y  S  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s3 (AM939770)
82.4%
82.4%
  A  I  A             Y  S  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s4 (AM939771)
82.4%
82.4%
  A  I  A             Y  D  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s5 (AM939772)
87.8%
87.8%
  A  I  A             Y  D  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s6 (AM939773)
82.4%
86.5%
  A  I  A             Y  D  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s11 Ps(AM939703)
82.4%
82.4%
  A  I  —             Y  S  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s8 (AM939705)
82.4%
82.4%
  A  I  —             Y  S  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s9 Ps(AM939706)
83.8%
83.8%
  A  I  —             Y  S  G  S  T  Y  Y  S  P  S  L  K  S


LpVH2-s10 (AM939702)
83.8%
83.8%
  A  I  —             Y  S  G  S  T  Y  Y  S  P  S  L  K  S












                            FR3









Name
 66    67
 68 69 70 71 72 73 74 75 76 77 78 79 80





Z14238|IGHV4-30-4*01
  R     V
  T  I  S  V  D  T  S  K  N  Q  F  S  L


LpVH2-s2 (AM939769)
  R     T
  S  I  S  R  D  T  S  N  N  Q  F  S  L


LpVH2-s3 (AM939770)
  R     T
  S  I  S  R  D  T  S  N  N  Q  F  S  L


LpVH2-s4 (AM939771)
  H     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L


LpVH2-s5 (AM939772)
  R     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L


LpVH2-s6 (AM939773)
  H     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L


LpVH2-s11 Ps(AM939703)
  R     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L


LpVH2-s8 (AM939705)
  R     T 
  S  I  S  R  D  T  S  N  N  Q  F  S  L


LpVH2-s9 Ps(AM939706)
  H     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L


LpVH2-s10 (AM939702)
  R     T
  S  I  S  R  D  T  S  K  N  Q  F  S  L












                             FR3









Name
 81    82
82a 82b 82c 83 84 85 86 87 88 89 90 91 92 





Z14238|IGHV4-30-4*01
  K     L    
  S  S   V   T  A  A  D  T  A  V  Y  Y  C


LpVH2-s2 (AM939769)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s3 (AM939770)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s4 (AM939771)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s5 (AM939772)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s6 (AM939773)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s11 Ps(AM939703)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s8 (AM939705)
  Q     L
  S  S   V   T  P  E  G  T  C  V  Y  Y  C


LpVH2-s9 Ps(AM939706)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C


LpVH2-s10 (AM939702)
  Q     L
  S  S   V   T  P  E  G  T  A  V  Y  Y  C





Color codes


Residue found in closest matching germline


Residue found in other germlines of the same subclass (VH3, VK4, . . . )


Residue found in other germlines of the same class (VH, VK or VL)


Residue found in any germline of the same class (VH, VK or VL)


Primer-encoded residue


Scores


% Identity: fraction of framework residues which is found in the closest matching germline


% Homology: fraction of framework residues which is found in the closest matching germline or other germlines of the same subclass
















10.11 Lama glama derived VH analysis (SEQ ID NOS: 326-332)






























Name
% Ident
% Homol
1
2
3
4
5
6
7
8
9
10
11
12 
13





AJ879486|IGHV3-23*04


E
V
Q
L
V
E
S
G
G
G
L
V
Q


S-VH1
88.5%
93.1%
E
V
Q
L
V
E
S
G
G
G
L
V
Q


S-VH3
87.4%
90.8%
E
V
Q
L
V
Q
S
G
G
G
L
V
Q


S-VH4
92.0%
96.6%
E
E
Q
L
V
E
S
G
G
G
L
V
Q


L33851|IGHV3-74*01


E
V
Q
L
V
E
S
G
G
G
L
V
Q


S-VH2
93.2%
95.5%
E
V
Q
L
V
E
S
G
G
G
L
V
Q


S-VH6
93.1%
96.6%
E
V
Q
L
V
E
S
G
G
G
L
V
Q


S-VH5
93.1%
96.6%
E
V
Q
L
V
E
S
G
G
G
L
V
Q





Name
% Ident
% Homol
14 
15
16
17
18
19
20
21
22
23
24
25
26





AJ879486|IGHV3-23*04


P
G
G
S
L
R
L
S
C
A
A
S
G


S-VH1
88.5%
93.1%
P
G
G
S
L
R
L
S
C
A
A
S
G


S-VH3
87.4%
90.8%
H
G
G
S
L
R
L
S
C
A
A
S
G


S-VH4
92.0%
96.6%
P
G
G
S
L
R
L
S
C
A
A
S
G


L33851|IGHV3-74*01


P
G
G
S
L
R
L
S
C
A
A
S
G


S-VH2
93.2%
95.5%
P
G
G
S
L
R
L
S
C
A
A
S
G


S-VH6
93.1%
96.6%
P
G
G
S
L
R
L
S
C
A
A
S
G


S-VH5
93.1%
96.6%
P
G
G
S
L
R
L
S
C
A
A
S
G





Name
% Ident
% Homol
27
28
29
30
31
32
33
34
35
36
37
38
39





AJ879486|IGHV3-23*04


F
T
F
S
S
Y
A
M
S
W
V
R
Q


S-VH1
88.5%
93.1%
F
T
F
G
R
Y
A
M
S
W
V
R
Q


S-VH3
87.4%
90.8%
F
A
F
S
S
A
G
M
S
W
V
R
Q


S-VH4
92.0%
96.6%
F
T
F
G
S
Y
D
M
Y
W
V
R
Q


L33851|IGHV3-74*01


F
T
F
S
S
Y
W
M
H
W
V
R
Q


S-VH2
93.2%
95.5%
F
T
F
S
S
Y
Y
M
S
W
V
R
Q


S-VH6
93.1%
96.6%
F
T
F
S
S
A
V
M
S
W
V
R
Q


S-VH5
93.1%
96.6%
F
T
F
S
S
A
V
M
S
W
V
R
Q


Name
% Ident
% Homol
40
41
42
43
44
45
46
47
48
49
50
51
52





AJ879486|IGHV3-23*04


A
P
G
K
G
L
E
W
V
S
A
I
S


S-VH1
88.5%
93.1%
A
P
G
K
G
P
E
W
V
S
A
I
S


S-VH3
87.4%
90.8%
A
P
G
K
G
L
E
G
V
S
A
I
N


S-VH4
92.0%
96.6%
A
P
G
K
G
P
E
W
V
S
A
I
R


L33851|IGHV3-74*01


A
P
G
K
G
L
V
W
V
S
R
I
N


S-VH2
93.2%
95.5%
A
P
G
K
G
L
E
W
V
S
S
I
Y


S-VH6
93.1%
96.6%
A
P
G
K
G
L
E
W
V
S
G
I
G


S-VH5
93.1%
96.6%
A
P
G
K
G
L
E
W
V
S
T
I
G





Name
% Ident
% Homol
52a
53
54
55
56
57
58
59
60
61
62
63
64





AJ879486|IGHV3-23*04


G
S
G
G
S
T
Y
Y
A
D
S
V
K


S-VH1
88.5%
93.1%
W
N
S
G
R
I
Y
D
A
E
S
M
K


S-VH3
87.4%
90.8%
T
R
S
G
T
T
Y
Y
A
D
F
T
K


S-VH4
92.0%
96.6%
S
G
G
G
S
T
Y
Y
A
D
S
V
K


L33851|IGHV3-74*01


S
D
G
S
S
T
S
Y
A
D
S
V
K


S-VH2
93.2%
95.5%
S
D
G
S
Y
T
Y
Y
A
D
S
V
K


S-VH6
93.1%
96.6%
S
G
G
S
T
T
S
Y
A
D
S
V
K


S-VH5
93.1%
96.6%
A
A
G
S
T
T
S
Y
A
D
S
V
K





Name
% Ident
% Homol
65
66
67
68
69
70
71
72
73
74
75
76
77





AJ879486|IGHV3-23*04


G
R
F
T
I
S
R
D
N
S
K
N
T


S-VH1
88.5%
93.1%
G 
R
F
T
V
S
R
D
N
T
K
N
T


S-VH3
87.4%
90.8%
G 
R
F
T
I
S
R
D
N
A
K
N
T


S-VH4
92.0%
96.6%
G
R
F
T
I
S
R
D
N
A
K
N
T


L33851|IGHV3-74*01


G
R
F
T
I
S
R
D
N
A
K
N
T


S-VH2
93.2%
95.5%
G
R
F
T
I
S
R
D
N
A
K
N
T


S-VH6
93.1%
96.6%
G
R
F
T
I
S
R
D
N
A
K
N
T


S-VH5
93.1%
96.6%
G
R
F
T
I
S
R
D
N
A
K
N
T





Name
% Ident
% Homol
78
79
80
81
82
82a
82b
82c
83
84
85
86
87





AJ879486|IGHV3-23*04


L
Y
L
Q
M
N
S
L
R
A
E
D
T


S-VH1
88.5%
93.1%
L
Y
L
Q
M
N
A
L
K
T
D
D
T


S-VH3
87.4%
90.8%
V
Y
L
Q
M
N
S
L
K
P
E
D
T


S-VH4
92.0%
96.6%
L
Y
L
Q
M
N
S
L
K
P
E
D
T


L33851|IGHV3-74*01


L
Y
L
Q
M
N
S
L
R
A
E
D
T


S-VH2
93.2%
95.5%
L
Y
L
Q
M
N
S
L
K
S
E
D
T


S-VH6
93.1%
96.6%
L
Y
L
Q
M
N
S
L
K
P
E
D
T


S-VH5
93.1%
96.6%
L
Y
L
Q
M
N
S
L
K
P
E
D
T





Name
% Ident
% Homol
88
89
90 
91
92
93
94
95
96
97
98
99
100





AJ879486|IGHV3-23*04


A
V
Y
Y
C
A
K








S-VH1
88.5%
93.1%
A
V
Y
Y
C
A
R
S
T
A
E
S
N


S-VH3
87.4%
90.8%
A
V
Y
Y
C
N
A
G
F
P
S




S-VH4
92.0%
96.6%
A
V
Y
Y
C
A
K
P
S
T
I
A
T


L33851|IGHV3-74*01


A
V
Y
Y
C
A
R








S-VH2
93.2%
95.5%
A
V
Y
Y
C
A
N
W
D
Y
S
G
S


S-VH6
93.1%
96.6%
A
V
Y
Y
C
T
G
R
G
F





S-VH5
93.1%
96.6%
A
V
Y
Y
C
T
G
R
G
F





Name
% Ident
% Homol
100a
100b
100c
100d
100e
100f
100g
101
102
103
104
105
106





AJ879486|IGHV3-23*04

















S-VH1
88.5%
93.1%
W
I
P




L
D
W
G
Q
G


S-VH3
87.4%
90.8%







R
Y
W
G
Q
G


S-VH4
92.0%
96.6%
I
L
F




T
S
W
G
Q
G


L33851|IGHV3-74*01

















S-VH2
93.2%
95.5%
Y
Y
A
P
A
T
F
G
S
W
G
Q
G


S-VH6
93.1%
96.6%







S
S
W
G
Q
G


S-VH5
93.1%
96.6%







S
S
W
G
Q
G





















Name
% Ident
% Homol
107
108
109
110
111
112
113






AJ879486|IGHV3-23*04












S-VH1
88.5%
93.1%
T
Q
V
T
V
S
S



S-VH3
87.4%
90.8%
T
Q
V
T
V
S
S



S-VH4
92.0%
96.6%
T
Q
V
T
V
S
S



L33851|IGHV3-74*01












S-VH2
93.2%
95.5%
T
R
V
T
V
S
S



S-VH6
93.1%
96.6%
T
Q
V
T
V
S
S



S-VH5
93.1%
96.6%
T
Q
V
T
V
S
S





Chart codes


Residue found in closest matching germline


Residue found in other germlines of the same subclass (VH3, VK4, . . . )


Residue found in other germlines of the same class (VH, VK or VL)


Residue not found in any germline of the same class (VH, VK or VL)


Primer-encoded residue


Scores


% Identity: fraction of framework residues which is found in the closest matching germline


% Homology: fraction of framework residues which is found in the closest matching germline or other germlines of the same subclass
















10.12 Lama glama derived VL analysis (SEQ ID NOS: 333-346)















Lambda











                                                    2 2 2 



%
                  1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 7 7 7 2 2 3 3 3 3 3


Name
Homol
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 a b c 8 9 0 1 2 3 4





D86994|IGLV3-25*02

S Y E L T Q P P S V S V S P G Q T A R I T C             


VL-25-28
91.3%
N F M L T Q P S A L S V T L G Q T A K I T C Q G G S       L G S S Y A H







                                  5 5 5 5 




3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 1 1 1 1 5 5 5 5 5 5 5 5 6 6 


Name
%
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 a b c d 2 3 4 5 6 7 8 9 0 1





D86994|IGLV3-25*02
Homol
W Y Q Q K P G Q A P V L V I Y                  G I P E R


VL-25-28
91.3%
W Y Q Q K P G Q A P V L V I Y D D         D S R P S G I P E R      







                                                    2 2 2



%
                  1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 7 7 7 2 2 3 3 3 3 3


Name
Homol
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 a b c 8 9 0 1 2 3 4





Z73672|IGLVS-37*01

Q P V L T Q P P S S S A S P G E S A R L T C  


VL2, 12, 15
97.5%
Q A V L T Q P P S L S A S P G S S V R L T C T L S S G N S V G S Y D I S 







                                  5 5 5 5 



%
3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 1 1 1 1 5 5 5 5 5 5 5 5 6 6 


Name
Homol
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 a b c d 2 3 4 5 6 7 8 9 0 1





Z73672|IGLVS-37*01

W Y Q Q K P G S P P R Y L L Y             G V P S R 


VL2, 12, 15
97.5%
W Y Q Q K A G S P P R Y L L Y Y Y S D S F N H Q G S G V P S R







                                                    2 2 2



%
                  1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 7 7 7 2 2 3 3 3 3 3


Name
Homol
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 a b c 8 9 0 1 2 3 4





Z73650|IGLV8-61*01

Q T V V T Q E P S F S V S P G G T V T L T C  


VL3, 5
90.0%
Q A V V T Q E P S L S V S P G G T V T L T C G L S S G S V T S S N Y P G


VL17-24, 29-32
90.0%
Q A V V T Q E P S L S V S P G G T V T L T C G L S S G S V T T S N Y A A 


VL10
91.3%
S S E L T Q E P S L S V S P G G T V T L T C G L S S G S V T S S N Y P G


VL4, 6, 7, 8, 9,
97.5%
S Y E L T Q D P S L S V S P G E T V T L T C G L N S G S V T S H N Y P A


13, 14







                                  5 5 5 5



%
3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 1 1 1 1 5 5 5 5 5 5 5 5 6 6


Name
Homol
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 a b c d 2 3 4 5 6 7 8 9 0 1





Z73650|IGLV8-61*01

W Y Q Q T P G Q A P R T L I Y                  G V P D R  


VL3, 5
90.0%
W Y Q Q K P G Q A P R T L I Y N T         N S R Y S G V P N R


VL17-24, 29-32
90.0%
W F Q Q A P G Q A P R T L I Y K T         N S R H S G V P S R


VL10
91.3%
W Y Q Q K P G Q A P R T L I Y N T         N S R Y S G V P N R 


VL4, 6, 7, 8, 9,
97.5%
W Y Q Q K P G Q A P R T L M Y N T         N S R Y P M V P P R


13, 14







                6 6



%
6 6 6 6 6 6 6 6 8 8 6 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8 


Name
Homol
1 2 3 4 5 6 7 8 a b 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8





D86994|IGLV3-25*02

R F S G S S S G     T T V T L T I S G V Q A E D E A D Y Y C 


VL25-28
91.3%
R F S G S S S G     G R A T L T I S G A Q A E D E G D Y Y C







              9 9 9         1 1 1 1 1 1 1 1



%
8 9 9 9 9 9 9 5 5 5 9 9 9 9 0 0 0 0 0 0 0 0


Name
Homol
9 0 1 2 3 4 5 a b c 6 7 8 9 0 1 2 3 4 5 6 7





D86994|IGLV3-25*02

               


VL25-28
91.3%
Q S A D S S G N     A V F G G G T H L T V L 







                6 6






%
6 6 6 6 6 6 6 6 8 8 6 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8


Name
Homol
1 2 3 4 5 6 7 8 a b 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8





Z73672|IGLV5-37*01

R F S G S K D A S A N T G I L L I S G L Q S E D E A D Y Y C


VL2, 12, 15
97.5%
R F S G S K D A S A N A G L L L I S G L Q P E D E A D Y Y C







              9 9 9         1 1 1 1 1 1 1 1



%
8 9 9 9 9 9 9 5 5 5 9 9 9 9 0 0 0 0 0 0 0 0


Name
Homol
9 0 1 2 3 4 5 a b c 6 7 8 9 0 1 2 3 4 5 6 7





Z73672|IGLV5-37*01

               


VL2, 12, 15
97.5%
S A Y K S G S Y N   P T F G G G T K L T V L







                6 6



%
6 6 6 6 6 6 6 6 8 8 6 7 7 7 7 7 7 7 7 7 7 8 8 8 8 8 8 8 8 8


Name
Homol
1 2 3 4 5 6 7 8 a b 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8





Z73650|IGLV8-61*01

R F S G S I L G     N K A A L T I T G A Q A D D E S D Y Y C


VL3, 5
90.0%
R F S G S I S G     N K A V L T I T G A Q P E D E A D Y Y C 


VL17-24, 29-32
90.0%
R F S G S I S G     N K A A L T I T G A Q P E D E A D Y Y C


VL10
91.3%
R F S G S I S G     N K A A L T I T G A Q P E D E A D Y Y C


VL4, 6, 7, 8, 9, 
97.5%
R F S G S I S G     M K A A L T I T G A Q A E D E A D Y Y C


13, 14







              9 9 9         1 1 1 1 1 1 1 1



%
8 9 9 9 9 9 9 5 5 5 9 9 9 9 0 0 0 0 0 0 0 0


Name
Homol
9 0 1 2 3 4 5 a b c 6 7 8 9 0 1 2 3 4 5 6 7





Z73650|IGLV8-61*01

                


VL3, 5
90.0%
A V Y T G S S N Y P A V F G G G T H L T V L


VL17-24, 29-32
90.0%
S L Y P G S D I     S V F G G G T H L T V L


VL10
91.3%
A V Y I G S G G Y P P V F G G G T K L T V L


VL4, 6, 7, 8, 9,
97.5%
A V Y I R S R T     L E F G G G T H L T V L


13, 14










Kappa











%
%
                  1 1 1 1 1 1 1 1 1 1 2 2 2 2


Name
Ident
Homol
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 





U41644|IGHV2D-29*02


D I V M T Q T P L S L S V T P G Q P A S I S C


KAPPA 33-36, 38, 39
86.3%
90.0%
D I V M T Q T P G S L S V V P G E S A S I S C  


42, 4





KAPPA 41, 43 44
86.3%
90.0%
D I V M T Q T P G S L S V V P G E S A S I S C


KAPPA 40, 44
86.3%
90.0%
D I V M T Q T P G S L S V V P G E S A S I S C


KAPPA 37, 46, 48
83.3%
90.0%
E I V L T   T P G S L S V V P G E S A S I S C








        2 2 2 2 2



%
%
2 2 2 2 7 7 7 7 7 2 2 3 3 3 3 3


Name
Ident
Homol
4 5 6 7 a b c d e 8 9 0 1 2 3 4 





U41644|IGHV2D-29*02


 


KAPPA 33-36, 38, 39
86.3%
90.0%
K A S Q S L V H S D G K T Y L Y


42, 4


K A S Q S L V H S D G K T Y L Y


KAPPA 41, 43 44
86.3%
90.0%
K A S Q S L V L S G G K T Y L Y


KAPPA 40, 44
83.3%
90.0%
K A S Q S L V R S D G K T Y L Y


KAPPA 37, 46, 48
86.3%
90.0%






%
%
3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5


Name
Ident
Homol
5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9





U41644|IGKV2D-29*02


W Y L Q K P G Q S P Q L L I Y         G V P


KAPPA 33-36, 38,
86.3%
90.0%
W L L Q K P G Q S P Q R L I Y Q V S N R G S G V P  


39, 42, 4





KAPPA 41, 43, 44
86.3%
90.0%
W L L Q K P G Q S P Q R L I Y Q V S N R G S G V P


KAPPA 40, 44
86.3%
90.0%
W L L Q K P G Q S P Q R L I Y Q V S N R G S G V P


KAPPA 37, 46, 48
86.3%
90.0%
W L L Q K P G Q S P Q R L I Y Q V S N R G S G V P









Example 11
Analysis of Key Residues for Canonical Folds of H1 and H2 and Comparison of H1 and H2 Residues with Human Germline
Structural analysis of antibodies revealed the relationship between the sequence and the shape of the binding site formed by the complementarity determining regions (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987); Tramontano et al., J. Mol. Biol. 215:175-82 (1990)). Despite their high sequence variability, five of the six loops adopt just a small repertoire of main-chain conformations, called “canonical structures”. These conformations are first of all determined by the length of the loops and secondly by the presence of key residues at certain positions in the loops and in the framework regions that determine the conformation through their packing, hydrogen bonding or the ability to assume unusual main-chain conformations.
We have analyzed the predicted canonical structures of H1 and H2 for the germline dromedary and llama VH segments based on the length of these loops and the presence of the previously mentioned key residues. The comparison was made with the key residues as they occur in the closest matching human germline in terms of the presence of identical combination of canonical folds and overall sequence homology (Table 1); in addition the amino acids compatible with the corresponding canonical fold as proposed by Morea and colleagues (Morea et al., Methods 20:267-279 (2000)) are shown. For the dromedary germline VH family IGHV1S(1-19), which has canonical fold 1 for H1 (coded as H1: 1 in Table 1) and fold 1 for H2 (H2: 1), and family IGHV1 S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1S8 with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2), the key residues 24, 26, 27, 29, 34 and 94 for the canonical fold of H1 are shown along with these from the analogue human germline family with the same canonical fold combination (upper part of Table 1). Also for dromedary germline VH family IGHV1S(1-19) with fold 1 for H1 (H1: 1) and fold 1 for H2 (H2: 1), and family IGHV1 S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1 S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1 S8 with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 1) the key residues 52a or 54 or 55 in combination with residue 71 are shown along with these from the analogue human germline families with the same canonical fold combinations (lower part Table 1).
The analysis clearly demonstrates the “human nature” of the canonical loops, since the key residues found in the camelid VH segments are identical to what is found in the corresponding human VH segments. For example, all 19 germline VH segments from dromedary coded IGHV1S(1-19) have Alanine on position 19, Glycine on 26, Phenylalanine on 27 and 29 and Methionine on 34 as they predominantly occur in human germline family 3 members, which like these dromedary germline sequences have a canonical fold type 1 for H1 and fold type 1 for H2. Position 94 is encoded only in a single germline dromedary (out of the total of 39 germline VH segments) meaning that a proper analysis is not possible. Nguyen and colleagues (Nguyen et al., EMBO J. 19:921-930 (2000)) noticed that the dromedary germline VH and VHH segments “span from the conserved octamer (i.e. recombination signal) to the Cysteine residue 92 of FR3” (end of citation), whereas the human segments encode two additional residues (93 and 94). However, we will discuss this residue during the analysis of the only six known Somatically mutated VH segments derived from llama derived conventional antibodies.
There are virtually no exceptions for the perfect match with the human germline segments and the key residues proposed by Morea and colleagues (Morea et al., Methods 20:267-279 (2000)), besides residue 52a for llama germline IGHV1 S6 for canonical fold type 2 for loop H2, which has Serine on this position, while the human analogue uses Threonine. It is encouraging to observe that in four of the six published llama VH derived from somatically mutated conventional antibodies (Vu et al., Mol. Immunol. 34:1121-31 (1997) Threonine is found on position 52a. It is worthwhile to mention that Serine and Threonine are closely related, since they both have a polar hydroxyl group and small sidegroups, suggesting that it might be possible to exchange both residues during humanization.
Glutamine on position 71, which occurs in 1 out of 19 dromedary germline VH segments with a canonical fold type 1 for loop H2 and in 4 out of 16 dromedary germline VH with a canonical fold type 2 for H2, seems to be rather extraordinary. The H2 loop packs against the residue at site 71 and the position of the loop relative to the framework is mainly determined by the size of the residue at this site. Canonical structures 2 and 3 are found in H2 loops with 6 residues. Structure 2 occurs when residues 52a and 71 are small or medium sized hydrophobic residues, while canonical fold 3 occurs when residue 71 is Arginine or Lysine. It can not be predicted how often the dromedary germline segments with Glutamine on position 71 will be used in somatically mutated conventional antibodies, but the humanization of this residue in antibody leads with this particular residue needs to be carefully examined. The presence of Arginine and Glutamine on position 71 in the dromedary IGHV1 S(20, 22, 23, 24) family members with canonical fold 2 for H2 is rather unexpected, but on the other hand human germline VH1 family members VH1-9, VH1-10 and VH1-11 with canonical fold 2 for H2 have Arginine as well, while VH5 member 5-1 with fold 2 for H2 carries Glutamine on this position.
As Chothia and colleagues did when discussing the structural repertoire of the human VH segments (Chothia et al., J. Mol. Biol. 227:799-817 (1992)) we examined the individual amino acid residues of the H1 and H2 loops of the dromedary and llama VH segments along with the key residues and compared these with the human counterparts having the same canonical fold combination (Table 2). For dromedary germline VH family IGHV1S(1-19) with canonical fold 1 for H1 and fold 1 for H2, and family IGHV1 S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1S8 with fold 1 for H1 and fold 2 for H2 the H1 residues 26 to 33 and the are shown together with the key residues 24 and 94 located outside of H1 (Table 2A). In addition, for dromedary germline VH family IGHV1S(1-19) with canonical fold 1 for H1(H1: 1) and fold 1 for H2 (H2: 1), and family IGHV1 S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1 S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1 S8 with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) the H2 residues 52 to 56 were analyzed with key residue 71, which is located outside H2 (Table 2B).
It is surprising to see the very high degree of sequence homology in the variable loops, especially in H1 there are hardly differences with the relevant human sequences. For instance, germline dromedary family IGHV1S(1-19) with canonical fold combination H1: 1/H2: 1 contains predominantly Alanine on position 24, Glycine on 26, Phenylalanine on 27, Threonine on 28, Phenylalanine on 29, Serine on 30 and 31, Tyrosine on 33, Methionine on 34 and Serine on 35, which completely match the human germline family 3 members that share the same combination of H1 and H2 canonical folds. Exceptions are residue 27 (Phenylalanine) and 32 (Serine) of the only publicly known llama germline VH segment, but again in 4 out of 6 somatically mutated llama VH which are publicly known (Vu et al., Mol. Immunol. 34:1121-1131 (1997)). Tyrosine is present on 32 as is found in the analogue human germlines. The same high degree of sequence homology is found for the H2 loops of dromedary germline VH segments with the exception of residue 54 of family IGHV1S(1-19). Especially dromedary family IGHV1S(21, 25-39) deviates on a number positions in the H2 loop (i.e. 53, 54, 56 and 58). The H2 loop of the llama germline VH segment with the same fold scores much better, but as well contains a number of deviating residues on position 50, 52, 52a, 54, 55 and 58, but the interpretation is rather difficult, since the analysis was performed with the only known germline segment. The analysis of somatically mutated VH derived from llama shows that certain residues on these positions occur, which also appear in the corresponding human germline sequences, although infrequently (f.i. Glycine on 50, Asparagine on 52 and 58, Threonine on 52a and Glycine on 55).
We also analyzed the panel of six publicly known somatically mutated VH sequences from llama (Vu et al., Mol. Immunol. 34:1121-31 (1997)). Below the alignment with human VH3 member 3-23 is shown, demonstrating a very high degree of sequence homology: overall, only 3 deviating residues were observed, one of which is encoded by the primer used for amplification, while the other two occur in human germlines of the same class. Even the CDRs show to have a very high degree of sequence homology: CDR1 is probably identical, while only three residues of CDR2 are different. Canonical fold analysis reveals that two VH have fold 1 for H1 and fold 2 for H2, as was observed for the only available llama derived germline VH, but the other four have fold 1 for H1 and fold 3 for H2 as occurs in 3-23 and the majority of the human family VH3 germline segments. This might be suggesting that these are derived from other, not yet known germline VH segments. Examination of the key residues supporting the canonical folds gives the perfect match with those occurring in human germline with the same canonical fold combination as was already observed for the llama germline VH segment listed in Table 1. It is very interesting to see that key residue 94 in these somatically mutated sequences is Lysine (2 out of 5), Serine (1 out of 5) and Arginine (1 out of 5), which are all found in the human germlines with the same fold combination or are proposed by Morea and colleagues (Morea et al., Methods 20:267-279 (2000)).










11.1 Somatically mutated Llama VH from conventional antibodies (SEQ ID NOS: 104-110)
















IGHV
         FR1-IMGT         CDR1-IMGT        FR2-IMGT       CDR2-IMGT


gene
          (1-26)           (27-38)         (39-55)         (56-65)






1       10        20         30         40        50         60 



.........|.........|...... ...|........ .|.........|..... ....|.....


M99660, IGHV3-23
EVQLLESGG.GLVQPGGSLRLSCAAS GFTFSSYA.... MSWVRQAPGKGLEWVSA ISGSGGST..


IVH28
EVQLVESGG.GLVQPGGSLRLSCAAS GFAFSSYD.... MSWVRQAPGKGLEWVSA INSGGIST..


IVH69
EVQLVESGG.GLVQPGRSLRVSYAAS GFTFSSHY.... MSWVRQDPEKGLEWVSE IATGGTIT..


IVH47
EVQLVESGG.GLVQPGGSLRLSCAAS GLTFDDYA.... MSWVRQAPGKGLEWVST IYTHSRNT..


IVH48
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYV.... MSXVRQAPGKGPEWVSG VNTDGRSI..


IVH70
EVQLVESGG.GLVQPGGSLRVSCAAS GFTFSSLY.... MSWVRQVPGKGLEWVST IHTASGST..


IVH71
EVQLVESGG.GLVQPGGSLRLSCAAS GFTFSSYD.... MSWVRQAPGKGLEWVSG IYSDGTTT..





IGHV
                FR3-IMGT               CDR3-IMGT


gene
                (66-104)               (105-115)






   70        80        90        100       110 



....|.........|.........|.........|.... .....|.....



  (J1, 4, 5)


M99660, IGHV3-23
YYADSVK.GRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AK.........     WGQGTLVTVSS


IVH28
YNADSMK.GRFTISRDNAKNTVYLQMNSLKPEDTAVYYC NADTWYCDQLDSSDY WGQGTQVTVSS


IVH69
SYADSVK.GRFTISRDNANNMLFLQMNNLKPEDTALYYC VRRGRAIA....FDV WGQGTLVTVSS


IVH47
YYADSVK.GRFTISRDNAKNTLYLQMNSLKSDDTALYYC AKEWVGSVVEGRYRG WGQGTLVTVSS


IVH48
TYADSVK.GRFTISRDNAKNTLYLQMNSLKPEDTAVYYC TKICTVITGRPGYDY WGQGTLVTVSS


IVH70
FYADSVQ.GRFLVSRDNAKNTLYLQMDSLKPEDTARYYC ASAILGQ.....YDY WGQGTLVTVSS


IVH71
YDGDSVK.GRFTISRDNAKNMLYLQMNSLKPEDAAVYYC ASAIRGW.....YDY WGQGTLVTNSS










A) Sequence homology:


1) position 5 Valine (primer encoded) also found in f.i. IGHV3-15


2) position 83 Alanine is found more often in human VH3 germlines then Serine of 3-23


3) position 95/96 Lysine/Proline occurs in IGHV3-15/49/73 as Lysine/Threonine


4) CDR1 is completely human-like, in CDR2 only residues 57, 58 and 59 seem to deviate


from human germline 3-23 (57 Serine, 58 Glycine, 59 Serine)


5) FR4 gives perfect match with human J1, J4 and J5


 


B) Canonical fold analysis


1) combination fold 1 for H1 and fold 2 for H2 for IVH28 and 1VH69 (as in 3 out of


11 human germline family VH1 members and both human germline family VH5 members)


2) for IVH47, 48 70 and 71 combination fold 1 for H1 and fold 3 for H2 as found in


3-23 and majority of family VH3 members


 


Examples of analysis:


IVH28:


CDR H1 Class ?


! Similar to class 1/10A, but:


! H33 (Chothia Numbering) = D (allows: YAWGTLV)


! H94 (Chothia Numbering) = A (allows: RKGSHN)


 


CDR H2 Class ?


! Similar to class 2/10A, but:


! H33 (Chothia Numbering) = D (allows: YWGATL)


! H59 (Chothia Numbering) = N (allows: Y)


! H71 (Chothia Numbering) = R (allows: VAL)


 


IVH47:


CDR H1 Class 1/10A [2fbj]


CDR H2 Class ?


! Similar to class 3/10B, but:


! H52 (Chothia Numbering) = Y (allows: SFWH) 


! H53 (Chothia Numbering) = H (allows: DGSN)









Example 12
Analysis Key Residues for Canonical Folds of L1(λ) and L2(λ) and Comparison of L1(λ) and L2(λ) Residues with Human Germline
Also the predicted canonical structures of L1 and L2 were analyzed for the somatically mutated dromedary VLambda segments based on length of the loops and the presence of the key residues relevant for the canonical folds. The comparison was made with the key residues occurring in the closest matching human germline with the same combination of canonical folds and overall sequence homology (Table 3). For the somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-12/32 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the key residues 2, 25, 29, 30, 33 and 71 relevant for the canonical fold of L1 are shown along with these from the analogue human germline family with the same canonical fold combination (upper part of Table 3). For somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-12/32 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the key residues 48 and 64 important for the canonical fold of L2 are shown along with the key residues from the analogue human germline families having the same canonical fold combinations (lower part Table 3).
As observed for VH the analysis reveals the “human nature” of both canonical loops L1 and L2, because here also the key residues of the camelid VLambda segments are identical to those of the corresponding human VLambda segments. For example, in dromedary VL3-12/32, VL1-40 and VL2-18 all key residues of L1 are identical to those occurring in the corresponding human germlines, and in dromedary VL3-1, VL3-12/32 and VL2-18 the key residues of L2 completely match with the corresponding human germline VL segments. Basically there are only two exceptions. First of all, L2 key residue 64 of VL1-40 is Glutamate, which is rather different from Glycine that is present in human germline Vλ1 with the same L1/L2 combination of canonical folds as VL1-40. It is difficult to draw general conclusions, since VL1-40 only consists of an orphan (i.e. Camvl44). The second exception is VL3-1, where Phenylalanine is the most dominantly occurring L1 key residue on position 30, whereas Leucine is frequently found in human Vλ family 3 members that share fold 11 for L1 and fold 7 for L2 with VL3-1. However, Leucine is also present in one out of the five VL3-1 members.
We analyzed the individual amino acid residues of the L1 and L2 loops of the somatically mutated dromedary VLambda segments along with the key residues and made the comparison with the human counterparts sharing the same canonical fold combination (Table 4). For the somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-12/32 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), the L1 residues 27 to 33 together with key residue 71 outside L1 are compared with the same residues present in the corresponding human germline Vλ with same combination of folds for L1 and L2 (upper part of Table 4A). For dromedary somatically mutated dromedary VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the L1 residues 26 to 33 together with key residues 2 and 71 outside L1 are compared with the same residues present in the corresponding human germline Vλ family with same combination of folds for L1 and L2 (lower part of Table A). In addition, for somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-12/32 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the L2 residues 49 to 53 together with key residues 48 and 64 located outside L2 are compared with the same residues present in the corresponding human germline Vλ family with the same combination of canonical folds for L1 and L2 (Table 4B). There is a high degree of sequence homology between the L1, L2 and key residues with the human germline sequences and only few exceptions exist, which mainly can be found in the orphan members of the VL3-12/32 and VL1-40 families. For L1 of VL3-12/32 residues 27, 28, 30, 30a and 30b deviate from the corresponding human germline Vλ family 3, while for the same loop residues 30b, 31 and 32 of VL1-40 are different from the matching human germline Vλ family 1. In the orphan member of VL3-12/32 L2 residue 50 differs from the human analogue, while for the only member of VL1-40 key residue 64 differs from the human analogue. A fundamental difference can be observed for L1 residue 28 of dromedary family VL2-18 (Asparagine or Glutamate versus Serine in analogue human Vλ family 2).
Example 13
Analysis Key Residues for Canonical Folds of L1(κ) and L2(κ)) and Comparison of L1(κ)) and L2(κ)) Residues with Human Germline
The predicted canonical structures of L1(κ)) and L2(κ)) were analyzed for the somatically mutated dromedary VKappa segments based on loop length and presence of key residues. As before the comparison was made with the key residues occurring in the closest matching human germline with the same combination of canonical folds and overall sequence homology (Table 5). For the somatically mutated dromedary VK family VK2-40 (Kp1, 3, 6, 7, 10, 20 and 48), with fold 3 for L1 (L1: 3) and fold 1 for L2 (L2: 1) the key residues 2, 25, 29, 30e, 33 and 71 relevant for the canonical fold of L1 are shown along with these from the analogue human VKappa germline family 2 with the same canonical fold combination. In addition the key residues compatible with the corresponding canonical fold as proposed by Morea et al. are shown in the bottom line. There is a perfect match for key residues 2, 25, 33 and 71 and to a certain degree for residue 29. Residue 30e of the dromedary VKappa is Glutamine in stead of Glycine, but Morea and colleagues (Morea et al., Methods 20:267-279 (2000)) suggested this residue to be perfectly compatible with the fold 3 for L1.
For the same somatically mutated dromedary VK family VK2-40 (Kp1, 3, 6, 7, 10, 20 and 48) with fold 3 for L1 (L1: 3) and fold 1 for L2 (L2: 1) the key residues 48 and 64 determining the canonical fold of L1 are shown together with these from the analogue human VKappa germline family 2. Here again the match is perfect.
The individual amino acid residues of the L1 and L2 loops of the somatically mutated dromedary VKappa segments along with the key residues were compared with those occurring in the human counterpart (VK family 2) that shares the same canonical fold combination (Table 6). For the somatically mutated dromedary VK family VK2-40 (Kp1, 3, 6, 7, 10, 20 and 48) with fold 3 for L1 (L1: 3) and fold 1 for L2 (L2: 1) the L1 and L2 residues were compared with those found in germline VK family 2 that has the identical canonical loop combination. The majority of the residues are shared between the dromedary somatically mutated VK and the human germline, such as Isoleucine on position 2, Serine on 25, 26 28 and 30b, Glutamine on 27, Tyrosine on 32, Leucine on 33 and Phenylalanine on 71. However, a few differ from the human analogue, i.e. Valine on 29 (although Leucine of human germline also occurs in the dromedary VK), Phenylalanine on 30 (again human residue Leucine is found as well in dromedary VK), Serine on 30a (human residue Glutamate occurs infrequently in dromedary VK), Serine on 30c, Asparagine on 30d, Glutamine on 30e, Lysine on 30f and finally Serine on 31.
Together with the key residues the residues of the L2 loop of the somatically mutated dromedary VKappa segments were compared those occurring in the human counterpart (VK family 2) that shares the same canonical fold combination (Table 6). Here again a perfect match was observed from residue Isoleucine on 48, Tyrosine on 49, Serine on 52 and Glycine on 64, while deviations were found on position 50 (Tyrosine in stead of Threonine from human VK family 2), and 51 (Alanine on 51 instead of Leucine).
Overall Conclusion
This analysis of the camelid VH and VL sequences demonstrates a very high homology if not identity to the human key residues defining the canonical folds as well as to the residues found in the hypervariable loops themselves. This suggests that the vast majority of the camelid immunoglobulin sequences will adopt the canonical folds as found in the human germlines, not only for the individual hypervariable loops but as well as for the combination of canonical folds found in human VH and VL.







TABLE 1







Sites of key residues for determining canonical folds in germline dromedary and llama VH. 












Canonical
Closest hu
H1 key residues
H2 key residues



















Sequence
structure
GL family
24
26
27
29
34
94
52a
54
55
71





GI Drom IGHV1S
H1: 1
(3-53)
A(19)
G(19)
F(19)
F(19)
M(19)
G(1); -(18)






(1-19)














Hu GI family 3


A(23); 
G(24)
F(24)
F(22); 
M(23); 
R(18); 









G(1)


V(2)
T(1)
K(5); 














T(1)






GI Drom IGHV1S
H1: 1
(3-23)
A(4)
G(4)
F(4)
F(4)
M(4)
—






(20, 22, 23, 24)














Hu GI family 3


A(23); 
G(24)
F(24)
F(22); 
M(23);
R(18); 









G(1 )


V(2)
T(1)
K(5);














T(1)






GI Drom IGHV1S
H1: 1
(VI-4, 1b)
A(16)
G15; 
F(16)
F(14); 
M(13); 
—






(21, 25-39)



A(1)

S(1);
I(2);













Y(1)
V(1)







Hu GI family 1


A(19); 
G(21)
Y(18); 
F(20); 
M(13); 
R(17); 









V(2)

F(1);
L(1)
I(5);
T(2);











G(2)

L(2); 
A(1)













V(1)







GI Llama IGHV1S6
H1: 1
(3-23)
A(1)
G(1)
F(1)
F(1)
M(1)
A(1)






Hu GI family 1


A(19); 
G(21)
Y(18); 
F(20); 
M(13); 
R(17); 









V(2)

F(1);
L(1)
I(5);
T(2);











G(2)

L(2);
A(1)













V(1)








H1: 1 

A; V; 
G
F; Y; 
F; L; 
M; V; 
R; G; 







(Morea)

S; T

S; D
I
I; Y; W
N; K; S






GI Drom IGHV1S
H2: 1
(3-53)






—
—
G(19)
R(18); 


(1-19)











Q(1)


Hu GI family 3








—
—
G(4)
R(4)



H2. 1 









G, D
K, R, 



(Morea) 










V, I


GI Drom IGHV1S
H2: 3
(3-23)






—
G(4)
—
R(4)


(20, 22, 23, 24)














Hu GI family 3








—
G(13); 
—
R(14)












S(3)





H2: 3 







—
G; S; 
—
R; K



(Morea)








N; D




GI Drom IGHV1S
H2: 2
(VI-4, 1b)






S(10); 
—
G(16)
R(8); 


(21, 25-39)








T(6)


K(4);














Q(4)


Hu GI family 1








P(3); 
—
G(7)
A(3); 











T(2);


T(2);











A(2)


L(2)



H2: 2 







P; T; 

G; N; 
A; L; 



(Morea)







A

D; S
T


GI Llama IGHV1S6
H2: 2
(3-23)






S(1)
—
S(1)
T(1)


Hu GI family 1








P(3); 
—
G(7)
A(3); 











T(2);


T(2);











A(2)


L(2)



H2: 2 







P; T; 

G; N; 
A; L; 



(Morea)







A

D; S
T





Number between brackets indicates frequency of residue as found in dromedary/llama or human germline; numbering of key residues according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)) and key residues proposed by Morea and colleagues. (Morea et al., Methods 2000).


Ha: b indicates canonical fold type b for loop Ha.













TABLE 2(A)







Comparison of H1 sequences for dromedary and llama germline VH with human germlines; numbering according to 


Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)). 











H1: 1 residue no.
























2
2
2
2
2
3
3
3
3
3
3
3
3
9




4
6
7
8
9
0
1
1a
1b
2
3
4
5
4




*
*
*

*






*

*
























GI Drom IVHG1S
A(19)
G(19)
F(19)
T(19)
F(19)
S(19)
S(19)
—
—
Y(19)
Y(14);
M(19)
S(17);
G(1)


(1-19)










D(2);

Y(2)



































W(2);

















A(1)





Family 3
Hu GL
A(3);
G(4)
F(4)
T(4)
V(2);
S(4)
S(4)
—
—
N(2);
Y(2);
M(4)
S(2);
R




G(1)



F(2)




Y(2)
A(1);

H(2)















D(1)
























GI Drom IGHV1S
A(4)
G(4)
F(4)
T(4)
F(4)
S(4)
S(4)
—
—
Y(4)
W(3);
M(4)
Y(3); 
—


(20, 22, 23, 24)










Y(1)

S(1)























Family 3
Hu GL
A(16)
G(16)
F(16)
T(16)
F(16)
S(13);
S(11);
—
—
Y(15);
A(6); 
M(15);
H(9);
R(11);









D(3)
D(4);


H(1)
G(3);
T(1)
S(5);
K(5)










N(1)



Y(2); 

N(2)















W(2);

















S(1); 

















E(1);

















T(1)
























GI Drom IGHV1S
A(16)
G(15);
F(16)
T(16)
F(14);
S(16)
S(16)
—
—
Y(15);
W(7); 
M(13);
Y(8);
—


(21, 25-39)

A(1)


S(1);




C(1)
A(4);
I(2);
S(8)








Y(1)





D(3); 
V(1)















Y(1);





































C(1)





Family 1
Hu GL
A(6);
G(7)
Y(5);
T(7)
F(7)
T(5);
S(6);
—
—
Y(7)
A(4);
I(4);
S(4);
R(4);




V(1)

G(2)


S(2)
D(1)



G(2);
M(3)
N(2);
T(1); -(1)














Y(1)

H(1)






















GI Llama IGHV1S6
A(1)
G(1)
F(1)
T(1)
F(1)
S(1)
S(1)
—
—
S(1)
A(1)
M(1)
S(1)
A(1)






















Family 1
Hu GL
A(6);
G(7)
Y(5);
T(7)
F(7)
T(5);
S(6);
—
—
Y(7)
A(4);
I(4);
S(4);
R(4);




V(1)

G(2)


S(2)
D(1)



G(2);
M(3)
N(2);
T(1); -(1)














Y(1)

H(1)





Asterisks indicate key residues important for canonical folds.













TABLE 2(B)





Comparison of H2 sequences for dromedary and llama germline VH with human germlines; numbering 


according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)).



















H2: 1 residue no.























5
5
5
5
5
5
5
5
5
5
5
5
7




0
1
2
2a
2b
2c
3
4
5
6
7
8
1












*



*






GI Drom IGHV1S
G(17);
(18);
Y(16); 
—
—
—
S(19)
D(18); 
G(19)
S(18); 
T(19)
Y(17); 
R(18);



(1-19)
A(2)
N(1)
N(2);




R(1)

G(1)

N(1);
Q(1)















H(1)



Family 3
Hu GL
V(2); 
I(4)
Y(2); 
—
—
—
S(2); 
G(3); 
G(4)
S(2); 
T4
Y(4)
R(4)




A(2)

G(2)



T(2)
A(1)

G(1);
















D(1)














H2: 3 residue no.























5
5
5
5
5
5
5
5
5
5
5
5
7




0
1
2
2a
2b
2c
3
4
5
6
7
8
1











*




*






GI Drom IGHV1S 
T(3);G(1)
I(4)
N(4)
S(4)
—
—
G(3); 
G(4)
G(3); 
S(3); 
T4
Y(4)
R(4)



(20, 22, 23, 24)






D(1)

S(1)
N(1)





Family 3
Hu GL
V(5); 
I(15); 
S(12); 
Y(5); 
—
—
D(8); 
G(13); 
S(10); 
S(6); 
T(6); 
Y(12); 
R(16)




Y(4);
S(1)
N(2);
S(5);


S(4);
S(3)
G(6)
N(5); 
K(6) 
G(2); 





G(2);

W(1);
W(3); 


N(4)


T(3);
I(4)
T(1); 





A(2);

K(1)
G(2);





Y(1);

N(1)





R(1);


Q(1)





E(1)







N(1);
















L (1)














H2: 3 residue no.























5
5
5
5
5
5
5
5
5
5
5
5
7




0
1
2
2a
2b
2c
3
4
5
6
7
8
1











*




*






GI Drom IGHV1S 
A(9); 
I(16)
N(10); 
S(10); 
—
—
G(14); 
G(16)
G(16)
S(16)
T(16)
Y(16)
R(8); 



(21, 25-39)
S(4);

Y(6)
T(6)


A(2)





K(4);




T(2);











Q(4)




G(1)














Family 1
Hu GL
W(4); 
I(6); 
S(2); 
P(3); 
—
—
Y(2); 
N(2); 
G(7)
N(4); 
T(3); 
N(4); 
A(3); 




R(1);
V(1)
N(2);
T(2);


N(2);
T(2);

T(1);
P(2);
T(2);
L(2);




G(1);

I(2);
A(2)


I(2);
L(1);

I(1);
A(2)
I(1)
T(2)




L(1)

D(1)



E(1)
F(1);

E(1)














D(1)














H2: 2 residue no.























5
5
5
5
5
5
5
5
5
5
5
5
7




0
1
2
2a
2b
2c
3
4
5
6
7
8
1












*



*






GI Llama IGHV1S6
S(1)
I(1)
Y(1)
S(1)
—
—
Y(1)
S(1)
S(1)
N(1)
T(1)
Y(1)
T(1)


Family 1
Hu Gl
W(4); 
I(6); 
S(2); 
P(3); 
—
—
Y(2); 
N(2); 
G(7)
N(4); 
T(3); 
N(4); 
A(3); 




R(1);
V(1)
N(2);
T(2); 


N(2);
T(2);

T(1);
P(2);
T(2);
L(2);




G(1);

I(2);
A(2)


I(2);
L(1);

I(1);
A(2)
I(2)
T(2)




L(1)

D(1)



E(1)
F(1);

E(1)














D(1)





Asterisks indicate key residues important for canonical folds.













TABLE 3







Sites of key residues for determining canonical folds in somatically mutated dromedary VLambda sequences; numbering 


according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)) and key residues proposed by 


Morea and colleagues (Morea et al., Methods 2000).













Closest





Canonical 
hu GL 
L1(λ) key residues
L2(λ) key residues

















Sequence
structure
family
2
25
29
30
33
71
48
64





Som Mut Dron VL3-1 
L1: 11 (or 2)
(IGLV3-1*01)
—
G(5)
—
F(4);
T(2);
T(4);




(CamvI8, 18, 19, 20, 23)





L(1)
A(1); 
A(1)











V(1);












E(1)





Hu GI Vλ family 3


—
G(10)
—
L(6);
A(6);
A(5);










I(3);
V(3);
T(3);










M(1)
E(1)
V(2)





L1: 2 (Morea)

—
G
—
I
V
A




Som Mut Dron VL3-12/32
L1: 11 (or 2)
(IGLV3-1*01)
—
G(1)
—
L(1)
A(1)
I(1)




(CanvI11)












Hu GI Vλ family 3


—
G(10)
—
L(6);
A(6);
A(5);










I(3);
V(3);
T(3);










M(1)
E(1)
V(2)





L1: 2 (Morea)

—
G
—
I
V
A




Som Mut Dron VL1-40 
L1: 14 (or 6)
(IGLV1-40*01)
S(1)
G(1)
N(1)
—
V(1)
A(1)




(CamvI44)












Hu GI Vλ family 


S(2)
G(2)
N(2)
—
V(2)
A(2)





L1: λ6 (Marin)

S
G
N
—
V
A




Som Mut Dron VL2-18
L1: 14 (or 6)
(IGLV2-18*02)
S(11);
G(12)
D(12)
—
V(12)
A(11);




(CamvI5, 17, 30-33, 36, 52, 57,


A(1)




V(1)




59, 60, 65)












Hu GI Vλ family 2


S(6)
G(6)
D(6)
—
V(6)
A(6)





L1: λ6 (Marin)

S
G
N
—
V
A




Som Mut Dron VL3-1
L2: 7
(IGLV3-1*01)






I(4);
G(3);


(CamvI8, 18 19, 20, 23)








L(1)
A(2)


Hu GI Vλ family 3








I(10)
G(10)



L2 1 (Morea)







I; V
G


Som Mut Dron VL3-12/32
L2: 7
(IGLV3-1*01)






(1)
G(1)


(CanvI11)












Hu GI Vλ family 3








I(10)
G(10)



L2 1 (Morea)







I; V
G


Som Mut Dron VL1-40
L2: 7
(IGLV1-40*01)






(1)
E(1)


(CamvI44)












Hu GI Vλ family 








(2)
G(2)



L2 1 (Morea)







I; V
G


Som Mut Dron VL2-18
L2: 7
(IGLV2-18*02)






I(12)
G(11);


(CamvI5, 17, 30-33, 36, 52, 57, 59,









S(1)


60, 65)












Hu GI Vλ family 2








(6)
G(6)



L2 6 (Morea)







I; V
G
















TABLE 4(A)





Comparison of L1 sequences of dromedary VLambda with human germlines; numbering according to Kabat et al.


(Sequences of Proteins of Immunological Interest, 5th ed. (1991)).

















L1:11 residue no.


























3





3
7



0
2
2
2
2
0
3
3
3
3
3
3
1



2
6
7
8
9
*
0a
0b
0c
1
2
*
*





Som Mut Drom VL3-1
—
—
G(4);
N(3);
—
F(4);
G(5)
S(4);
Y(4);
—
Y(4);
T(2);
A(5)


(Camv18, 18, 19, 20, 23)


D(1)
D(1);

L(1)

D(1)
K(1)

K(1)
A(1);







I(1)







V(1);















F(1)



Family 3















Hu G1 Vλ family 3
—
—
D(6); 
N(3);
—
L(6);
G(5);
S(4);
K(6);
—
Y(7);
A(6);
A(3);





N(3);
A(3);

I(3);

K(3);
Y(1)

A(1);
V(3);
T(3);





E(1)
S(2);

M(1)

D(1);
N(1);

S(1);
E(1)
V(2);






K(1);


E(1)
E(1) 
Q(1);

N(1)








V(1)



G(1)
S(1)












L1:11 residue no.


























3






7



0
2
2
2
2
0
3
3
3
3
3
3
1



2
6
7
8
9
*
0a
0b
0c
1
2
3
*





Som Mut Drom VL3-
—
—
S(1)
L(1)
—
R(1)
N(1)
Y(1)
Y(19);
—
A(1)
A(1)
A(1)


12/32 (Camv111)








C(1)






Family 3















Hu G1 Vλ family 3
—
—
C(6);
N(3);
—
L(6); 
G(5);
S(4);
K(6);
—
Y(7);
A(6);
A(3);





N(3);
A(3);

I(3);
P(3);
K(3); 
Y(1);

A(1);
V(3);
T(3);





E(1)
S(2);

M(1)
R(1);
D(1);
N(1);

S(1);
E(1)
V(2)






K(1);


E(1)
E(1);
Q(1);

N(1)








V(1)



G(1)
S(1)












L1:14 residue no.





















0



2






3
7



2
2
2
2
9
3
3
3
3
3
3
3
1



*
6
7
8
*
0
0a
0b
0c
1
2
*
*





Som Mut Drom VL1-
S(1)
S(1)
S(1)
S(1)
N(1)
I(1)
G(1)
G(1)
G(1)
S(1)
G(1)
V(1)
A(1)


40 (Camv144)















Family 1















Hu G1 Vλ family 1
G(2)
E(2)
S(2)
S(2)
N(2)
I(2)
G(2)
A(2)
G(2)
Y(2)
D(1);
V(2)
A(2)













V(1)












L1:14 residue no.





















0 



2






3
7



2
2
2
2
9
3
3
3
3
3
3
3
1



*
6
7
8
*
0
0a
0b
0c
1
2
*
*





Som Mut Drom VL2-
S(1);
T(12)
S(10);
N(3);
D(11);
V(12)
G(12)
G(5); 
Y(2)
N(11);
Y(12)
V(12)
A(1);


18 (Camv15, 17,30-
A(1)

F(2)
D(3)
G(1)


R(4); 

A(1)


N(1)


33,36,52,57,59,60,65)







K(2);















A(1)







Family 2















Hu G1 Vλ family 2
S(6)
T(6)
S(6)
S(6)
D(6)
V(6)
G(6)
G(3);
Y(6)
N(5);
Y(3);
V(6)
A(6)










S(2);

D(1)
F(1);












D(1)


L(1);















Y(1)





Asterisks indicate key residues important for canonical folds.













TABLE 4(B)







Comparison of L2 sequences of dromedary VLambda with human germlines; numbering according to 


Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)). 











L2: 7 residue no.

















4





6




8
4
5
5
5
5
4




*
9
0
1
2
3
*



















Som Mut Drom VL3-1
I(4);
Y(5)
K(3);
D(4);
S(2);
A(1);
G(3);



(Camv8, 18, 19, 20, 23)
L(1)

R(1);
N(1)
T(2);
L(1);
A(2)






G(1)

D(1)
E(1);










N(1);










S(1)



Family 3
Hu GI Vλ family 3
I(10)
Y(10)
E(2);
D(8);
S(9);
E(3);
G(10)






K(2);
K(1);
N(1)
N(3);







D(1);
S(1)

K(2);







Q(1);


D(2)







R(1);










S(1);










G(1);










Y(1)







Som Mut Drom VL3-12/32
I(1)
Y(1)
N(′)
D(1)
N(1)
N(1)
G(1)



(CamvI11)









Family 3
Hu GI Vλ family 3
I(10)
Y(10)
E(2);
D(8);
S(9);
E(3);
G(10)






K(2);
K(1);
N(1)
N(3);







D(1);
S(1)

K(2);







Q(1);


D(2)







R(1);










S(1);










G(1);










Y(1)







Som Mut Drom VL1-40
I(1)
Y(1)
G(′)
N(1)
S(1)
N(1)
E(1)



(CamvI44)









Family 1
Hu GI Vλ family 1
I(2)
Y(2)
G(2)
N(2)
S(2)
N(2)
G(2)



Som Mut Drom VL2-18
I(12)
Y(12)
Q(11);
V(9);
N(10);
K(12)
G(11);



(CamvI5, 17, 30-33, 36, 52, 57,


D(1)
I(2);
S(1);

S(1)



59, 60, 65)



D(1)
D(1)




Family 2
Hu GI Vλ family 2
I(6)
Y(6)
E(4);
V(6)
S(5);
K(3);
G(6)






D(′);

N(1)
N(2);







N(1)


T(1)





Asterisks indicate key residues important for canonical folds.













TABLE 5







Sites of key residues for determining canonical folds in somatically mutated dromedary VKappa sequences; 


numbering according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)) and 


key residues proposed by Morea and colleagues (Morea et al., Methods 2000).












Canonical
Closest
L1(κ) key residues
L2(κ) key residues

















Sequence
structure
hu GL family
2
25
29
30e
33
41
48
64





Som Mut Drom VK2-10
K1: 3
IGKV2-40
I(7) 
S(7)
V(6);
Q(7)
L(7)
F(7)




(Kp1, 3, 6, 7, 10, 20, 48)

(2_1 or 011 */01)


L(1)







Hu GL VK family 2


I(1)
S(1)
L(1)
G(1)
L(1)
F(1)





K1: 0 

I
O
L; V
C; Q; G
L
T





(Morea)











Som Mut Drom VK2-40
K2: 1
IGKV2-40






I(7)
G(7)


(Kp1, 3, 6, 7, 10, 20, 48)

(2_1 or 011 */01)










HuGL VK family 2








I(1)
G(1)



H2: 1 







I; V 
G



(Morea)
















TABLE 6





Comparison of (A) L1 and (B) L2 sequences of dromedary VKappa with human germline; numbering 


according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)).



















L1(κ): 11 residue no.




























2



2









3
7




2
5
2
2
2
9
3
3
3
3
3
3
3
3
3
3
1




*
*
6
7
8
*
0
0a
0b
0c
0d
0e
0f
1
2
*
*






Som Mut 
I
S
S
Q
S
V
F
S
S
S
N
Q
K
S
Y
L
F



Drom
(7)
(7)
(7)
(7)
(5);
(6);
(3);
(5);
(4);
(7)
(4);
(7)
(6);
(7)
(3);
(7)
(7)



VK2-40




N
L
L
D
D

S

R

L





(Kp1, 




(1);
(1)
(2);
(1);
(1);

(2);

(1)

(2);





3, 6,




H

I
A
T

R



Q





7, 10,




(1)

(1);
(1)
(1);

(1)



(1);





20, 48)






V

V





F












(1);

(1)





(1)




Fam- 
Hu GI 
I
S
S
Q
S
L
L
D
S
D
D
G
N
T
Y
L
F


ily
VK
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)


2
family 2




















(011 */01)
























(B)











L2(κ): 11 residue no.
















4




6




8
4
5
5
5
4




*
9
0
1
2
*






Som Mut 
I(7)
Y(7)
Y(7)
A(7)
S(7)
G(7)



Drom









VK2-40









(Kp1, 3, 









6, 7, 10, 









20, 48)








Fam- 
Hu GI VK 
I(1)
Y(1)
T(1)
I(1)
S(1)
G(1)


ily
family 2








2
(011 */01)





Asterisks indicate key residues important for canonical folds.






Example 14
Sequence Analysis of Somatically Mutated VH, VK and VL from Llama
From four llamas peripheral blood lymphocytes were isolated, RNA extracted and random primed cDNA synthesized as described before (de Heard et al, JBC 1999). Amplification of VHCH1, VLCL and VKCK was performed and the amplicons were cloned in vector pCB3 yielding heavy chain or light chain libraries. After screening of clones with PCR to check for the presence of the antibody domain insert, individual clones were grown and plasmid DNA was purified for sequence analysis.
Section 14.A shows the lambda light chain variable regions grouped into families according to the closest human germline analogue with the same CDR1 and CDR2 length and presumable having the same canonical fold combination. The lambda germlines most frequently used in humans, i.e. VL1, VL2 and VL3, are also often found in the analyzed llama sequences and in addition VL4, VL5, VL6 (not shown in section 14.A) and VL8, meaning that 7 out of the 10 lambda families as found in humans are used as well in the llama. Section 14.B shows two of the three kappa light chain variable regions (i.e. VK1, and VK4; VK2 is not shown), which occur in about 50% of kappa containing human antibodies. Members of the VK3 family, which is used most frequently (50%) in human antibodies, were not identified, but it can well be that the used primers for amplification are responsible for this and that these have to be adapted. Section 14.0 shows the alignment of the VH sequences revealing a high sequence homology to the most often used human VH3 segment (occurs 34% in human antibodies) and VH1 (17%). It must be noted that the recent publication of Achour et al (J Immunol 2008) mentions the presence of a VH2 family in the germline of Alpaca which is most closely related to the human VH 4 family (see example 10.10).
Overall it can be concluded that camelids use a high diversity of heavy chain and light chain families similar to what is found in the human immune system, meaning that by active immunization with human disease targets an excellent choice of lead antibodies can be expected with a high sequence homology to human antibodies, which therefore can be easily engineered for therapeutic applications.










14.(A) VLAMBDA (SEQ ID NOS: 111-138) SEQ ID NOS: 139-149)

















   FR1              CDR1             FR2         CDR2






               2             3             4          5 



1234567891234567890123 45678901abc234 567890123456789 01abcde


HuVL1-1(3/4/5)
QSVLTQPPSVSEAPRQRVTISC SGSSSNIGNN AVN WYQQLPGKAPKLLIY YD


LAMBDA#14
QPVLTQPPSVSGSPGQKFTISC TGSSSNIGNN YVN WYQHLPGTAPRLLIY SN


LAMBDA#16
QSALTQPPSVSGSPGQKFTISC TGSSSNIGDN YVN WYQHLPGTAPKLLIY SN


LAMBDA#46
NFMLTQPPSVSGSPGQKFTISC TGSSSDIGNN YVN WYQHLPGTAPKLLIY ST


LAMBDA#45
NFMLTQPPSVSGSPGQKFTISC TGSSSNIGEN FVN WYQHLPGTAPKLLIY ST


LAMBDA#15
NFMLTQPPSVSGSPGQKFTISC TGSNNNIGNN YVN WYQHLPGTAPKLLIY SN






 CDR2              FR3                     CDR3          FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde


HuVL1-1(3/4/5)
DLLPS GVSDRFSGSKSG  TSASLAISGLQSEDEADYYC AAWDDSLNG


LAMBDA#14
NNRAS GVPDRFSGSKSG  SSASLTITGLQAEDEAEYYC SSWDDSLSGTV  FGGGTHLTVL


LAMBDA#16
SNRAS GVPDRFSGSKSG  SSASLTITGLQAEDEADYYC SSWDDSLSGHPV FGGGTKLTVL


LAMBDA#46
DKRAS GVPDRFSGSKSG  SSASLTITGLQAEDEADYYC SSWDDNLGTYV  FGGGTSVTVL


LAMBDA#45
DKRAS GVPDRFSGSKSG  SSASLTITGLQAEDEADYYC SSWDDNLGTYV  FGGGTSVTVL


LAMBDA#15
NYRAS GVPDRFSGSKSG  SSASLTITGLQAEDEADYYC SSWDESLSGRYV FGGGTKLAVL






   FR1              CDR1             FR2         CDR2






               2             3             4          5



1234567891234567890123 45678901abc234 567890123456789 01abcde


HuVL1-2
QSVLTQPPSVSGAPGQRVTISC TGSSSNIGAGYDVH WYQQLPGTAPKLLIY GN


LAMBDA#47
QSALTQPPSVSGTLGKTVTISC AGTSNDIGRYNYVA WYQQLPGTAPKLLIY AV


LAMBDA#18
QSALTQPPSVSGTLGKTLTISC AGTSSDVGYGNYVS WYQQLPGTAPKLLIY RV


LAMBDA#32
QSALTQPPSVSGTLGKTVTISC AGTRTDVGYGDYVS WYQHVPNTAPRLLIY AV


LAMBDA#28
QAVLTQPPSVSGTLGKAVTISC AGTGSDVGYGDYVS WYQQLPDTAPKLLVY AV


LAMBDA#29
NFMLTQPPSVSGSPGKTVTISC AGTSSDVGYGNYVS WYQQLPGMAPKLLLY NI


LAMBDA#27
QSALTQPPSVSGTLGKTVTISC AGTNSDIGDYNFVS WYQHLPGMAPKLLIY DV


LAMBDA#17
QAGLTQPPSVSGSLGKTITISC AGTRNDIGGHGYVS WYQQLPGTAPKLLIY KI


LAMBDA#4
SSELTQPPSVSGTLGKTVTISC AGTSNDIGAHNYVS WYQQLPGTAPKLLIN KV


LAMBDA#7
QPVLTQPPSVSGSPGKTVTISC AGTSSDIGYGNYVS WYQLLPGTAPKLLIY DV


LAMBDA#8
QSALTQPPSVSGSLGKTVTISC AGTIGDIGAGNYVS WYRQTPGTAPKLLLY EV


LAMBDA#5
QPVLTQPPSVSGSLGKTVTISC AGTWSDIGGYNYIS WYRQLPGTAPRLLIY EV






 CDR2              FR3                     CDR3          FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde


HuVL1-2
SNRPS GVPDRFSGSKSG  TSASLAITGLQAEDEADYYC QSYDSSLSG


LAMBDA#47
SYRAS GIPDRFSGSKSG  NTASLTISGLQSGDEADYYC VSYRSGGTNV   FGGGTHLTVL


LAMBDA#18
SYRPS GIPDRFSGSKSG  NTASLTISGLQSEDEADYYC TSYTYKGGGTAV FGGGTHLTVL


LAMBDA#32
SARAS GIPSRFSGSKSG  NTASLTISGLQSEDEADYYC ASYRDGNYAV   FGGGTHLTVL


LAMBDA#28
NTRAS GIPDRFSGSRSG  NTASLTISGLQSEDEGDYYC ASYRSYNNYV   FGGGTHLTVL


LAMBDA#29
NKRAS GIADRFSGSKSG  NTASLTISGLQSEDEAVYYC ASYRSGNNYV   FGGGTELTVL


LAMBDA#27
NKRAS GIADRFSGSKSG  NTASLTISGLQSEDEADYYC ASYRSSNNYV   FGGGTKLTVL


LAMBDA#17
NTRAS GIPDRFSGSKSG  NTASLTISGLQSEDEADYFC VADINGDTNV   FGGGTHLTVL


LAMBDA#4
STRAS GIPDRFSGSKSG  NTASLTISGLQSEDEADYYC AAYRTGDARI   FGGGTHLTVL


LAMBDA#7
NKRPS GIPDRFSGSKSG  NQAYLTISGLQSEDEADYYC VSYREPNNFV   SGGGTHLVVL


LAMBDA#8
NKRTS GIPDRFAGSRSG  NTASLIISGLQAEDEADYYC ASYRIGSRGV   FGGGTHLTVL


LAMBDA#5
DKRAP GIPDRFSGSKSG  TTASLVISGLQSEDEADYYC ASYKSSENAV   FGGGTHLTVV






          FR1              CDR1             FR2        CDR2






                  2          3             4          5



1234567891234567890123 45678901abc234 567890123456789 01abcde 


HuVL2-1
QSALTQPPSASGSPGQSVTISC TGTSSDVGSYNYVS WYQQHPGKAPKLMIY EV


LAMBDA#1
QSVLTQPPSVSGTLGKTLTISC AGTSSDVGYGNYVS WYQQLPGTAPKLLIY RV


LAMBDA#8
QSVLTQPPSVSGTLGKTVTISC AGTSSDVGYGNYVS WYQKLPGTAPKLLIY AV


LAMBDA#5
LPVLTQPPSVSGTLGKSLTISC AGTSSDVGNGNYVS WYQQLPGTAPKLLIY RV


LAMBDA#11
QPVLTQPPSVSGTLGKTVTISC AGTSTDIGGYNYVS WYQQVPGTAPKLLIY EV






 CDR2               FR3                     CDR3         FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde 


HuVL2-1
SKRPS GVPDRFSGSKSG  NTASLTVSGLQAEDEADYYC SSYAGSNNF


LAMBDA#1
STRAS GIPDRFSGSKSG  NTASLTISGLQSEDEADYYC SSYRSTGTAV   FGGGTHLSVL


LAMBDA#8
SYRAS GIPDRFSGSKSG  NTASLTISGLQSEDEADYYC ASYRDSNNAV   FGGGTHLTAL


LAMBDA#5
TSRAS GVPDRFSGSKSG  NTASLTISGLQPEDEADYYC ASYKRGGTSV   FGGGTHLTVL


LAMBDA#11
NKRPS GIPDRFSGSKSG  NTASLTISGLQSEDEADYYC ASYRSSNNVV   FGGGTHLTVL






          FR1              CDR1             FR2        CDR2






                  2          3             4          5



1234567891234567890123 45678901abc234 567890123456789 01abcde


HuVL3-2
SYELTQPLSVSVALGQTARITC GGNNIGSK   NVH WYQQKPGQAPVLVIY RD


LAMBDA#13
LPVLTQPSALSVTLGQTAKITC QGGSLGSS   YAH WYQQKPGPAPVLVIY DD


LAMBDA#40
QAVLTQPSAVSVSLGQTARLTC QGDNVETA   GTS WYRQKPGQAPSLIIY GD


LAMBDA#2
QAGLTQPSAVSVSLGQTARITC RGDSLERY   GAN WYQQKPGQARVQVIY GD


LAMBDA#14
QSALTQPSAVSVSLGQTAEITC RGRNFESG   FPH WYRQKPGQSPELVMF IV






 CDR2               FR3                     CDR3         FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde 


HuVL3-2
SNRPS GIPERFSGSNSG  NTATLTISRAQAGDEADYYC QVWDSSTA


LAMBDA#13
ANRPS GIPERFSGSRSG  GTATLTISGAQAEDEGDYYC QSVDNSGNVV   FGGGTHLTVL


LAMBDA#40
SSRPS EISERFSASTSG  NTATLTITGAQAEDEADYYC LSADSDLDSV   FGGGTLLTVL


LAMBDA#2
DIRPS GIPERFSGSRLG  GTATLTISGAQAEDEADYYC QSSDSSGYMND  FSSRTHLTVL


LAMBDA#14
NNRWS GIPDRFSGTRSG  DAATLTITGVQAEDEADYYC QMWDGEGAV    FGGGTHLTVL






          FR1              CDR1             FR2        CDR2






                  2          3             4          5



1234567891234567890123 45678901abc234 567890123456789 01abcde


HuVL4-1
LPVLTQPPSASALLGASIKLTC TLSSEHSTY  TIE WYQQRPGRSPQYIMK VKSDGS


LAMBDA#10
QSVLTQPPSASASLGASAKLTC TLSSGYSSY  NVD WYQQVPGKSPWFLMR VGSSGV






 CDR2               FR3                     CDR3         FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde 


HuVL4-1
HSKGD GIPDRFMGSSSG  ADRYLTFSNLQSDDEAEYHC GESHTIDGQVG


LAMBDA#10
GSKGS GVSDRFSGSSSG  LERYLTIQNVQEEDEAEYIC GADHASSMYT   FGGGTHLTVL






          FR1              CDR1             FR2        CDR2






                  2          3             4          5



1234567891234567890123 45678901abc234 567890123456789 01abcde


HuVL5-1
QPVLTQPPSSSASPGESARLTC TLPSDINVGSYNIY WYQQKPGSPPRYLLY YYSDSD


LAMBDA#3
LPVLTQPPSLSASPGASARLTC SLNSGTIVGGYHIN WYQQKAGSPPRYLLR FYSDSN


LAMBDA#7
LPVLTQPPSLSASPGASARLTC VLSSGTVVGGYHIN WYQQKPGSPPRYLLR FYSDSS


LAMBDA#9
LPVLNQPPSLSASPGESARLTC SLSSETIVGGYQIA WYQQTAGSPPRYLLR FYSDSN


LAMBDA#26
LPVLTQPPSLSASPGSSVRLTC TLSSGKSVGMYDIS WYQQKAGSPPRYLLY YYSDTS


LAMBDA#12
QSVLTQPPSLSASPGSSVRLTC TLSSANSVDNYYIS WYQQKPGSPPRYLLY YYSDSY






 CDR2               FR3                     CDR3         FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde 


HuVL5-1
KGQGS GVPSRFSGSKDASANTGILLISGLQSEDEADYYC MIWPSNAS


LAMBDA#3
KHQGS GVPSRFSGSKDASANAGLLLISGLQVEDEADYYC GIYDSNTGTYV  FGGGTKLTVL


LAMBDA#7
KQQGS GVPSRFSGSKDASANAGLLLISGLQPEDEADYYC GTYHSNTGTYV  FGGGTKLTVL


LAMBDA#9
KHQGS GVPSRFSGSKDASANAGILFISGLQPEDEADYYC GIYHYNSDTYV  FGGGTRLTVL


LAMBDA#26
NHQGS GVPSRFSGSKDASANAGLLLISGLQPEDEADYYC ATGDRSSNPHV  FGGGTKLTVL


LAMBDA#12
MQRDS GLPDRFSVSKDASTNAGLLLISGLQPEDEADYYC ASGDRNSNPHSV FGGGTHLTVL






          FR1              CDR1             FR2        CDR2






                  2          3             4          5



1234567891234567890123 45678901abc234 567890123456789 01abcde


HuVL8-1
QTVVTQEPSLTVSPGGTVTLTC ASSTGAVTSGYYPN WFQQKPGQAPRALIY ST


LAMBDA#42
QAVVSQEPSLSVSPGGTVTLTC GLSSGSVTTSNYPG WFQQTPGQAPRTLIY ST


LAMBDA#31
QTVVTQEPSLSVSPGGTVTLTC GLTSGSVTASNLPG WFQQTPGQAPRTLIF DT






 CDR2               FR3                     CDR3         FR4






         6           7         8          9



23456 789012345678ab90123456789012345678 9012345abcde 


HuVL8-1
SNKHS WTPARFSGSLLG  GKAALTLSGVQPEDEAEYYC LLYYGGAQ


LAMBDA#42
SSRHS GVPSRFSGSISG  NKAALTITGAQPEDEADYYC ALDIGSYTV     FGGGTKLTVL


LAMBDA#31
IYHHS GVPSRFSGSIAG  NKATLTITGAQPEDEGDYFC VLWMDRIEAGSIM FGGGTHLSVV



















14. (B) VKA.PPA (SEQ ID NOS: 150-186)

















                                L1                         L2



         FR1                   CDR1             FR2       CDR2






         1         2          3                4          5 



12345678901234567890123 45678901abcdef234 567890123456789 0123


HuVK1-1
DIQMTQSPSSLSASVGDRVTITC RASQSI      SSYLN WYQQKPGKAPKLLIY AASS


KAPPA#39
DIQLTQSPSSLSASLGDRVTITC QASQSI      STELS WYQQKPGQTPKLLIY GASR


KAPPA#22
DIQLTQSPSSLSASLGDRVTITC QASQSI      STELS WYQQKPGQTPKLLIY DRSR


KAPPA#24
DIVMTQTPSSLSASLGDRVTITC QASQSI      NTELS WYQQKPEQPPKLLIY AASR


KAPPA#21
DIVMTQSPSSLSASLGDRVTITC QATQSI      NTELS WYQQKPGQSPKLLIY EASR


KAPPA#23
DIVMTQTPSSLSASLGDRVTITC QASQSI      STELA WYQQKPGQTPKLLIY GASK


KAPPA#7
AIQMTQSPSSLSASLGDRVTITC QASQSI      STELS WYQQKPGQTPKLLIY GASR


KAPPA#19
DIQLTQSPSSLSASLGDRVTITC QASQSI      STELS WYQQKPGQTPKLLIY GASR


KAPPA#25b
DIVMTQTPPSLSASLGDRVTITC QASQSI      RNELA WYQQKPGQTPKLLIY GASR


I-_8
AIQMTQSPSSLSASLGDRVTITC QASQSI      SSYLA WYQQKPGQAPKLLIY GAST


KAPPA#43
AIQMTQSPSSLSASLGDRVTITC QASQSI      SSYLA WYQQKPGQAPKLLIY GASR


KAPPA#44
VIQMTQSPSSLSASLGDRVTITC QASQSI      SNYLA WYQQKPGQAPKLVIY GASR


KAPPA#20b
DIQLTQSPSSLSASLGDIVTITC QASQSI      TTELS WYQQKPGQTPKLLIY GAFR






 L2                                     L3



CDR2               FR3                 CDR3






       6         7         8          9



456 78901234567890123456789012345678 9012345


HuVK1-1
LQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTP


KAPPA#39
LQT GVPSRFSGSGSGTSFTLTISGLEAEDLATYYC LQDYSSPYS  FGSGTRLEIK


KAPPA#22
LQI GVPSRFSGSGSGTTYTLTISDLEAEDLATYYC LQDDSWPYS  FGSGTRLEIK


KAPPA#24
LQT GVPSRFSGSGSGTSFTLTISGLEAEDLATYYC LQDSDWPLT  FGQGTKVELK


KAPPA#21
LQT GVPSRFSGSGSGTSFTLTISGLEAEDLATYYC MADLDWPLV  FGQGTKVELK


KAPPA#23
LQT GVPSRFSGSGSGTSFTLTISGLEAEDLATYYC LQGYSSPLT  FGQGTEVDLK


KAPPA#7
LQT GVPSRFSGSGSGTSFTLTISGLESEDLATYYC LQDYSWPLT  FGQGTKVELT


KAPPA#19
LQT GVPSRFSGSGSGTSFTLTISGLEAEDLATYYC LQDYSWPRT  FGQGTKLEIK


KAPPA#25b
LQT GVPSRFSGSGSGTSFTLTISGLEAEDLATYYC LQDDSWPLT  FGQGTKVELK


I-_8
LQT GVPSRFSGSGSGTSFTLTISGLEAEDAGTYYC QQYYSIPVT  FGQGTKVELR


KAPPA#43
LQT GVPSRFSGSGSGTSFTLTISGLEAEDAGTYYC QLYGSRPS   FGQGTKVELK


KAPPA#44
LQT GVPSRFSGSGSGTSFTLTISGLEAEDAGTYYC QQYYSTYS   FGSGTRLEIK


KAPPA#20b
LQA GVPSRFSGSRSGTTFTLTISGLEAEDLATYYC LQDYSWPPYS FGSGTRLEIK






                                L1                         L2



         FR1                   CDR1             FR2       CDR2






         1         2          3                4          5 



12345678901234567890123 45678901abcdef234 567890123456789 0123


HuVK4-1
DIVMTQSPDSLAVSLGERATINC KSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIY WAST


KAPPA#53
ETTLTQSPSSVTASVGEKVTINC KSSQNVGSGSNQKSILN WIQQRPGQSPRLLIY YAST


KAPPA#50
EIVMTQSPSSVTASAGEKVTINC KSSQSVFQSSNQKNYLG WYQQRIGQSPRLLIN WAST


KAPPA#20
DIVMTQTPSSVTASIGEKVTINC KSSQSVLYSSNQKNYLT WYQQRLGQSPRLLIY WAST


KAPPA#48
ETTLTQSPSSVTASAGEKVTINC KSSQSVLLDSNQKNYLA WYQQRLGQSPRLLIY WAST


KAPPA#55
EIVLTQSPSSVTASAGEKVTINC KSSQSVLYSSDQKNYLA WYQQRPGQSPRLLIY WAST


KAPPA#9
ETTLTQSPSSVTASAGEKVTINC KSSQSVLYRSDQKNVLS WYQQRLGQSPRLLIY WAST


KAPPA#51
DIVMTQTPSSVTASAGEKVTINC KSSQSVLNNSDQKIYLA WYQQRLGQSPRLLIY WAST


KAPPA#10
DIVMTQSPGSVTASTGENITINC KSSQNVLLSSDQKNYLN WYQQRLGQSPRLLIY WAST


KAPPA#54
DIVMTQTPTSVTASAGEKVTINC KSSQSLLYSANQKVYLA WYQQRLGQSPRLLFR WTST


KAPPA#49
DIVMTQTPTSVTASAGEKVTINC KSSQSLLYSANQKVYLA WYQQRLGQSPRLLFR WTST


KAPPA#52
EIVMTQSPTSVTASVGEKVTINC KSSQSLLYSANQKVYLA WYQQRLGQSPRLLFY WTST


KAPPA#13
EIVLTQSPSSVTASVGEKVTINC KSSQSVKSGSNQITYLN WYQQTPGQSPRLLIY YAST


KAPPA#11
ETTLTQSPSSVTASVGEKVTINC KSSQSVVSGSNQKIYLN WYQQRPGQSPRLLIY YAST


KAPPA#36
DIVMTQTPSSVTASVGETVTIGC KSSQSVVSGSSQKSFLN WYQQRPGQSPRLLIY YAST


KAPPA#25
DIVMTQTPRSVTASVGEKVTINC KSSQSVLSGSNQKSYLN WYQTRPGQSPRLLIY YAST


KAPPA#12
DVVMTQSPSSVTASVGEKVTINC KSSQSVRSGSNEKSSLN WYQQRPGQSPRLLIY YAST


KAPPA#34
DVVMTQSPSSVTASVGEKVTIDC KSSQILVSGSDQKSYLS WYQQRPGQSPRLLIY YAST


KAPPA#48b
EIVMTQTPSSVTASVGEKVTINC KSSQSVVLASNQKTYLN WYQQRPGQSPRLLIY YAST


KAPPA#21
DVVMTQSPSSVTASVGEKVTINC KSSQSVVSGSNQKSYLN WYQQRPGQSPRLLIY YAST


KAPPA#24
EIVMTQSPSTVTASVGEKVTIKC KSSQSVVSGSNQKTYLN WYQQRPEQSPRLLMY YAAT


KAPPA#22b
DVVMTQSPSSVTASAGEKVTINC KSSQSLLWSDNKKNYLS WYQQRLGQSPRLLIY WAST


KAPPA#45
DIVLTQSPSSVTASAGEKVTITC ESSQSVLRSSNQRNYLN WYQQRLGQSPRLIIY WAST


KAPPA#46
EIVLTQSPSSVTASAGEKVTINC KSSQSVLYSSNQKNYLA WYQQRLGQSPRLLIY WAST






 L2                                     L3



CDR2               FR3                 CDR3






       6         7         8          9



456 78901234567890123456789012345678 9012345


HuVK4-1
RES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQYYSTP


KAPPA#53
RDA GIPDRFSGSGSATDFTLTIRSVQPEDAAVYYC QQVNIAPYT FGSGTRLEIR


KAPPA#50
RES GVPDRFSGSGSTTDFTLTINPFQPEDAAVYYC QQGKSAPLT FGQGTKVELK


KAPPA#20
RES GVPDRFSGSGSLTTFTLTISSFQPEDAAVYFC QQGYSVPLT FGRGTKVELK


KAPPA#48
RQS GVPDRFSGSGSTTDFTLTISSFQPEDAAVYYC QQGITIPVT FGQGTKVELK


KAPPA#55
RES GVPDRFSGSGSTTDFTLTISSFQPEDAAVYYC QQGYSSPHS FGSGTRLEIK


KAPPA#9
RES GVPDRFSGSGSTTDFTLTISSFQPEDAAVYYC QQGYSRPYS FGNGTRLEIK


KAPPA#51
RES GVPDRFSGSGSTTDFTLTISSFQPEDAAVYYC QQEYSAPAS FGSGTRLEIK


KAPPA#10
RKS GIPDRFSGRGSTTDFTLTINSFQPEDAAVYYC QQGYSIPHT FGGGTRLEIK


KAPPA#54
RQP GIPDRFSGSGSTTDFTLTISRVQPEDAAVYYC QQAYARPHT FGSGTRLEIK


KAPPA#49
RQP GIPDRFSVSGSTTDFTLTISSVQPEDAAVYYC QQAYARPHT FGSGTRLEIK


KAPPA#52
RQS GIPDRFSGSGSTTSFTLTISGVQPEDAAVYYC QQAYTRPHT FGSGTRLEIR


KAPPA#13
QEL GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQAYSAPFS FGSGTRLEIK


KAPPA#11
QES GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQGASAPVS FGSGTRLEIK


KAPPA#36
LEL GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQAYSTPST FGPGTKLEIR


KAPPA#25
QES GIPDRFSGSGSTTDFTLTISGVQPEDAAVYYC QQAYSAPAT FGQGTTVEVI


KAPPA#12
QES GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQAYSYPIT FGQGTKVELK


KAPPA#34
QKL GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQTYEAPYS FGNGTRLEIK


KAPPA#48b
QQL GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQALSAPYS FGSGTRLEIK


KAPPA#21
QEL GIPDRFSGSGSTTDFTLTISSVQPEDAAVYYC QQAYSTPYS FGSGTRLEIK


KAPPA#24
PEL GIPDRFSGSGSTTDFTLTINSVQPEDAAVYYC QQTYSPPN  FGSGTRLEIA


KAPPA#22b
RES GAPDRFSGSGSTTDFTLTISNFQPEDAAVYYC QQGYSIPIT FGQGTKVELS


KAPPA#45
RES GVPDRFSGSGSTTDFTLTISSFQPEDAAVYYC QQASSLPFT FGQGTKVELK


KAPPA#46
RES GVPDRFSGSGSTTDFTLTISSFQPEDAAVYYC QQYLSGVT  FGQGTKVELK



















14. (C) VH (SEQ ID NOS: 187-226)

















                              H1                           H2



            FR1                 CDR1        FR2              CDR2






         1         2         3             4          5            6



123456789012345678901234567890 1ab2345 67890123456789 012abc3456789012345


VH1(1-02)
QVQLVQSGAEVKKPGASVKVSCKASGYTFT G--YYMH WVRQAPGQGLEWMG WINP--NSGGTNYAQKFQG


1C2
EVQLVQSGAELRNPGASVKVSCKASGYTFT S--YYID WVRQAPGQGLEWMG RIDP--EDGDTKYAPKFQG


1G5
EVQLVQSGAELRNPGASVKVSCKASGYTFT S--YYIE WVRQAPGQGLEWMG RIDP--EDGGTKYAQKFQG


VH3(3-23)
EVQLLESGGGLVQPGGSLRLSCAASGFTFS S--YAMS WVRQAPGKGLEWVS AISG--SGGSTYYADSVKG


5B12
EVQLVESGGGLVQPGGSLRLSCTTSGFTFE D--YPMN WVRQAPGKGLEWVS VISR--NGGSTYYAESMKG


1G4
EVQLVESGGGLVQPGGSLRLSCAASGFTFD D--YGMS WVRQAPGKGLEWVS GITW--NGGTTNYADSVKG


5G7
EVQLVESGGGLVQPGGSLRVSCAASGFTFS T--YYMS WVRQAPGKGLEWVS GINT--GGDSTYYADSVMG


VH_99
EVQLVESGGGLVQPGGSLRLSCSASGFRFS T--YAMT WVRQAPGKGLVWVS TVDA--SGATTSYAESVKG


VH_76
EVQLVESGGGLVQSGGSLRLSCAASGFTFS D--YAMS WVRQAPGKGLEWVS SINN--GGWSTRYADSVKG


VH_86
EVQLVQSGGGLVQPGGSLRLSCAASGFTFS R--YSMS WVRQAPGQGLEWVS YIDS--DGATTTYADSVKG


VH_98
EVQLVESGGGLVQPGGSLRLSCAASGFTFS I--YGMS WVRQAPGKGLEWVS VINS--GGDSTSYADSVKG


VH_89
EVQLVESGGGLVQPGGSLRLSCSASGLTAS N--TAMA WVRQVPGKQLEWVS DINS--LGNNIFYSKSVKG


VH_82
EVQLMQSGGGLAQPGGSLRLSCAASGFTLS N--HWMY WVRQAPGKGLEWVS AISS--SGSSTYYIDSVKG


VH_68
EVQLVQSGGGLVQPGGSLRLSCAASGFAFS S--SDMS WVRQAPTKGLEWVS GINS--GGGSTYYGESMKG


VH_73
EVQLVQSGGDLVQPGGSLRLSCAASGFAFS S--YHIS WVRQAPGKGLEWVS IIGR--WGADIYYADSVKG


VH_107
EVQLVESGGGLVQPGGSLRLSCVGSGITFS K--YAMS WVRQAPGKGLEWVS NIDA--NSELTTYEDTVKG


VH_94
EVQLVQSGGGLVQPGGSLRLSCAASGFTFS S--YYMN WVRQPPGKGLEWLS VISS--SGGNTKYSDSVKG


VH_90
EVQLVQSGGGLVQPGGSLRLSCAASGFTFD D--YGKT WVRQAPGKGLEWVS SIYI--FVGNTYYADSVKG


VH_77
EVQLVQSGGGLVQPGGSLRLSCAASGFTFS S--YAMS WVRQAPGKGLEWVS TISS--GGASTTYADSVKG


VH_74
EVQLVQSGGGLVQPGGSLRLSCAASGFAFS D--YDMS WVRQAPGKGLEWVS IHVS--GDGRIFYADSMKG


VH_67
EVQLVQSGGGLVQPGGSLRLSCAASGFRFT D--YYMG WIRQTPGKGLEWVS SIYS--LGDPTYYADSVKG


VH_79
EVQLVESGGGLVQPGGSLRLSCAASGFAFS R--YWMY WVRQAPGKGLEWVS GMTT--GSDYIYSAVSVKG


VH_75
EVQLVGVWGRLGAPGGSLRLSCAASGFPFS I--YFMS WFRQRPEKGARMVS DIDK--SGGRTTYAPSVKG


VH_110
EVQLVQSGGDLVQPGGSLRVSCAVSGFTFI Y--YGMS WVRQSPGKGLEWIS TISN--GGSTANYADSVKG


VH_109
EVQLVESGGGLVQPGGSLRLSCTASGFTFS S--YGIS WVRQAPGKGLEWVS SVTG--DGLSTTAIDSVKG


VH_103
EVQLVQSGGGLVQPGGSLRLSCAASGFTFR S--YYMN WVRQAPGKGLEWVS VSSS--GGGTTYYADSVKG


VH_84
EVQLVESGGGLVQPGGSLRLSCAASGFTFS S--YAMS WVRQAPGKGLEWVS GINS--GGGSTSYADSVKG


VH_113
EVQLVESGGGLVQPGRSLRLSCAAAGFTFS T--YWMY WIRQAPGKGLEWVA TITS--LGGSQWYVDSVKG


VH_87
EVQLVESGGGLVKPGGSLRLSCAASGFTFS S--AYMN WVRQAPGKGLEWVS GLTN--YGSTSYYADSVKG


VH_105
EVQLVESGGGLVQPGGSLRLSCAASGFTFS N--YWMY WVRQAPGKGLEWVS SIDT--SGGITMYADSVKG


VH_101
EVQLVESGGGLVQPGVSLRLSCTTSGFTFS T--QGMN WVRQPPEKGLEWVS GIDS--RGNTTNYADSVKG


VH_108
EVQLVQSGGGLVQPGGSLRLSCAASGFTFS S--YWMY WVRQAPGKGLDWIS GISV--GGASTYYARSVQD


VH_106
EVQLVQSGGGLVQPGGSLRLSCAASGFNFD D--YPMT WIRQAPGKGLEWVA SIYS--GISTTYYPDSVKG


VH3(3-13)
EVQLVESGGGLVQPGGSLRLSCAASGFTFS S--YDMH WVRQATGKGLEWVS AIG---TAGDTYYPGSVKG


VH_115
EVQLVESGGGLVQPGGSLRLSCAASGFTSS T--YAMS WVRQGPGKALEWVS TIN---GADFTSYVDSVKG


VH_85
EVQLVQSGGGLVQPGGSLRLSCAASGFTFS T--YWMY WVRQAPGKGLEYVG SID---NDGFTYYSEDVKG


VH_114
EVQLVESGGGLVQPGGSLRLSCTASGFTFS T--HTMS WVRQAPGKGLEWVS GIN---SAYGTIYIDSVKG


VH_78
EVQLVESGGGLVQPGGSLRLSCAASRFTFG T--SGMT WVRQAPGKGLEWVS TIN---SGGLTTSADSVKG


3B5 
EVQLVQSGGGLVQPGGSLRLSCAASGFTFS S--YWMY WVRQAPGKGLEWVS TIT---KGGSTYYSDSVKG


3A3
EVQLVESGGGLVQPGDSLRLSCAASGFTFG N--YDMS WVRQAPGKGPEWVS GIN---SGGKTYSADSVKG






              FR3






    7         8            9



67890123456789012abc345678901234


VH1(1-02)
RVTMTRDTSISTAYMELSRLRSDDTAVYYCAR


1C2
RVTFTADTSTSTAYVELSSLRSEDTAVYYCAR SGRYELDY            WGLGTQVTVSS


1G5
RVTFTADTSTSTAYVELSSLRSEDTAVYFCAT SGATMSDLDSFGS       WGQGTQVTVSS


VH3(3-23)
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK


5B12
RFTISRDNAKNTLYLVMNSLTSEDTAVYYCTK PSTSWSTNYGMDY       WGKGTQVTVSS


1G4
RFTISRDSAKNMVHLQMDSLKSEDTAVYYCAK AYRGST              LGQGTQVTVSS


5G7
RFTISRDNAKNTLSLQMNSLKPEDTALYYCAR DLRDYYSDYTFVN       WGQGTQVTVSS


VH_99
RFTISRDNTKGALYLQMNSLKFEDTAVYYCGT RSGTWWRGSYIYTESEENG WGQGTQVTVSS


VH_76
RFTISRDNAKNTLYLQMNSLKPEDTALYYCAR EGYYSDYAAVGHAYDY    WGQGTQVTVSS


VH_86
RFTISRDNAKNTLNLQMNSLKPDDAGVYYCAS FGSSAYSWGYLGMDH     WGKGALVTVFS


VH_98
RFTISRDNAKNTLYLQMNNLKPEDTAVYYCAK GGVLGHSNYYAMDY      WGKGTLVTVSS


VH_89
RFTIARDKTKNTLVLSMNSLSPEDTAVYYCVA DASALSWSRPALEV      WGQGTLVTVSD


VH_82
RFTISRDNAKNTLYLQMNSLKAEDKGVYYCGK DESRGIEPGWGSIY      WGQGTQVTVSS


VH_68
RFTISRDNAKNTLYLQMSSLKPEDTAVYYCTR YDSFGWNVRYGMDY      WGKGTLVTVSS


VH_73
RLTISRDNAKNTVYLQMNSLKPEDTAVYYCTA ELNWEPENAYSDH       WGQGTQVTVSS


VH_107
RFTISRDNVKNTLYLQMNSLKPEDTAVYYCTK DPRNSWYTYGMDY       GGKGTLVVVSS


VH_94
RFTISRDNAKNMVYLQMNSLKPEDTAVYYCAK RIEGGMGYGMDY        WGKGTPVTVSS


VH_90
RFTISRDNAGNTLYLQMTNLKPEDTAKYFCVK SPEWTYYYGMDS        WGKGTLVTVSS


VH_77
RFTISRDNAKNTLYLQMNSLKPEDTAVYYCAK SFGLVTGVYFGS        WGQGTQVTVSS


VH_74
RFTISRDNAKNTMYLQLNSLKPEDTAVYYCAA DSYHAATGYLEQ        WGQGTLVTVSS


VH_67
RFTISRDNGKDTVYLEMNSLKSDDTGLYYCAR DHRGWGTIRYDY        WGQGTQVTVSS


VH_79
RFTISRDNAKNTLYLQMNSLKFEDTAVYYCAK GGVIDADHFES         WGQGTQVTVSS


VH_75
RFTASRDNAKNTLYLTINTLEPNDTAVYYCAK PTSSMWSPGDY         WGQGTQVTVAS


VH_110
RFTISRDNAKNTLYLEMNDLKPEDTALYYCAR ISTELGNTLDA         WGQGSLVTVSS


VH_109
RFTITRDNAKNTVYLQMNNLKLDDTAVYYCAK LDVYVDYGMDY         WGKGTLVTVSS


VH_103
RFTISRDNAQNTLYLQMNSLKPEDTALYYCAR ESGGPGMDLEV         WGQGTLVTVSS


VH_84
RFTISRDNAKNTLYLQMNSLKPEDTAVYYCAK WEVVTLDFGS          WGQGTQVTVSS


VH_113
RFTISRDNAKNTLYLQMNSLKPEDMAQYYCVR GGLYGYDYEH          WGQGTQVTVSS


VH_87
RFTISRDNTVNTVYLQLNSLKPEDTGLYYCAR VGNMWSSDY           WGQGTQVTVSS


VH_105
RFTISRDNAKNTLYLQMNSLKSEDTALYYCAK ALGYNAFDA           WGRGTLVTVSS


VH_101
RFTISRDNAKNALYLQMNDLRPDDTAMYYCTN TGPWYTYNY           WGQGTQVTVSS


VH_108
RFTISRDNTKNTLYLQMSSLRSEDTAVYWCTR GGNTPYDY            WGQGTQVTVSS


VH_106
RFTISTNDAKNTVYLQMNDLKSDDTAVYYCAN PRRNY               WGQGTHVTVSS


VH3(3-13)
RFTISRENAKNSLYLQMNSLRAGDTAVYYCAR


VH_115
RFTISRDNTKNTLYLQMNSLKPEDTAVYYCAK GLSGLNWYGFGDY       WGQGTQVTVSS


VH_85
RFTISGDNARNTLYLQINSVKPEDTALYYCVR GVYYMDYEPRMDY       WGKGTLVTVSS


VH_114
RFTISRDNAKNTLYLQMNSLKPDDTAVYYCVQ VVDTWDEYDY          WGQGTQVTVSS


VH_78
RFTISRDNGKNTLYLQMDSLKPDDTAVYYCAN LLELGH              WGRGTQVTVSS


3B5 
RFTISRDNAKNTLYLQMNSLKSEDTAVYYCAK SNSGTHWYEYYGMDY     WGKGTLVTVSS


3A3
RFTISRDNAKNTLYLQMNNLKPEDTAVYYCIL GIVTLGS             WGQGTQVTVSS









Example 15
Generating Fabs Against IL-1 Beta
Unless otherwise indicated, the materials and protocols used in the following study were analogous to those used in examples 1-9.
Llamas were Successfully Immunized with IL-1 Beta
Two llamas (Lama glama) were immunized with human IL-1Beta according to a standard protocol (as described in Example 1).
Sera from both llamas were tested for the presence of antibodies against IL-1Beta by ELISA prior (day 0) and after immunization (day 28). As shown in FIG. 1, a specific signal against IL-1Beta was observed in ELISA after immunization, even after 10,000 fold dilution of the serum. This high antibody titer indicates a specific and appropriate immune response.
Fab Libraries with Good Diversity were Constructed
PBLs isolated from both immunized llamas were used for RNA extraction, RT-PCR and PCR-cloning of Fab in a phagemid using the strategy described by de Haard et al (JBC 1999), to obtain a diverse library of good diversity (2−5×108).
The following primers were used:











Name
Sequence















Primers for cloning of lambda light chain (SEQ ID NOS: 227-240)








HuVI1A-BACK-ApaLI
GCC TCC ACC AGT GCA CAGTCTGTGYTGACKCAGCC


HuVI1B-BACK-ApaLI
GCC TCC ACC AGT GCA CAGTCTGTGYTGACGCAGCC


HuVI1C-BACK-ApaLI
GCC TCC ACC AGT GCA CAGTCTGTCGTGACGCAGCC


HuVI2-BACK-ApaLI
GCC TCC ACC AGT GCA CAGTCTGCCCTGACTCAGCC


HuVI3A-BACK-ApaLI
GCC TCC ACC AGT GCA CTT TCCTATGAGCTGACWCAGCC


HuVI3B-BACK-ApaLI
GCC TCC ACC AGT GCA CTT TCTTCTGAGCTGACTCAGGA


HuVI4-BACK-ApaLI
GCC TCC ACC AGT GCA CAGCYTGTGCTGACTCAATC


HuVI5-BACK-ApaLI
GCC TCC ACC AGT GCA CAGGCTGTGCTGACTCAGCC


HuVI6-BACK-ApaLI
GCC TCC ACC AGT GCA CTT AATTTTATGCTGACTCAGCC


HuVI7/8-BACK-ApaLI 
GCC TCC ACC AGT GCA CAGRCTGTGGTGACYCAGGA


HuVI9-BACK-ApaLI
GCC TCC ACC AGT GCA CWGCCTGTGCTGACTCAGCC


HuVI10-BACK-ApaLI
GCC TCC ACC AGT GCA CAGGCAGGGCTGACTCAGCC


caClambda1-FOR
CTAACACTGGGAGGGGGACACCGTCTTCTC


caClambda2-FOR
CTAACACTGGGAGGGNCTCACNGTCTTCTC


 







Primers for cloning of kappa light chain (SEQ ID NOS: 241-249)








HuVk1B-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GACATCCAGWTGACCCAGTCTCC


HuVk2-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GATGTTGTGATGACTCAGTCTCC


HuVk3B-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GAAATTGTGWTGACRCAGTCTCC


HuVk2/4-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GAYATYGTGATGACCCAGWCTCC


HuVk5-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GAAACGACACTCACGCAGTCTCC


HuVk6-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GAAATTGTGCTGACTCAGTCTCC


HuVk4B-BACK-ApaLI
GCC TCC ACC AGT GCA CTT GATATTGTGATGACCCAGACTCC


caCHkapFOR-AscI
GCC TCC ACC GGG CGC GCC TTA TTAGCAGTGTCTCCGGTCG



AAGCTCCT


caCHkap2FOR-AscI
GCC TCC ACC GGG CGC GCC TTA TTARCARTGYCTNCGRTCRAA


 







Non-tagged primers for cloning of Heavy chain


(step 1) (SEQ ID NOS: 347-351)








VH1a-BACK
CAGGTKCAGCTGGTGCAGTCTGG


VH5a-BACK
GARGTGCAGCTGGTGCAGTCTGG


VH4a-BACK
CAGSTGCAGCTGCAGGAGTCTGG


VH4b-BACK
CAGGTGCAGCTACAGCAGTCTGG


VH2b-BACK
CAGGTCACCTTGARGGAGTCTGG


 







Tagged primers for cloning of Heavy chain


(step 2) (SEQ ID NOS: 352-356)








VH1a-BACK-SfiI
CTC GCA ACT GCG GCC CAG CCG GCC ATG



GCCCAGGTKCAGCTGGTGCAGTCTGG


VH5a-BACK-SfiI
CTC GCA ACT GCG GCC CAG CCG GCC ATG



GCCGARGTGCAGCTGGTGCAGTCTGG


VH4a-BACK-SfiI
CTC GCA ACT GCG GCC CAG CCG GCC ATG



GCCCAGSTGCAGCTGCAGGAGTCTGG


VH4b-BACK-SfiI
CTC GCA ACT GCG GCC CAG CCG GCC ATG



GCCCAGGTGCAGCTACAGCAGTCTGG


VH2b-BACK-SfiI
CTC GCA ACT GCG GCC CAG CCG GCC ATG



GCCCAGGTCACCTTGARGGAGTCTGG









Independent VλCλ and VκCκ libraries were constructed using a single (tagged)-PCR step (30 cycles) to conserve a greater clonal diversity.
The VHCH1 libraries were built in parallel using a two step PCR (25 cycles with non tagged primers (step 1) followed by 10 cycles of tagged primers (step 2)).
Next, the light chain from the VλCλ and VκCκ libraries are re-cloned separately in the VHCH1-expressing vector to create the “Lambda” and “Kappa” llama Fab-library respectively (two for each immunized llama). Quality control of the libraries was routinely performed using PCR.
Up to 93% of the clones tested randomly contained full length Fab sequences, indicating a high quality of the libraries.
Human IL-1Beta Specific Fabs were Selected
Phage display was used to identify a large diversity of llama Fabs binding to biotinylated IL-1Beta. Biotinylated IL-1Beta was used for capturing to conserve the active conformation of the protein. After two rounds of selection, a good enrichment compared to control was observed. Phage ELISA revealed presence of clones expressing cytokine specific Fabs (data not shown).
The phage binding to biotinylated IL-1Beta were eluted by pH shock. Sequential dilutions of the output (10−1 to 10−5) were used to infect fresh E. coli TG1 cells. The number of colonies obtained indicate the number of phage bound during the selection. In the example above, 5 μl of output gave around 105 phage when selection was done with 100 nM and 10 nM of biot-IL-1Beta. Compared to the 102 phages obtained by non-specific binding, this gives a 1000 fold enrichment.
94 Single clones were grown and used to produce monoclonal phage. These phage were used in a phage ELISA. Many phage showed good binding to biot-IL-1Beta after two rounds of selection on biotinylated IL-1Beta.
Human IL-1Beta Specific Fabs have High Starting Homology to Human Germline
Target specific VH and Vλ domains were matched with those common human germlines showing an identical CDR1 and CDR2 length and corresponding canonical folds. Subsequently the closest human germline was selected based on sequence homology in their framework regions. Non-matching amino acid residues were checked for their presence in other, related human germlines. In case there was no match, these residues were counted as foreign.







TABLE 7







Overall sequence homology of llama VH to human germline











Closest





Human

% Sequence



Germline
Matching Clones
Homology







IGHV1-2
1C2/2B7/2C12
93




2D8
94




1G5/2D7
93




2E12/2G7
94



IGHV3-23
1F2
98




1G4
92




5G7
95




5B12
92




1A1/2B8/2B9
98




1C3/1E3/2A7
98



IGHV3-13
1E2
94




3A3/3B6/3E2/3E3
95




3B5/4F1
98



IGHV3-20
4H1
94




4H4
93

















TABLE 8







Overall sequence homology of llama VL to human germline











Closest





Human
Matching
% Sequence



Germline
Clones
Homology







IGLV8-61
1E2
90




1F2
90




3E2/3E3/3A3
86




3B5/4F1
86



IGLV2-18
3B6
91



IGLV5-52
1G4 VL
96



IGLV3-19
1C2/2B7/2D7
95




2E12/2G7
96




2D8
95










Discussion and Conclusions:

    
    
        A total of 14 target specific VH families, 9 target specific Vλ families and 3 Vκ families were identified based on this very first selection
        This initial panel of 14 anti-IL-1Beta WT VH's and 12 anti-IL-1Beta WT VL's shows a remarkably high sequence homology to the human germline.
        33% of those VH domains have a starting homology of 95% or more to the human situation and about 44% of the VL domains have a starting homology of 95% or more to the human situation, eliminating the need for further humanization.
        VH domain 2D8 is a humanized version of VH1C2 because it has one deviating amino acid residue less as compared to the closest human germline. Its corresponding VL domain (VL 2D8), had a starting homology of 95% which was further increased to 96% by 1 back mutation (VL 2G7) to the closest human germline.
        All VH and VL domains, without a single exception, exhibited human 3-D binding site structures (i.e. identical combinations of canonical folds for CDR1 and CDR2 as occurring in the matching human germline segments) when assessed using the methodology described above (data not shown).
    
    


Humanization of Fabs 1E2 and 1F2
Humanization was performed on two IL-1Beta specific Fabs coded 1E2 and 1F2. Based on the alignment against the closest human germlines, mutations in their VH and Vλ framework regions were proposed (FIG. 2). The germlining of VH matching to the human VH3 family will often involve a number of residues, which already deviate in publically known Lama glama, Lama pacos or Camelus dromedarius derived germline sequences. For instance, Alanine on position 71 (numbering according to Kabat) and Lysine on 83 and Proline on 84 might be changed into Serine (although Alanine exists in certain human germline VH3 members), Arginine (although Lysine is used by a number of human VH3 germlines) and Alanine, respectively. For light chain variable sequences no germline sequences are available for Camelids, but it is very likely that a number of deviations in FRs from human germline exists that will be changed in the majority of lead antibodies. Besides the fully humanized (hum) and the wild type (wt) V regions, also a “safe variant” with only three wild type residues remaining was proposed (safe).
Fab 1E2 was formatted in a step-by-step approach, whereby the different versions (wt, safe and fully humanized) of the Vλ fused to the human constant domain were combined with various versions of the VH fused to the human constant CH1 domain to generate the Fabs indicated in Table 9.







TABLE 9







Fab 1E2 formats









VH 1E2 + hum CH1











wt
safe
hum















VL 1E2 + humCL
wt
wt 1E2
wt/safe
wt/hum



safe
safe/wt
safe 1E2
safe/hum



hum
hum/wt
hum/safe
hum 1E2









The genes of these Fabs were ordered as synthetic genes with GeneArt (Germany) and were subsequently produced in E. coli, purified and tested for their ability to bind biot-IL-1Beta. For this the Fabs were captured on an anti-myc coated Maxisorp plate. Biotinylated human IL-1Beta was added and bound cytokine was detected using HRP-conjugated streptavidin. The read out of this assay is represented in FIG. 3 below.

    
    
        The replacement of the wild type constant domains CH1 and Cλ by their human counterpart did not affect the binding capacity.
        Partial (wt Vλ/safe VH) and complete (wt Vλ/hum VH) humanization of the VH domain of 1E2 generated a functional Fab.
    
    


The humanized variants of clone 1F2 were tested with phage expressing gene3-Fabs fusions (FIG. 4). Phage were produced from 4 independent clones for each construct:

    
    
        wt 1F2 and wt 1E2 (llama Vλ and VH fused to human Cλ and CH1)
        safe variant 1F2 and safe variant 1E2 (partially humanized Vλ fused to human Cλ and CH1)
        hum 1F2 and hum 1E2 (fully humanized Vλ and VH fused to human Cλ and CH1)
    
    


Four clones for each Fab were tested to overcome clonal variation (due to bacterial growth, phage production efficiency and toxicity etc. . . . ). Phage ELISA was performed by capturing of biotinylated IL-1Beta on neutravidin coated Maxisorp plate and subsequent incubation of crude phage extract (i.e. bacterial medium). After extensive washing, bound phages were detected with an anti-M13-HRP monoclonal antibody. The same phage preparations when tested on neutravidin coated wells (without biotinylated IL-1Beta) did not give signals (data not shown).

    
    
        Back mutations in the framework regions of 1F2 VL and VH domains to the closest human germline successfully yield partially (safe) and fully (hum) humanized variants, maintaining antigen specificity.
    
    


Successful Formatting of Camelid Variable Domains with Human Constant Domains
The VL and VH variable domains of the IL-1Beta specific clone 1E2 were successfully fused to the human Cλ and CH1 constant domains, resulting in a “chimeric” Fab which was produced and purified.
This chimeric 1E2 Fab was produced by performing the induction for 4 h at 37° C. (o/d) or for 16 h and 28° C. (o/n) from the pCB5 phagemid (Δgene3). The wild type llama 1E2 Fab was produced by performing induction for 16 h at 30° C. from pCB3 (gene3 containing phagemid). After purification, these Fabs were loaded on SDS-PAGE with (reducing) or without (non-reducing) DTT. Coomassie staining was performed, nicely showing the presence of these Fabs or their composing light and heavy chains at the expected molecular weight band (not shown).
The purified llama and chimeric 1E2 Fabs described above were captured on anti-myc coated maxisorp plates. After incubation with biotinylated human IL-1Beta and extensive washing, the biotinylated IL-1Beta bound to the Fab was detected using HRP-conjugated streptavidin. Both the purified llama and chimeric 1E2 Fabs exhibited functional target binding (FIG. 5). This finding demonstrates the feasibility to associate Camelid derived variable domains with the constant domains of human IgGs
A Subset of Fabs Showed Functional Inhibition of the Target
The table below shows the OD values resulting from the following ELISA experiment. Wells were coated with a mouse monoclonal antibody known to inhibit the binding of IL1-Beta with its receptor (provided by Diaclone SAS).
Biotinylated IL-1Beta was added to the wells together with periplasmic extracts of Fabs identified after 2 rounds of selection against biotinylated IL-1Beta. Detection of the bound biotinylated IL-1Beta happened through HRP labeled streptavidin. A reduced signal indicated the competition of a specific Fab with the blocking mouse monoclonal antibody, suggesting antagonism.
A positive control was included in well G12 by spiking in a large amount of the competing mouse monoclonal (well 12G in Table 10).







TABLE 10







Results of competition assay















A number of Fabs were identified which successfully compete with the blocking mouse monoclonal antibody (indicated by shaded cells in Table 10). Sequence analysis of the competing clones revealed the presence of three Fabs with different VH, which were present in 48 screened clones (part of the plate coded 6A in Table 10). The sequences alignments (SEQ ID NO: 21 and SEQ ID NO: 250; SEQ ID NO: 21 and SEQ ID NO: 251; and SEQ ID NOS: 254, 252, and 253) against the closest human germline and the structural homology analysis of the VH of the antagonistic Fab 1A1 (giving a signal of 0.205 in the competition assay of Table 10), 1B3 (signal of 0.444) and the related clone 1G1 (signal of 0.498) and finally 1C3 (signal of 0.386) are shown below.
All three have a very high degree of sequence homology with the matching human germline and have the identical canonical fold combinations as found in the human germline. This was also observed for the lambda light chain in the three antagonistic leads (data not shown). Fab 1A1 competes strongly with the antagonistic reference monoclonal antibody (IC50 of 12 μg/ml in ELISA based competition assay), whereas Fab 1C3 hardly shows competition (only at concentrations of more than 50 μg/ml). However, in the bioassay 1C3 is more potent (IC50 of 3 μg/ml) than 1A1 (IC50 of 10 μg/ml), which suggests a different epitope recognition. The high frequency of different antagonistic Fabs (3 different antibodies in 48 screened clones) and the difference in epitope recognition as found for two of these illustrates the high diversity of antibodies as the result of the outbred nature of the lama. The high degree of sequence homology with human germline V regions combined with the high diversity of (potent) antibodies and the broad epitope coverage enables the identification of panels of therapeutic antibodies from immunized camelids.
















IGHV gene

CDR1

CDR2


Kabat FR/CDR
FR1-Kabat
Kabat
FR2-Kabat
Kabat





IMGT numbering   M99660,IGHV3-23 VH-IA1,3B8,3D9































IGHV gene

CDR3




Kabat FR/CDR
FR3-Kabat
Kabat
FR4 (IGHJ)






IMGT numbering   M99660,IGHV3-23 VH-IA1,3B8,3D9














 










5V
primer encoded and also in all other class 3 except 3-23



83A
occurs in all VH3 family members except 3-23



95 K
also in IGHV3-13/49/66/72 and classes 5 and 7



96 S
not in class 3 but in class 1



127 Q
not in human germline









Overall homology



84/86 framework residues = 98% homology



Canonical folds analysis



CDR H1 Class 1/10A [2fbj]



CDR H2 Class ?



! Similar to class 3/10B, but:



! H56 (Chothia Numbering) = A (allows: SYTNDR)














IGHV gene

CDR1

CDR2


Kabat FR/CDR
FR1-Kabat
Kabat
FR2-Kabat
Kabat





IMGT numbering   M99660,IGHV3-23 VH-1C3,1E3,2A7































IGHV gene

CDR3




Kabat FR/CDR
FR3-Kabat
Kabat
FR4 (IGHJ)






IMGT numbering   M99660,IGHV3-23 VH-1C3,1E3,2A7














 










5V
primer encoded and also in all other class 3 except 3-23



83A
occurs in all VH3 family members except 3-23



95 K
also in IGHV3-13/49/66/72 and classes 5 and 7



96 S
not in class 3 but in class 1



127 Q
not in human germline









Overall homology



84/86 framework residues = 98% homology



Canonical folds analysis



CDR H1 Class 1/10A [2fbj]



CDR H2 Class ?



! Similar to class 2/10A, but:



! H71 (Chothia Numbering) = R (allows: VAL)









Example 16
The following example demonstrates the functional diversity which can be achieved with the current invention, in comparison with the established mouse monoclonal antibody approach.
10 BALB/c mice were immunized with a recombinant produced cytokine with a small molecular weight. After completion of the immunization protocol, the animals were sacrificed, and hybridomas were generated by immortalizing their spleen cells. Supernatant of the resulting hybridomas was tested in the cytokine binding ELISA and subsequently in a suitable bioassay. One highly potent antagonist and one weaker antagonist could be identified.
Also, 4 llamas were immunized with the same recombinant produced cytokine, using the general protocol described herein. After completion of the immunization protocol, peripheral B lymphocytes were harvested and their RNA was extracted and purified. Using a set of llama specific primers, Fab libraries were generated using the phage display technique. Those Fabs were tested in the cytokine/cytokine receptor binding ELISA. 5 different VH families could be identified from the first 2 llamas, and 6 additional different VH families from the next 2 llamas, which blocked the cytokine/receptor interaction with high potency, meaning that those VH domains contained uniquely different CDRs, both in length and amino acid sequence.
Thus a higher functional diversity could be achieved from a small number of outbred llamas as opposed to a higher number of inbred BALB/c mice. All VH families obtained by active immunisation of llamas exhibited an extraordinary sequence homology as compared to the closest human germline and had the same canonical fold combinations for CDR1 and CDR2 as the matching human germlines.
Example 17
The following table summarises the results of amino acid sequence homology comparisons between germline VH domains of alpaca (Lama pacos) and the closest matching human germline VH domains. % homology was calculated using the same algorithm as described herein for Lama glama. Raw VH sequence data for Lama pacos is not shown:







TABLE 11







amino acid sequence homology germline VH of Lama pacos vs human











% amino acid sequence




homology with closest


Alpaca (Lama pacos)

matching human germline


germline VH family
Frequency
VH





VH3
70% (36/51)
≧95%


VH1
10% (5/51) 
90-92%


VH2 (NB Lama pacos VH2
20% (10/51)
81-88%


aligns to human VH4)









The following table is provided to cross-reference nucleotide and amino acid sequences listed herein with the sequence listing submitted in ST.25 format for searching purposes.







TABLE 12







cross-reference to sequence identifiers








SEQ ID No.
Sequence name











1
M99679, IGHV3-53


2
AF000603, IGHV1S1


3
AJ245151, IGHV1S2


4
AJ245152, IGHV1S3


5
AJ245153, IGHV1S4


6
AJ245154, IGHV1S5


7
AJ245155, IGHV1S6


8
AJ245157, IGHV1S7


9
AJ245158, IGHV1S8


10
AJ245159, IGHV1S9


11
AJ245160, IGHV1S10


12
AJ245164, IGHV1S11


13
AJ245165, IGHV1S12


14
AJ245167, IGHV1S13


15
AJ245168, IGHV1S14


16
AJ245170, IGHV1S15


17
AJ245171, IGHV1S16


18
AJ245173, IGHV1S17


19
AJ245174, IGHV1S18


20
AJ245156, IGHV1S19


21
M99660, IGHV3-23


22
AJ245177, IGHV1S20


23
AJ245178, IGHV1S21


24
AJ245183, IGHV1S22


25
AJ245185, IGHV1S23


26
AJ245186, IGHV1S24


27
AJ245187, IGHV1S25


28
AJ245189, IGHV1S26


29
AJ245191, IGHV1S27


30
AJ245192, IGHV1S28


31
AJ245193, IGHV1S29


32
AJ245194, IGHV1S30


33
AJ245195, IGHV1S31


34
AJ245179, IGHV1S32


35
AJ245180, IGHV1S33


36
AJ245182, IGHV1S34


37
AJ245190, IGHV1S35


38
AJ245196, IGHV1S36


39
AJ245197, IGHV1S37


40
AJ245181, IGHV1S38


41
AJ245198, IGHV1S39


42
AJ245199, IGHV1S40P


43
AF305949, IGHV1S6


44
M94116, IGLV1-40


45
Camv144


46
Z73642, IGLV2-18


47
Camvl17


48
Camvl33


49
Camvl36


50
Camvl59


51
Camvl30


52
Camvl32


53
Camvl57


54
Camvl5


55
Camvl65


56
Camvl51


57
Camvl31


58
Camvl60


59
Camvl52


60
X57826, IGLV3-1


61
Camvl19


62
Camvl20


63
Camvl8


64
Camvl18


65
Camv123


66
Z73658, IGLV3-12


67
Camvlll


68
X59314, IGKV2-40


69
Kp6


70
Kp48


71
Kp3


72
Kp20


73
Kp7


74
Kp10


75
Kp1


76
J00256, IGHJ1


77
J00256, IGHJ2


78
J00256, IGHJ3


79
J00256, IGHJ4


80
J00256, IGHJ5


81
J00256, IGHJ6


82
AF305952, IGHJ2


83
AF305952, IGHJ3


84
AF305952, IGHJ4


85
AF305952, IGHJ5


86
AF305952, IGHJ6 (1)


87
X04457, IGLJ1


88
M15641, IGLJ2


89
M15642, IGLJ3


90
X51755, IGLJ4


91
X51755, IGLJ5


92
M18338, IGLJ6


93
X51755, IGLJ7


94
Camvl19 etc.


95
Camvl8/18/4


96
Camvl58/28/5


97
J00242, IGKJ1


98
J00242, IGKJ2


99
J00242, IGKJ3


100
J00242, IGKJ4


101
J00242, IGKJ5


102
Kp6/48/3/20/10/1


103
Kp7 (1/7 analyzed)


104
M99660, IGHV3-23


105
IVH28


106
IVH69


107
IVH47


108
IVH48


109
IVH70


110
IVH71


111
HuVL1-1(3/4/5)


112
LAMBDA#14


113
LAMBDA#16


114
LAMBDA#46


115
LAMBDA#45


116
LAMBDA#15


117
HuVL1-2


118
LAMBDA#47


119
LAMBDA#18


120
LAMBDA#32


121
LAMBDA#28


122
LAMBDA#29


123
LAMBDA#27


124
LAMBDA#17


125
LAMBDA#4


126
LAMBDA#7


127
LAMBDA#8


128
LAMBDA#5


129
HuVL2-1


130
LAMBDA#1


131
LAMBDA#8 (2)


132
LAMBDA#5 (2)


133
LAMBDA#11


134
HuVL3-2


135
LAMBDA#13


136
LAMBDA#40


137
LAMBDA#2


138
LAMBDA#14 (2)


139
HuVL4-1


140
LAMBDA#10


141
HuVL5-1


142
LAMBDA#3


143
LAMBDA#7 (2)


144
LAMBDA#9


145
LAMBDA#26


146
LAMBDA#12


147
HuVL8-1


148
LAMBDA#42


149
LAMBDA#31


150
HuVK1-1


151
KAPPA#39


152
KAPPA#22


153
KAPPA#24


154
KAPPA#21


155
KAPPA#23


156
KAPPA#7


157
KAPPA#19


158
KAPPA#25b


159
I-_8


160
KAPPA#43


161
KAPPA#44


162
KAPPA#20b


163
HuVK4-1


164
KAPPA#53


165
KAPPA#50


166
KAPPA#20


167
KAPPA#48


168
KAPPA#55


169
KAPPA#9


170
KAPPA#51


171
KAPPA#10


172
KAPPA#54


173
KAPPA#49


174
KAPPA#52


175
KAPPA#13


176
KAPPA#11


177
KAPPA#36


178
KAPPA#25


179
KAPPA#12


180
KAPPA#34


181
KAPPA#48b


182
KAPPA#21 (2)


183
KAPPA#24 (2)


184
KAPPA#22b


185
KAPPA#45


186
KAPPA#46


187
VH1(1-02)


188
1C2


189
1G5


190
VH3(3-23)


191
5B12


192
1G4


193
5G7


194
VH_99


195
VH_76


196
VH_86


197
VH_98


198
VH_89


199
VH_82


200
VH_68


201
VH_73


202
VH_107


203
VH_94


204
VH_90


205
VH_77


206
VH_74


207
VH_67


208
VH_79


209
VH_75


210
VH_110


211
VH_109


212
VH_103


213
VH_84


214
VH_113


215
VH_87


216
VH_105


217
VH_101


218
VH_108


219
VH_106


220
VH3(3-13)


221
VH_115


222
VH_85


223
VH_114


224
VH_78


225
3B5


226
3A3


227
HuVl1A-BACK-ApaLI


228
HuVl1B-BACK-ApaLI


229
HuVl1C-BACK-ApaLI


230
HuVl2-BACK-ApaLI


231
HuVl3A-BACK-ApaLI


232
HuVl3B-BACK-ApaLI


233
HuVl4-BACK-ApaLI


234
HuVl5-BACK-ApaLI


235
HuVl6-BACK-ApaLI


236
HuVl7/8-BACK-ApaLI


237
HuVl9-BACK-ApaLI


238
HuVl10-BACK-ApaLI


239
caClambda1-FOR


240
caClambda2-FOR


241
HuVk1B-BACK-ApaLI


242
HuVk2-BACK-ApaLI


243
HuVk3B-BACK-ApaLI


244
HuVk2/4-BACK-ApaLI


245
HuVk5-BACK-ApaLI


246
HuVk6-BACK-ApaLI


247
HuVk4B-BACK-ApaLI


248
caCHkapFOR-AscI


249
caCHkap2FOR-AscI


250
VH-1A1, 2B8, 2B9


251
VH-1C3, 1E3, 2A7


252
VH-1B3, 1G2, 2D8


253
VH-1G1, 2B7


254
X07448, IGHV1-2


255
1F2 VH


256
Humanized VH 1F2


257
Safe Variant VH 1F2


258
X92218, IGHV3-66


259
1E2 VH


260
Humanized VH 1E2


261
Safe Variant VH 1E2


262
Z73650, IGLV8-61


263
1F2 VL


264
Humanized 1F2 VL


265
Safe Variant VL 1F2


266
1E2 VL


267
Humanized VL 1E2


268
Safe Variant VL 1E2


269
X92343|IGHV1-46*01


270
LpVH1-s6 (AM939701)


271
LpVH1-s2 (AM939697)


272
LpVH1-s3 (AM939698)


273
LpVH1-s4 (AM939699)


274
LpVH1-s5 Ps (AM939700)


275
M99660|IGHV3-23*01


276
AM939712


277
AM939713


278
AM939730


279
AM939731


280
AM939744


281
AM939726


282
AM939727


283
AM939739


284
AM939740


285
AM939741


286
AM939742


287
AM939743


288
U29481|IGHV3-23*03


289
AM939716


290
AM939728


291
AM939738


292
AM939710


293
AM939748


294
Am939750


295
AM939751


296
AM939767


297
AM939768


298
AM939707


299
AM939708


300
AM939709


301
AM939732


302
AM939733


303
AM939717


304
AM939734


305
AM939735


306
AM939736


307
AM939737


308
L33851|IGHV3-74*01


309
AM939749


310
AM939724


311
AM939725


312
AM939745


313
AM939723


314
X92229|IGHV4-30-2*03


315
LpVH2-s7 (AM939704)


316
Z14238|IGHV4-30-4*01


317
LpVH2-s2 (AM939769)


318
LpVH2-s3 (AM939770)


319
LpVH2-s4 (AM939771)


320
LpVH2-s5 (AM939772)


321
LpVH2-s6 (AM939773)


322
LpVH2-s11 Ps (AM939703)


323
LpVH2-s8 (AM939705)


324
LpVH2-s9 Ps (AM939706)


325
LpVH2-s10 (AM939702)


326
AJ879486|IGHV3-23*04


327
S-VH1


328
S-VH3


329
S-VH4


330
S-VH2


331
S-VH6


332
S-VH5


333
D86994|IGLV3-25*02


334
VL25-28


335
Z73672|IGLV5-37*01


336
VL2, 12, 15


337
Z73650|IGLV8-61*01


338
VL3, 5


339
VL17-24, 29-32


340
VL10


341
VL4, 6, 7, 8, 9, 13, 14


342
U41644|IGKV2D-29*02


343
KAPPA 33-36, 38, 39, 42, 4


344
KAPPA 41, 43, 44


345
KAPPA 40, 44


346
KAPPA 37, 46, 48


347
VH1a-BACK


348
VH5a-BACK


349
VH4a-BACK


350
VH4b-BACK


351
VH2b-BACK


352
VH1a-BACK-SfiI


353
VH5a-BACK-SfiI


354
VH4a-BACK-SfiI


355
VH4b-BACK-SfiI


356
VH2b-BACK-SfiI

## Claims

1. A chimeric antigen binding polypeptide that specifically binds to a target antigen, the polypeptide comprising a VH domain and a VL domain, said VH domain comprising hypervariable loops H1, H2 and H3, wherein said VH domain polypeptide is paired with a VL domain comprising hypervariable loops L1, L2 and L3, wherein said VH domain and said VL domain are each fused to one or more IgG constant domains of a human antibody, wherein at least the H3 hypervariable loop is obtained from a conventional antibody of a species in the family Camelidae, and wherein said conventional antibody is a heterotetrameric IgG antibody composed of two identical light chains and two identical heavy chains, wherein at least one of the hypervariable loops H1, H2, L1, L2 and L3 exhibits a predicted or actual canonical fold structure which is identical or substantially identical to a canonical fold structure of a corresponding H1, H2, L1, L2 or L3 hypervariable loop which occurs in human antibodies.

2. The chimeric antigen binding polypeptide of claim 1 wherein either hypervariable loop H1 or hypervariable loop H2, or both hypervariable loop H1 and hypervariable loop H2 are obtained from the conventional antibody of a species in the family Camelidae.

3. The chimeric antigen binding polypeptide of claim 1 wherein either hypervariable loop L1 or hypervariable loop L2 or both hypervariable loop L1 and hypervariable loop L2 are obtained from the conventional antibody of a species in the family Camelidae.

4. The chimeric antigen binding polypeptide of claim 1 wherein hypervariable loop L3 is obtained from the conventional antibody of a species in the family Camelidae.

5. The chimeric antigen binding polypeptide of claim 1 wherein each of the hypervariable loops H1-H3 and L1-L3 are obtained from the conventional antibody of a species in the family Camelidae.

6. The chimeric antigen binding polypeptide of claim 1 wherein the conventional antibody is obtained by active immunisation of the species in the family Camelidae with the target antigen, or with a polynucleotide encoding said target antigen.

7. The chimeric antigen binding polypeptide of claim 6 which contains at least one amino acid substitution in at least one hypervariable loop in comparison to a corresponding hypervariable loop in the conventional antibody.

8. The chimeric antigen binding polypeptide of claim 6 which contains at least one amino acid substitution in at least one framework region of either the VH domain or the VL domain, in comparison to a corresponding framework region in the conventional antibody.

9. The chimeric antigen binding polypeptide of claim 1 wherein the VH domain of the polypeptide exhibits a sequence identity of 90% or greater with one or more human VH domains across the framework regions FR1, FR2, FR3 and FR4.

10. The chimeric antigen binding polypeptide of claim 9 wherein the VH domain of the polypeptide exhibits a sequence identity of 95% or greater with one or more human VH domains across the framework regions FR1, FR2, FR3 and FR4.

11. The chimeric antigen binding polypeptide of claim 10 wherein the VH domain of the polypeptide exhibits a sequence identity of 97% or greater with one or more human VH domains across the framework regions FR1, FR2, FR3 and FR4.

12. The chimeric antigen binding polypeptide of claim 1 wherein the VL domain of the polypeptide exhibits a sequence identity of 90% or greater with one or more human VL domains across the framework regions FR1, FR2, FR3 and FR4.

13. The chimeric antigen binding polypeptide of claim 12 wherein the VL domain of the polypeptide exhibits a sequence identity of 95% or greater with one or more human VL domains across the framework regions FR1, FR2, FR3 and FR4.

14. The chimeric antigen binding polypeptide of claim 13 wherein the VL domain of the polypeptide exhibits a sequence identity of 97% or greater with one or more human VL domains across the framework regions FR1, FR2, FR3 and FR4.

15. The chimeric antigen binding polypeptide of claim 1 wherein hypervariable loop H1 and hypervariable loop H2 each exhibit a predicted or actual canonical fold structure which is identical or substantially identical to a canonical fold structure of a corresponding H1 or H2 hypervariable loop which occurs in human antibodies.

16. The chimeric antigen binding polypeptide of claim 15 wherein hypervariable loop L1 and hypervariable loop L2 each exhibit a predicted or actual canonical fold structure which is substantially identical or substantially identical to a canonical fold structure of a corresponding L1 or L2 hypervariable loop which occurs in human antibodies.

17. The chimeric antigen binding polypeptide of claim 16 wherein hypervariable loop L1 and hypervariable loop L2 in the VL domain form a combination of predicted or actual canonical fold structures which is identical or substantially identical to a combination of canonical fold structures known to occur in corresponding hypervariable loops in a human germline VL domain.

18. The chimeric antigen binding polypeptide of claim 17 wherein the combination of canonical fold structures occurring in the human VL domain is selected from the group consisting of: 11-7, 13-7(A,B,C), 14-7(A,B), 12-11, 14-11, 12-12, 2-1, 3-1, 4-1 and 6-1.

19. The chimeric antigen binding polypeptide of claim 1 wherein hypervariable loop H1 and hypervariable loop H2 form a combination of predicted or actual canonical fold structures which is identical or substantially identical to a combination of canonical fold structures known to occur in corresponding hypervariable loops in a human germline VH domain.

20. The chimeric antigen binding polypeptide of claim 19 wherein the combination of canonical fold structures occurring in the human VH domain is selected from the group consisting of: 1-1, 1-2, 1-3, 1-4, 1-6, 2-1, 3-1 and 3-5.

21. The chimeric antigen binding polypeptide of claim 1 wherein the target antigen is a non-camelid antigen.

22. The chimeric antigen binding polypeptide of claim 21 wherein the target antigen is a human antigen.

23. The chimeric antigen binding polypeptide of claim 21 wherein the target antigen is a viral antigen or a bacterial antigen.

24. The chimeric antigen binding polypeptide of claim 1 wherein the target antigen is a target of therapeutic importance.

25. The chimeric antigen binding polypeptide of claim 1 which is an Fab, Fab', F(ab′)2, bi-specific Fab′, Fv fragments, diabody, linear antibody, a single chain variable fragment (scFv), antibody or multispecific antibody formed from antibody fragments.

26. The chimeric antigen binding polypeptide of claim 1, wherein the species in the family Camelidae is camel, llama, dromedary, vicunia, guanaco or alpaca.

27. The chimeric antigen binding polypeptide of claim 1, which is an antibody.

28. The chimeric antigen binding polypeptide of claim 1, wherein said IgG constant domains comprise at least one of a CH1 domain, hinge region, CH2 domain, and CH3 domain of the human antibody.

29. The chimeric antigen binding polypeptide of claim 28, wherein the IgG constant domains further comprise a human CL domain.

30. A pharmaceutical formulation comprising the chimeric antigen binding polypeptide of claim 1 and at least one pharmaceutically acceptable diluent, excipient or carrier.

31. A test kit comprising the chimeric antigen binding polypeptide of claim 1.

32. The test kit of claim 31 which additionally comprises at least one additional reagent required to perform an immunoassay using said chimeric antigen binding polypeptide.